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AntICAnCer druG studIes
Over the last 40 years, hundreds of new anticancer drugs have been developed.1 Part of 
this progress was driven by an increased understanding of cancer biology, which allowed 
scientists to develop new classes of drugs.2 These classes of drugs include therapies aimed 
at specific molecular targets. Such targeted therapies block the growth and spread of cancer 
by interfering with molecules involved in tumour progression.2
Despite these new types of drugs, for most types of cancer enduring responses are still rare, 
and cures even rarer.1 One of the reasons for this is tumour heterogeneity, which means 
that attributes of tumour cells differ within and between tumours, thereby influencing their 
susceptibility to treatment.2 When (part of the) tumour cells are not susceptible to a drug, 
they can continue to progress during or after treatment. Therefore, responses to anticancer 
drugs are often temporary and the unmet medical need remains substantial.3 New drugs or 
new combinations of drugs may, hopefully, overcome this problem.4
Efforts to develop new drugs and other (non-pharmaceutical) treatments continue. This is a 
lengthy process, usually starting in the laboratory, the pre-clinical phase, and slowly moving 
to large, randomised controlled trials (RCTs) to assess treatment safety and efficacy (phase 
III, see Table 1.1). When clinical evidence shows the drug to be safe and efficacious, market 
licensing authorities can evaluate it and approve the drug for marketing. In the European 
Union (EU) and the United States (US) this approval is performed by the European Medicines 
Agency (EMA) and the US Food and Drug Administration.5
However, after marketing approval, important questions still remain to be answered. While 
the drug has been extensively tested in the study setting, the real-world (RW) setting may 
be different. In the real world, the drug may be used differently from how it was used 
in clinical trials. Furthermore, due to selection, patients included in clinical trials may be 
table 1.1 Drug development process
Marketing approval
Preclinical Phase I Phase II Phase III Phase IV
Molecule 
discovery and 
characterisation, 
biological activity, 
safety
Dosage, safety Efficacy, safety Efficacy, safety Real-world outcomes: 
(appropriate) use, 
effectiveness, safety, 
budget impact, cost-
effectiveness
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different from the general patient population. In addition, monitoring practices in trials 
may differ from the real world; they can have a therapeutic effect as such and/or may allow 
clinicians to respond earlier to changes in a patient’s clinical condition. These and other 
differences can limit the generalisability of trial results to the actual RW patients in need of 
the drug.
Therefore, in various countries, RW evidence is required in addition to trial results, for 
example to approve a drug for continued reimbursement. This evidence is often collected 
in observational studies and may include RW effectiveness and safety evidence, but also 
information on appropriate use, patient-reported outcomes, budget impact and/or cost-
effectiveness.6 Given the fact that national healthcare budgets are limited, information 
about RW budget impact and cost-effectiveness is increasingly important to ensure rational 
allocation of scarce resources.
In this thesis, the value of RW evidence will be evaluated. Observational outcome studies 
from two clinical areas will be presented: head and neck cancer oncology and lung oncology. 
In both of these areas, substantial clinical progress has been made over the last decade, in-
cluding the market approval of targeted therapies. Also in both of these areas, RW evidence 
has been scarce.
First, in the following paragraphs (“clinical background”), a general overview of head and 
neck and lung oncology will be provided. Secondly, (in “RW data”) various types of RW data 
and their relevance will be introduced. The last part of the introduction will discuss the aim, 
research questions and structure of the thesis.
ClInICAl bACkGround
the case of head and neck cancer
The term “head and neck cancer” covers malignant tumours of a number of anatomic 
regions in the body, depicted in Figure 1.1. Head and neck cancer constitutes 5% of the 
total number of cancer cases worldwide.3 In the Netherlands the annual incidence of head 
and neck cancer is approximately 3,000 and mortality is 875 per year.7 The incidence of 
squamous cell carcinoma of the oral cavity, oropharynx and hypopharynx has risen in the 
last decennia in the Netherlands. The incidence of laryngeal carcinoma has decreased in 
men and remained stable in women.8 Risk factors for developing head and neck cancer are 
exposure to tobacco, excessive alcohol use and human papilloma virus (HPV).9,10
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Traditionally, treatment of head and neck cancer consists of surgery, radiotherapy, chemo-
therapy, or combinations of these, depending on the disease stage. Recently, targeted therapy 
was added to this range of treatment options. In 2006 and 2008 study results demonstrated 
the efficacy of cetuximab in locally advanced (LA) and recurrent and/or metastatic (RM) squa-
mous cell carcinoma of the head and neck (SCCHN).11,12 Cetuximab is a monoclonal antibody 
aimed at the epidermal growth factor receptor (EGFR). In the clinical trials, the overall survival 
of patients treated with cetuximab in addition to radiotherapy (in LA SCCHN) or chemotherapy 
(in RM SCCHN), was median 19.7 (LA SCCHN) and 2.6 (RM SCCHN) months longer, respectively, 
than the overall survival of patients treated with radiotherapy or chemotherapy alone.11,12 RW 
use, costs and effects were previously unknown and will be discussed in this thesis.
Head and neck cancer care is relatively well organised in the Netherlands. Approximately 
90% of patients with head and neck cancer are treated in specialised head and neck treat-
ment centres.13 Strict standards exist for head and neck treatment centres in order to ensure 
quality. These standards were drafted by the profession and include minimum treatment 
volumes and requirements regarding (multidisciplinary) staff composition. For example, 
each patient should be discussed in a multidisciplinary head and neck working group with 
Head and Neck Cancer Regions
Nasopharynx
Oropharynx
Hypopharynx
Pharynx
Paranasal
sinuses
Nasal cavity
Oral cavity
Salivary gland
Larynx
Figure 1.1. Head and Neck Cancer Regions.
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a medical oncologist, radiotherapists, head and neck cancer surgeons, and expertise about 
reconstructive surgery.14 The locations of the head and neck treatment centres are indicated 
in Figure 1.2.13
the case of lung cancer
Lung cancer is the most commonly diagnosed cancer (1.8 million cases, 12.9% of the total 
cancer cases in 2012) and the most common cause of cancer death (1.6 million cases, 19.4% 
of the total in 2012) worldwide.3 Also in the Netherlands, lung cancer incidence as well 
as mortality has remained relatively high, despite medical advances and a reduction in 
smoking. In 2012, incidence was 66.1 males and 44.5 females per 100,000 person years 
(European Standardised Rates). Lung cancer mortality was 59.6 males and 35.6 females per 
100,000 person years.15 More than 85% of lung cancers are of the non-small cell type.7 
Figure 1.3 shows a picture of the respiratory anatomy, including the lungs.
        Nijmegen
(UMC-St-Radboud)
Den Haag
(MCH)
Leiden
(LUMC)
Amsterdam 
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Amsterdam
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Leeuwarden
(MCL/RIF) Groningen
(UMCG)
Maastricht
(MUMC)
Arnhem (Rijnstate)
Enschede (MST)
Tilburg (St Elisabeth)
Alkmaar (MCA)
Rotterdam 
(Erasmus MC)
Figure 1.2. Head and neck treatment centres in the Netherlands.
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Treatment of lung cancer traditionally consists of surgery, radiotherapy, chemotherapy, 
or combinations of these, depending on the disease stage. Commonly prescribed chemo-
therapy regimens include combinations of a platinum agent (cisplatin, carboplatin) with a 
third-generation agent (paclitaxel, docetaxel, gemcitabine or vinorelbine), or pemetrexed. 
Furthermore, targeted therapies have recently been added to the range of treatment op-
tions. Amongst others, erlotinib and gefitinib are being prescribed, both of which target 
EGFR. New targeted therapies that target, amongst others, KRAS (Kirsten Rat Sarcoma Viral 
Oncogene Homolog), ALK (Anaplastic Lymphoma Kinase), HER2 (Human Epidermal Growth 
Factor Receptor 2) and BRAF (V-Raf Murine Sarcoma Viral Oncogene Homolog B) are being 
studied extensively.16 Other advances in lung cancer treatment include the use of new tech-
niques for the planning and administration of radiotherapy, and new surgical approaches.17 
In the last decades, NSCLC treatment has improved and survival has slightly improved as 
well, within all disease stages.18,19
Trachea
Bronchi
Upper lobe
Diaphragm
Artery
Alveoli
Vein
Bronchiole
Middle lobe
Lower lobe
Left lung:
Right lung:
Upper lobe
Lower lobe
Lymph node
Figure 1.3. Respiratory Anatomy.
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Unlike the treatment of head and neck cancer, NSCLC treatment is not centralised in the 
Netherlands. However, similarly to head and neck cancer, standards exist for hospitals 
treating patients with lung carcinoma. These standards were drafted by the profession and 
include minimum treatment volumes and requirements regarding (multidisciplinary) staff 
composition and available facilities.14 Further, a Dutch evidence-based guideline for the 
diagnosis and treatment of NSCLC exists and (modular) revisions are performed regularly to 
ensure actuality.20 However, better compliance with the guideline as well as further centrali-
sation may be needed to further improve NSCLC management.21
In this thesis, current NSCLC treatment patterns will be discussed. Furthermore, RW in-
formation is provided with regard to clinical outcomes and costs of NSCLC diagnosis and 
treatment.
rW dAtA
Various types of RW data exist, including data on treatment patterns, clinical outcome 
measures, budget impact and cost-effectiveness.
treatment patterns / (appropriate) use
Data on treatment patterns can be used to evaluate how a certain treatment is being pre-
scribed. For example, one can measure the uptake of new drugs by looking at how often 
they are prescribed and how this changed over time, from market access onwards. Also, one 
can evaluate for which indications a drug is used and which type of patients are receiving it. 
This can be compared to the drug’s label and/or the national or international clinical guide-
lines to evaluate if the drug is being used appropriately. National reimbursement authorities 
including the Dutch National Health Care Institute (ZIN, previously called the “College voor 
Zorgverzekeringen”, CVZ) require information on appropriate use (on-label use, use accord-
ing to guidelines) of certain types of new drugs as a condition for continued reimbursement.
Furthermore, treatment sequences can be evaluated to check, for example, treatment ef-
fectiveness and safety dependent on treatment history. Moreover, RW data on treatment 
patterns can also be used to assess treatment variability between hospitals. Treatment vari-
ability can be an important indication of differences in quality of care. In the Netherlands, 
large differences exist in the proportion of surgeries hospitals perform for (up to 5.5 times 
difference, for the same indication).22 The same is likely true for pharmaceutical treatments. 
Differences can be caused by e.g. patient heterogeneity, undertreatment or overtreatment 
in some of the hospitals. Comparing treatment patterns and clinical outcomes, corrected 
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for differences in patient populations, can point towards best practices and possibilities for 
improvement.
Clinical outcome measures
Clinical outcomes are valuable for assessing the RW impact of new drugs. There is a difference 
between treatment efficacy and treatment effectiveness. While the efficacy of a treatment 
refers to its performance “under ideal and controlled circumstances”, the effectiveness of 
a treatment refers to its performance “under usual or ‘real-world’ circumstances”.23 As is 
shown in Table 1.1, treatment efficacy has usually been proven within clinical trials before 
marketing approval. Effectiveness needs to be measured in daily clinical practice.
Important efficacy and effectiveness measures include overall survival24, progression-free 
survival25 and treatment response.26 Furthermore, treatments can positively or negatively 
affect the quality of life of patients. Impact on quality of life can be the result of (an increase 
or decrease in) adverse events, during and (in the case of long-term or delayed adverse 
events) after treatment. Furthermore, treatments can impact quality of life by reliev-
ing symptoms of the disease. Quality of life is multiplied with overall survival to obtain a 
composite measure incorporating both the quantity and quality of life: quality-adjusted life 
years (QALYs).27
Overall survival, progression-free survival, response, safety and quality-adjusted life years 
gained can be compared between treatment alternatives and inform decision making on the 
individual as well as the macro level.
budget impact
In order for national healthcare decision makers to approve a drug for reimbursement, they 
generally also require information regarding budget impact. Since healthcare budgets are 
limited, payers need to know to what extent new drugs will take up available resources. The 
number of cancer patients is large and rising, as are the number and prices of new pharma-
ceuticals. More and more innovative cancer drugs are being developed and their prices have 
increased from 300-500 euro per month in the nineties to 10,000 euro per month in 2014.28 
Therefore, the budget impact of cancer drugs is increasing.
The total budget impact of a drug should be based on the size and characteristics of the 
affected population, the current intervention mix without the new intervention, the costs of 
the current intervention mix, the new intervention mix with the new intervention, the cost 
of the new intervention mix and the use and cost of other health condition and treatment 
related healthcare services.29
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Just like clinical outcome measures, budget impact can be compared between treatment al-
ternatives and inform decision making. Budget impact analyses are usually performed from 
the perspective of the national healthcare decision maker29, not the individual clinician or 
oncology practice. In the Netherlands, economic evaluations (including evidence on budget 
impact and cost-effectiveness) are required for drugs with an added therapeutic value and 
for expensive specialist drugs.30
Cost-effectiveness
In addition to information about budget impact, national healthcare payers generally re-
quire information on drug cost-effectiveness. This is also true for the National Health Care 
Institute in the Netherlands. Cost-effectiveness is calculated by dividing the cost of a treat-
ment by its effects. A subtype of cost-effectiveness is cost-utility. In this case, effects are 
expressed in QALYs.
The cost-effectiveness (or cost-utility) of a new treatment can be compared to the cost-
effectiveness (or cost-utility) of another treatment alternative to calculate the incremental 
cost-effectiveness ratio (ICER): (cost of the treatment – cost of the comparator) / (effects 
of the treatment – effects of the comparator). Usually the ICER is expressed in costs per 
QALY gained, because this measure can be used generically and allows decision makers to 
compare treatments for different diseases.
Various methods exist to calculate cost-effectiveness. Generally data from clinical studies 
is used and health-economic modelling is needed to extrapolate cost and effects over a 
longer period of time than the study duration (e.g.: a patient’s lifetime). Furthermore, 
cost-effectiveness analyses include various types of sensitivity analyses to quantify the 
uncertainty of the outcomes. Additionally, scenario analyses can be performed to quantify 
the impact of alternative assumptions for model inputs.31
In the Netherlands, ICERs for new pharmaceuticals are evaluated by the National Health 
Care Institute. However, no formal cost-effectiveness threshold exists for approving or deny-
ing a drug for reimbursement. A threshold range was suggested depending on the severity 
of the disease (i.e. €10,000-80,000 per QALY gained), but was never confirmed nor endorsed 
by the Ministry of Health. While the requirement to deliver cost-effectiveness evidence ex-
ists in policy procedures, it does not (yet) seem to influence reimbursement decisions in the 
Netherlands.30
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AIM And reseArCh questIons oF thIs thesIs
The aim of this thesis is to assess the value of RW evidence in addition to RCT evidence in 
lung and head and neck oncology. The following research questions will be answered:
– What are the differences between RW evidence and evidence obtained in RCTs?
– How can the addition of RW evidence to RCT evidence support decision making?
– How can RW cost data improve lung and head and neck cancer care?
– How can RW data on treatment patterns improve lung and head and neck cancer care?
– How can patient registries be used to collect high-quality RW data?
In the discussion of this thesis, the results from the various chapters will be combined and 
used to answer these research questions.
struCture oF thIs thesIs
First, in Chapter II-IV of this thesis, several outcome studies in head and neck cancer will 
be discussed. Chapter II discusses the use of cetuximab in locally advanced squamous cell 
carcinoma of the head and neck. It compares the RW setting to the pivotal clinical trial 
setting and stresses the differences. Chapter III builds on these outcomes to model the cost-
effectiveness of cetuximab in the locally advanced setting, in order to inform reimburse-
ment decisions. Multiple scenarios are presented, showing the impact of an alternative 
assumption regarding the prognosis of RW versus clinical trial patients.
The fourth chapter discusses a different indication in head and neck cancer, namely recur-
rent and/or metastatic disease. It describes RW treatments and costs for a patient group 
with a poor prognosis and small expected treatment gains.
Chapter V discusses treatment and survival of non-small cell lung cancer patients in the 
Netherlands. It presents differences in survival between patients treated in different hos-
pital types. Chapter VI and VII discuss the costs of non-small cell lung cancer care. Chapter 
VI zooms in on the costs for laboratory tests, amongst others genetic biomarker tests to 
assess eligibility for treatment with targeted therapies. Chapter VII uses these and other 
costs to provide an overview of all hospital costs associated with non-small cell lung cancer 
management.
Chapter II to VII all provide practical examples of possible questions to be answered with 
RW evidence. However, disregarding the question at hand, the value of RW evidence largely 
depends on the quality of the data. An increasingly popular way to collect RW data is via 
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patient registries. Chapter VIII therefore provides a practical guide to setting up patient reg-
istries for the collection of high-quality RW data for decision making. It provides important 
prerequisites to ensure proper design and management of the patient registry.
Chapter IX draws together the results of previous chapters in the general discussion. 
Furthermore, it summarises the limitations of this thesis.
Chapter II
Cetuximab in locally advanced squamous cell 
carcinoma of the head and neck: generalisability of 
eMr 062202-006 trial results
Naomi van der Linden, Chantal W.M. van Gils, Chris P. Pescott, 
Jan Buter and Carin A. Uyl-de Groot
Published in the European Archives of Otorhinolaryngology 2014; 271 (6): 1673-1678
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AbstrACt
In a randomised controlled trial in patients with locally advanced squamous cell carcinoma 
of the head and neck (LA SCCHN), treatment with radiotherapy plus cetuximab (RT+C) 
resulted in improved survival compared to treatment with RT alone. Uncertainty exists 
about the generalisability of the trial results for the Dutch healthcare setting due to possible 
discrepancies in treatment allocation.
Retrospective patient chart review was performed for 141 patients treated with first-line 
RT+C or RT alone, diagnosed in 2007–2010 in two head and neck treatment centres. 
Combined with aggregated population-based data from the Netherlands Cancer Registry 
and patient-level clinical trial data, use of cetuximab in Dutch daily practice was assessed 
through comparison of patient characteristics, treatment characteristics and treatment 
outcomes between trial and daily practice.
Sixty-one daily practice patients fulfilled the selection criteria. In line with Dutch guidelines, 
RT+C is prescribed in patients requiring combined therapy unfit to receive traditional 
platinum-based chemotherapeutics. These patients have unfavourable baseline charac-
teristics, due to selection on—amongst others—high age of the patients. Beyond 1 year 
after treatment start, patients treated with RT+C in daily practice died earlier than patients 
treated with RT+C in the trial.
Selective treatment allocation in daily practice limits generalisability of EMR 062202-006 
trial results. Evidence is needed about the effectiveness of RT+C compared to other treat-
ments for patients with unfavourable clinical baseline characteristics.
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IntroduCtIon
Each year in Europe over 130,000 cases of head and neck cancer are diagnosed, associated 
with high morbidity and 63,000 deaths annually.15 For decades, the mainstay treatment for 
locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) consisted of 
surgery or radiotherapy, alone (RT) or combined with platinum-based chemotherapy (CRT), 
according to disease stage and clinical characteristics.32-37 In 2006, Bonner et al. published the 
results of a phase III study investigating the addition of cetuximab, a chimeric human-murine 
monoclonal IgG antibody, to RT in three fractionation regimens, to treat oropharyngeal, 
hypopharyngeal or laryngeal carcinoma (EMR 062202-006). Improved locoregional control 
(LRC), progression-free survival (PFS) and overall survival (OS) were demonstrated in the 
study arm receiving cetuximab, effectively expanding the range of treatment modalities.38 
Updated survival figures confirmed efficacy of RT plus cetuximab (RT+C) compared to RT. A 
median OS of 49.0 months (95% CI 32.8–69.5 months) was observed for RT+C versus 29.3 
months (95% CI 20.6–41.4 months) for RT (hazard ratio 0.73, 95% CI 0.56–0.95; p=0.018).11
The European Medicines Agency issued marketing authorisation for cetuximab in 2004 for 
the treatment of patients with squamous cell cancer of the head and neck in combination 
with radiation therapy for locally advanced disease. The Dutch Association for Medical On-
cology (NVMO) in current LA SCCHN treatment guidelines proposes RT, CRT or RT+C, guided 
by tumour characteristics and medical condition.34-37 Definitive criteria for prescription of 
cetuximab in LA SCCHN in the Netherlands have not been specified, although guidelines 
recommend RT+C in cases where RT is thought to be insufficiently effective and CRT is 
contraindicated. More research is needed to determine efficacy and effectiveness of RT+C 
compared to current, standard chemoradiation, as well as for the addition of cetuximab to 
standard chemoradiation.39-41
NVMO’s scientific committee (CieBOM) states that although the “Bonner trial” was not 
powered for subgroup analyses, results suggested cetuximab to be most efficacious when 
prescribed to patients with oropharyngeal carcinoma and when combined with concomitant 
boost RT regimen (hyperfractionated RT).41 CieBOM therefore recommended considering 
treatment with cetuximab + accelerated and/or hyperfractionated RT, only for the treatment 
of patients with an oropharyngeal carcinoma and a contraindication to chemoradiation. 
Subsequently, the Netherlands Healthcare Insurance Board’s committee for pharmaceuti-
cal aid (CFH) confirmed therapeutic added benefit of the combination of cetuximab and 
hyperfractionated or accelerated RT over treatment with RT alone, in patients with LA 
SCCHN with a contraindication to platinum-based chemoradiation, especially for patients 
with oropharyngeal carcinoma and a good general condition.42
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These recommendations for treatment allocation can result in dissimilarities between 
patients receiving RT+C in daily practice and those selected for the “Bonner trial”, possibly 
resulting in limited generalisability of trial results. The extent to which patients receiving 
RT+C in daily clinical practice match those in the trial has remained unknown. We designed 
a study to provide insight into the position of RT+C in the Netherlands. Further, we aim to 
determine applicability of the “Bonner trial” results to Dutch healthcare. In this paper, we 
present results on patient characteristics, treatment characteristics and clinical effective-
ness of RT+C in a sample of the Dutch LA SCCHN patient population, as compared to the 
trial. In a companion paper, an analysis of cost-effectiveness of RT+C in this indication will 
be presented.
Methods
study design
We performed a retrospective, observational study of LA SCCHN patients in the Netherlands 
treated with RT+C or RT alone. Although main interest lies with RT+C in daily practice, as 
such and as compared to the trial, characteristics of patients treated with RT alone, com-
parator arm in the “Bonner trial”, inform on daily practice treatment allocation. The study 
consisted of retrospective chart review of patients treated with first-line RT+C or RT for 
oropharyngeal, hypopharyngeal or laryngeal SCC between January 1, 2007 and December 
31, 2010 in two university medical centres. No further selection criteria were applied. In 
contrast, the “Bonner trial” accepted subjects only when the following criteria were ful-
filled: an expected survival of C12 months, normal renal, liver and hematopoietic function, 
no systemic chemotherapy or previously treated malignancy in the last 3 years, and no prior 
RT to the head and neck or surgery for the tumour. As our study design is not subject to the 
Medical Research Involving Human Subjects Act, the Medical Research Ethics Committee 
exempted the study from ethical appraisal. Informed consent was not required for chart 
review. Charts were obtained from VU University Medical Centre (VUMC) in Amsterdam and 
University Medical Centre Groningen (UMCG) for all LA SCCHN patients who had received 
first-line RT+C or definitive RT. Eligible patients were identified from hospital databases by 
one clinician in each hospital.
Patient charts (n=141 total, 61 RT+C and 80 RT) were manually reviewed. Detailed informa-
tion was collected about patient characteristics, tumour classification, treatment charac-
teristics, disease progression and survival. Data were recorded onto standardised paper 
case report forms. For a subsample of these patients (31 patients treated with RT+C and 
31 treated with RT), matched by year of treatment start, tumour site and disease stage, 
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additional data on toxicities and resource use were collected. Aggregated population data 
from the Netherlands Cancer Registry (NKR), available up to 2009, on disease stage and 
tumour location were used to inform on representativeness of the observational study 
data.43 Observational study results on baseline characteristics and OS were compared to 
the “Bonner trial” results. Patient-level data from the trial consisted of patient and tumour 
characteristics, treatment arm, date of randomisation, date of progression and date of 
death. These were obtained from the marketing authorisation holder.
data analysis
Patient characteristics consisting of age, sex, and WHO performance status, tumour classi-
fication comprising disease stage and tumour site, and treatment characteristics (modality, 
dosing, adverse events) were compared between patients from the trial and the observa-
tional study. In addition to descriptive statistics, differences were assessed by means of the 
independent samples t-test for variables showing a normal distribution and the Pearson 
Chi square test for variable fractions. Statistical significance was assumed if the two-tailed 
probability value was <0.05.
The clinical effectiveness measure reported in this paper is OS, defined as time from treat-
ment start to death. Survival curves were visualised according to the Kaplan Meier methods. 
OS was not corrected for covariates and compared between groups: the study aims to 
describe the position of RT+C in daily practice, not to compare its effectiveness between 
treatment settings. All statistical analyses were performed using the SPSS computer pack-
age, version 17.0.
results
Inclusion
Based on results from the National Cancer Registry (NKR), between January 1, 2007 and De-
cember 31, 2009, in the Netherlands 2,111 patients were diagnosed with locally advanced 
oropharyngeal, hypopharyngeal or laryngeal squamous cell carcinoma (Figure 2.1). Of 
these patients, 109 had received first-line treatment with RT+C. Forty-four of these patients 
(40.4%) had been treated in VUMC or UMCG and were therefore included in the observa-
tional study. We included an additional 17 patients from VUMC and UMCG diagnosed in 
2010, resulting in a patient population of 61 RT+C patients fulfilling the selection criteria. 
Median follow-up of these patients was 29 months (range 20–38 months).
24 | Chapter II
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During this timeframe, the proportion of patients receiving RT+C each year ranged from 
4.6 to 6.1% of LA SCCHN patients. Disease stage and tumour site in the sample (n=61) were 
representative for the population treated with RT+C on a national level as recorded by the 
NKR (n=109) (Table 2.1).
Patient and tumour characteristics
Demographics and tumour characteristics differed between the population treated in Dutch 
daily practice and the “Bonner trial” (Table 2.2). For both treatment arms, the patients in 
the observational study had a higher median age; 65 versus 56 (RT+C, p=0.00) and 62 versus 
58 (RT alone, p=0.00). In the RT+C group, the proportion of females was significantly higher 
in daily practice. For patients treated with RT+C, no statistical differences at baseline were 
found in disease stage between the trial population and our study sample. Tumours treated 
with RT+C were more often located in the hypopharynx in our sample (n=23, 38%) than in 
the “Bonner trial” (n=36, 17%). In patients receiving RT alone in daily practice, 70% (n=56) 
of carcinomas were laryngeal, compared to 24% (n=51) in the trial.
treatment
In 38% of our sample, treatment choice was motivated in patients’ files. The most common 
arguments for choosing RT+C over CRT were: weakened condition (n=8, 13%), impaired 
renal function (n=8, 13%) and high age (n=5, 8%).
Planned radiotherapy and pharmaceutical regimens in patients who had received RT+C were 
according to label. In 12 patients (39%) planned regimens were abandoned during the course 
of treatment, primarily for reasons of toxicity (n=8). This included immediate hypersensitiv-
table 2.1. Distribution of disease stage and site of primary tumours in patients treated with radio-
therapy plus cetuximab (RT+C), observational study versus national
observational study:
rt + C (n = 61, 2007–2010)
national:  
rt + C (n = 109, 2007–2009) p
disease stage
III 16 (26%) 22 (20%) 0.36
IV 45 (74%) 87 (80%)
tumour site 0.76
Oropharynx 32 (53%) 63 (58%)
Larynx 6 (10%) 11 (10%)
Hypopharynx 23 (38%) 35 (32%)
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ity to cetuximab (n=2), fever (n=1), and abnormal liver function tests (n=1). In four patients, 
cetuximab was planned treatment regimen occurred significantly more often in daily practice 
than in the “Bonner trial”, where deviations were reported in 1% of patients (n=3, p=0.00). 
RT regimens used in daily practice were diverse. Preferred regimen was accelerated RT, 35 
9 2 Gy, total dose 70 Gy, 6 fractions per week, radiobiologically similar to the concomitant 
boost regimen in the trial. No deviations from RT treatment plans were reported.
Clinical effectiveness
Kaplan Meier curves for both the outcomes study and clinical trial populations show simi-
lar patterns of OS (Figure 2.2). This is not the case when survival curves are corrected for 
treatment modality. Figure 2.3 shows Kaplan Meier curves for patients receiving RT+C in 
the outcomes study versus the clinical trial. As opposed to the patient group as a whole, 
patients receiving RT+C demonstrate lower OS in daily practice than in the “Bonner trial”, 
beyond 1 year of follow-up. Conversely, a higher OS was seen for RT alone (not shown).
table 2.2: Baseline characteristics within the ‘Bonner trial’ versus the observational study
rt+C rt alone
trial daily practice P trial daily practice P
N = 211 61 213 80
Age, yr
Median
Range
56
34-81
65
42-83
0.0011
58
35-83
62
40-87
0.0011
Sex, no. (%)
Male
Female
171 (81)
40 (19)
37 (61)
24 (39)
0.00
169 (79)
44 (21)
61 (76)
19 (24)
0.34
Disease stage, no. (%)
III
IV
55 (26)
156 (74)
16 (26)
45 (74)
0.98
52 (24)
161 (76)
35 (44)
45 (56)
0.00
Tumour site, no. (%)
Oropharynx
Larynx
Hypopharynx
118 (56)
57 (27)
36 (17)
32 (53)
6 (10)
23 (38)
0.00
135 (63)
51 (24)
27 (13)
20 (25)
56 (70)
4 (5)
0.00
Performance status, no. (%)
WHO ≤ 1
WHO 1 – 2
189 (90)
21 (10)
27 (82)
6 (18)
0.16
190 (90)
22 (10)
37 (95)
2 (5)
0.31
1 = The p-value is for the comparison between the number of patients less than 60 years of age and 
those 60 years of age or older.
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dIsCussIon
We demonstrate OS of patients in the daily practice sample matched survival of the “Bon-
ner trial subjects”. However, patients treated with cetuximab added to RT in daily practice 
had less favourable outcomes than their counterparts in the trial. The opposite was true 
for RT patients. This is likely due to treatment allocation, following differences in baseline 
characteristics.
Patient selection may influence generalisability of trial results. Two moments in patient 
selection are relevant. First, “trial patient selection” refers to the inclusion of a group of se-
lected patients to participate in a clinical trial, based on trial protocol in a randomised setting 
combined with explicit or implicit choices by clinicians enrolling these patients. Second, “daily 
practice patient selection” refers to non-randomised or planned treatment allocation, based 
on guidelines or hospital protocols and explicit or implicit choices by patients and clinicians.
Figure 2.2. Kaplan Meier curves of all patients within the “Bonner trial” versus all patients within the 
observational study.
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For RT+C, at least “daily practice patient selection” seems to limit the generalisability of 
the trial results. RT+C is prescribed in Dutch clinical practice to patients requiring combined 
treatment and who are contraindicated to receive CRT. As a result, patients receiving RT+C 
in Dutch clinical practice are more likely to have poor prognostic factors at baseline. Their 
median age has been found to be higher than the median age of patients who receive RT 
alone in daily practice, and higher than the median age of subjects in the “Bonner trial”. Tu-
mour characteristics at baseline were also indicative of poor prognosis. In patients following 
RT+C, we found a relative underrepresentation of laryngeal tumours, known to respond well 
to RT alone. Patients diagnosed with hypopharyngeal carcinoma, associated with poorer 
outcomes, were overrepresented in the patient group receiving RT+C. This is noteworthy 
since Dutch recommendations advocate use of RT+C mainly for oropharyngeal carcinoma.
Recently, Beijer et al. published a study on feasibility, effectiveness and toxicity of RT+C or 
platinum-based chemoradiation in Dutch daily practice LA SCCHN patients in 2008–2010. 
Thirty-two patients treated with RT+C were included, all ≥70 years and/or with significant 
Figure 2.3. Kaplan Meier curves of the patients treated with RT+C (radiotherapy+cetuximab) within 
the “Bonner trial” versus the patients treated with RT+C in the observational study.
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comorbidity. This study sample included patients with residual or locoregionally recurrent 
disease after previous surgery, as opposed to our study sample and the patients included 
in the “Bonner trial”. Beijer et al. show worse prognostic characteristics and worse OS for 
patients treated with RT+C compared to patients treated with chemoradiation. In line with 
our conclusion, Beijer et al.44 suggest this was “probably mainly due to patient selection and 
not to a treatment effect”.
Our study design has several limitations. First, information was collected in only two hos-
pitals: both large academic treatment centres. However, since the treatment of head and 
neck tumours in the Netherlands is centralised and both hospitals are members of the Head 
and Neck cancer working group, treatment in such centres is considered usual practice.13 
Our subsample of patients treated with RT+C for LA SCCHN, represents 40.4% of all patients 
receiving this treatment in the Netherlands within the timeframe.
Second, our data was dependent on the level of detail available in patient charts. Differences 
in reporting accuracy between clinicians introduce a bias, the direction of which cannot be 
determined. The same is true for missing data for patients who were lost to follow-up.
Obtaining more detailed information on the outcomes of cetuximab treatment is crucial, 
especially since there is little information about the benefit and toxicity of cetuximab in 
elderly and patients with comorbidity.45,46 The most reliable way to study this would be 
within a randomised controlled trial.
In conclusion, RT+C seems to be chosen by clinicians in daily practice to treat those patients 
with relatively unfavourable prognostic characteristics, while patients with a favourable 
prognosis had a greater chance of receiving RT alone. This can either be the result of good 
clinical reasoning or undertreatment with RT+C in the favourable group of patients. Regard-
less, the generalisability of the trial results to Dutch daily practice seems limited.
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AbstrACt
Clinical trial EMR 62202-006 demonstrates prolonged median locoregional control (24.4 vs. 
14.9 months), progression-free survival (17.1 vs. 12.4 months) and overall survival (49.0 vs. 
29.3 months) for patients who receive cetuximab added to the comparator radiotherapy for 
locally advanced squamous cell carcinoma of the head and neck (LA SCCHN). In the Nether-
lands, hospitals receive reimbursement for cetuximab conditional on cost-effectiveness in 
daily practice.
To estimate the real-world incremental cost per QALY gained for RT+C over radiotherapy 
alone in first-line treatment of LA SCCHN, a Markov model is constructed with health states 
“alive without progression”, “alive following progression” and “death”. Transition probabili-
ties per month are estimated from clinical trial data and retrospectively collected real-world 
data from two Dutch head and neck cancer treatment centres (2007–2010, n=141). Five-
year, ten-year and lifetime horizons are used, without and with discounting (4% costs, 1.5% 
effects) to calculate incremental cost-effectiveness ratios. Two scenarios explore different 
assumptions on prognosis of real-world versus trial patients.
Adding cetuximab to radiotherapy results in increased costs and health gains in both 
scenarios and across each of the time horizons. Incremental costs per QALY gained range 
between €14,624 and €38,543 in the base case. For a willingness to pay of €80,000 per QALY, 
the acceptability curves for the different scenarios show probabilities between 0.76 and 
0.87 of RT+C being cost-effective compared to radiotherapy alone.
Current results show the combined treatment of RT+C to be a cost-effective treatment op-
tion for patients with LA SCCHN.
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IntroduCtIon
Treatment options for locally advanced squamous cell carcinoma of the head and neck (LA 
SCCHN) include surgery and radiotherapy (RT). In case of RT, additional benefit is obtained 
with altered-fractionation RT, concurrent platinum-based chemoradiation, or RT combined 
with with cetuximab, a monoclonal antibody inhibiting the epidermal growth factor recep-
tor.47 Alongside the anti-tumour effect of cetuximab as a single modality, synergistic effects 
are demonstrated when combined with chemotherapy and/or radiation.47-49
Results from the pivotal randomised controlled clinical trial EMR 62202-006 (ClinicalTrials.
gov number, NCT00004227) demonstrate significantly prolonged median locoregional 
control (24.4 vs. 14.9 months), progression-free survival (17.1 vs. 12.4 months) and overall 
survival (49.0 vs. 29.3 months) for patients treated with RT+C compared to RT alone.11,38 As a 
result, RT+C gained a place in the therapeutic spectrum in clinical practice in the Netherlands. 
RT+C is prescribed to patients with a contraindication to platinum-based chemoradiation 
therapy. Patients who received RT+C in routine clinical practice, known as a real-world set-
ting (RW), were found to have relatively unfavourable prognostic characteristics compared 
to trial subjects, or RW patients receiving RT alone (see chapter II).
In the Netherlands, expensive medicines are conditionally and temporarily reimbursed. 
Evidence on RW cost-effectiveness following health outcomes and pharmacoeconomic 
research provide information to policy makers on continuing the reimbursement status. We 
designed an outcomes study to generate this requested data on RW costs and effects of 
RT+C in the indication LA SCCHN. Data from the clinical trial11,38 and the outcomes study 
(chapter II) were used to construct and populate a Markov model. The estimated incremen-
tal cost-effectiveness ratio of adding cetuximab to RT for these patients was then assessed.
Methods
outcomes study
RW data of LA SCCHN patients newly diagnosed between January 1st 2007 and December 
31st 2010 were retrospectively analysed. Medical charts of 61 patients treated with RT+C 
and 80 patients treated with definitive RT alone in two specialised head and neck treatment 
centres in the Netherlands were reviewed. Patient and tumour characteristics, treatment 
and progression-free and overall survival data were captured. Resource use was collected 
for a subset of these patients (n=62, 31 per treatment group), matched for year of treatment 
start, tumour site and disease stage.
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real-world vs. clinical trial outcomes
As our outcomes study was not designed or powered to provide accurate, matched, survival 
estimates, effectiveness information was drawn from trial results. In the cost-effectiveness 
(CE) modelling, trial effect estimates were adapted based on RW data (see “Scenario 2”). 
With respect to baseline patient and tumour characteristics, RW patients differed consider-
ably from trial subjects (Table 3.1). Higher median age and hypopharyngeal localisation of 
carcinomas, unfavourable prognostic characteristics, were more common in the RW RT+C 
population than in the trial population. Progression-free survival (PFS) and overall survival 
(OS) results following RT+C were worse in daily practice than in the corresponding group in 
the trial.11,38
Model structure and transition probabilities
A Markov model was constructed using TreeAge Pro 2009 Suite (TreeAge software, Inc, Wil-
liamstown, MA) to estimate clinical and cost outcomes of first-line treatment with RT+C vs. 
RT for patients diagnosed with locally advanced oropharyngeal, hypopharyngeal or laryn-
geal SSC. The model simulates transition through the following health states: alive without 
progression (A), alive following progression (B) and dead (C) (Figure 3.1). Time dependent 
transition probabilities were derived from patient-level progression-free and overall survival 
results from the trial. At a cycle length of 1 month, the model simulates patients transition-
ing to any health state once monthly, according to changes in their clinical condition (no 
change, progression or death). A half-cycle correction was applied to reflect the fact that 
transitions between health states occur on average halfway through the cycle, rather than 
at the beginning or the end. Patients in the alive-without-progression state (A) may stay in 
that phase (tp1), progress (tp2), or die (tp5). Patients in the alive-following-progression state 
(B) may stay in that phase (tp3), or die (tp4).
Incremental cost per QALY gained for RT+C over RT was the primary outcome measure. In-
cremental costs per life year gained (LYG) are also reported. Transition probabilities were de-
rived from PFS and OS data of the trial, without (scenario 1) and with (scenario 2) correction 
for the poorer PFS and OS observed in daily practice. For both scenarios, cost-effectiveness 
and cost-utility estimates are reported for 5-year, 10-year and lifetime horizons, without and 
with discounting. Discounting is a process by which future costs and effects are assigned a 
lower value, thereby incorporating time preference into the model. Future costs and effects 
were discounted at 4 and 1.5%, respectively, consistent with current Dutch guidelines.50 Our 
model was developed in collaboration with clinical experts and validated by comparing the 
model outputs with trial results.
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scenario 1
In scenario 1, transition probabilities were based on (1) the progression-free survival curve to 
estimate tp1 and (2) the survival before progression curve to estimate tp5, and (3) the updated 
survival following progression curve to estimate tp4, supplemented with Dutch life tables for 
extrapolated transition probabilities after 5 years. Dutch vital statistics were combined with 
25% excess mortality, since Van der Schroeff et al.51 showed conditional long-term survival 
of Dutch SCCHN patients to remain poorer compared to age and sex-matched counterparts 
in the general population. After four years in the progression health state (B) the transition 
probability was assumed to equal Dutch age-matched excess-adjusted background mortal-
ity. The average life expectancy of patients without progression after 5 years was assumed to 
be equal for both treatment arms. Furthermore, after 5 years of follow-up the probability of 
progression was assumed to be negligible and equal in both treatment arms.
The cumulative survival data were converted to time dependent transition probabilities 
using the following formula:
 
l  
A 
Alive without 
progression 
 
B 
Alive following 
progression 
 
C 
Dead 
 
 tp
2
  tp
4
 
 tp
5
 
 tp1 tp3  tp6 
Figure 3.1. Schematic of the Markov model.
The Markov model assumes that a patient is always in one of three discrete health states: A (alive 
without progression), B (alive following progression) or C (dead). Events are represented as transitions 
from one state to another:
tp1 = transition probability of staying in state A (alive without progression)
tp2 =  transition probability of moving from state A (alive without progression) to state B (alive follow-
ing progression): estimated by subtracting tp5 and tp1 from 1
tp3 =  transition probability of staying in state B (alive following progression): estimated by subtracting 
tp4 from 1
tp4 =  transition probability of moving from state B (alive following progression) to state C (dead)
tp5 =  transition probability of moving from state A (alive without progression) to state C (dead)
tp6 =  all patients entering state C (dead), stayed in state C (absorbing state)
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Hoofdstuk VII, p98: 
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En op dezelfde pagina, in de onderste zin (deze stond dubbel in de proef, maar moet 
gewoon enkel, zoals hier en in het origineel aangeleverde bestand!!!): 
 
 ̂(  )  
where Pt and Pt-1 denote the cumulative probability of surviving at the end of times t and t-1, 
respectively; Pt denotes the transition probability for time t. After 5 years, the probability of 
progression (tp2) was assumed to be zero.
scenario 2
Scenario 2 differs from scenario 1, on the premise that all RW patients had a less favourable 
prognosis than patients in the clinical trial. As was shown in the outcomes research, RW pa-
tients treated with RT+C had less favourable prognostic characteristics (age, disease stage, 
tumour site) than the trial patients or the RW RT patients (see chapter I). For scenario 2, this 
was assumed to result from confounding by indication. This scenario reflects the RW costs 
and effects of RT+C, as compared to the RW costs and effects of RT for fictitious patients 
with prognostic characteristics conform the RW RT+C population. The prognosis of patients 
was adjusted downwards, without altering the relative effect of the two treatments.
In order to do this, patients in both arms were considered to progress and die 1.5 times 
earlier than patients in the same treatment arm of th  trial. The factor 1.5 refl cts the dif-
ference between the trial survival curve of patients treated with RT+C11,38 and the outcomes 
research survival curve of RW patients treated with RT+C (chapter II). Hazard of progression 
and death were equally reduced for both treatment arms, combining trial outcomes on 
efficacy with real-world information on prognosis.52,53
Model input—health state utilities
Since quality of life was not measured in the trial, health utility scores for the base case were 
derived from a study among the nursing staff from British oncology centres (n=50), using 
EQ-5D.54 Utility scores are values reflecting the preferences for different health outcomes 
on an interval scale from zero to one. Utilities were estimated for 11 health states, 9 of 
which described toxicities, based on the National Cancer Institute common toxicity criteria 
for adverse events. The two remaining health states correspond to treatment success and 
treatment failure.
For the cost-effectiveness analysis, the utility estimates for the “progression-free state” (A) 
and the “progressed state” (B) were assumed to correspond to the utilities of “treatment 
success” (0.862) and “treatment failure” (0.284), respectively. Utility experienced during 
treatment was assumed to be a weighted average, derived by assigning a utility score to 
each patient within the trial, based on experienced toxicities per person per treatment arm 
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and average event duration. In case of multiple simultaneous toxicities, the toxicity with the 
lowest utility was used to inform the quality of life analyses. Utilities associated with adverse 
event health states ranged from 0.101 (grade IV haematological toxicity) to 0.659 (range of 
grade 0–1 toxicities).
Model input—costs
For CE modelling purposes, total treatment costs were assumed to take place in the first 
Markov cycle. The cost analysis was conducted using a hospital perspective. Costs were 
obtained by multiplying the quantity of healthcare resources consumed with the unit costs. 
Resource consumption was based on actual use in the outcomes study and included RW 
patient-level cetuximab use, RT, inpatient hospital days, intensive care days, outpatient 
visits, daycare treatments, consultations by telephone, laboratory services, medical imaging 
services, medical tests and procedures and pathology. Unit costs calculations of inpatient 
hospital days and intensive care days, outpatient visits, daycare treatments and consulta-
tions by telephone were based on detailed microcosting studies reflecting full hospital 
costs, including overhead costs.55-57 Resource use of radiotherapy, imaging services, tests, 
procedures and pathology was valued using tariffs issued by the NZa (Dutch Healthcare 
Authority). Costs for laboratory services were based on expert opinion. Costs were grouped 
into “treatment costs”, “follow-up costs” (after treatment, before progression) and “post-
progression costs”. Costs were reported in 2011 Euros. Detailed cost input and results are 
published as a supplement to this manuscript.
Mean total treatment costs in the RT+C and in the comparator group were estimated at 
€24,714 (SD €9,695) and €12,862 (SD €11,713), respectively. During the First 2 years of 
follow-up, monthly costs of €597 were applied. This estimate was derived from our out-
comes research and independent of treatment group. In subsequent cycles, from year 3 to 
5, no data from outcomes research were available. Here, a monthly cost of follow-up of €57 
was estimated, based on expected resource use according to current Dutch guidelines.34-36
Mean total post-progression costs gathered in our RW study were estimated at €18,244 (SD 
€30,475) per patient and assumed independent of treatment group. Mean duration of stay 
in health state B (alive following progression) was 6.75 months, resulting in a cost estimate 
of €2,703 per cycle in state B.
sensitivity analyses
For each scenario and for each time horizon, univariate sensitivity analyses were performed 
to examine the impact of alternative parametric assumptions on the estimated incremental 
cost-effectiveness ratios (ICERs), without and with discounting. Parameters were: hazard 
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ratio for PFS corresponding to the lower (scenario B) and higher limit (scenario C) of the 95% 
confidence interval found in the pivotal trial, indirect medical costs (scenario D), drug spill-
age (scenario E), costs of follow-up and disease progression (scenario F) and utility scores 
based on outcomes study results (scenario G). Parameter inputs for all sensitivity analyses 
are presented in Table 3.4.
A probabilistic sensitivity analysis (PSA) explored effects of the joint uncertainty across 
model input parameters in a single analysis. Each model parameter was assigned a unique 
probability distribution based upon estimates of uncertainty (Table 3.2). Monte Carlo simu-
lations (10,000 cycles) yielded distributions of lifetime costs and health outcomes for each 
scenario. PSA results are presented per scenario as incremental cost-effectiveness planes 
and acceptability curves.
results
Output of the Markov model matches the results of the trial (Figure 3.2) and is combined 
with RW data to estimate RW cost-effectiveness. Expected discounted costs and health 
outcomes are reported for both scenarios and three time horizons. All scenarios and time 
horizons show the addition of cetuximab to RT result in increased costs, while yielding 
additional LYs and QALYs (Table 3.3). The incremental costs gained range from €14,624 to 
€38,543 per QALY gained and from €11,640 to €32,405 per LYG.
sensitivity analyses
ICERs are robust for all alternative assumptions with the exception of adaptation of the 
hazard ratio for PFS to the higher limit of the 95% confidence interval found in the trial 
(scenario C) (Table 3.4).
Scatter plots reveal outliers in the lower right quadrants of the cost-effectiveness planes, 
due to bootstrapping of the treatment cost input (Figure 3.3). At a willingness to pay of 
€80,000 per QALY gained, a threshold suggested by the Dutch council for Public Health and 
care (RVZ)58, the acceptability curves (Figure 3.4) of the different scenarios show probabili-
ties between 0.76 and 0.87 of RT+C being cost-effective when compared to RT.
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Figure 3.2. Model validation; undiscounted results from modelled OS versus trial OS, per treatment 
group.
To test the internal validity of the Markov model, for both treatment strategies the modeled survival 
results (blue and purple lines) were compared with the observed survival results from the clinical trial 
data (red and green lines).
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Figure 3.3. Cost-effectiveness planes for RT+C (radiotherapy+cetuximab) versus RT alone, by scenario.
These cost-effectiveness planes show the incremental cost-effectiveness point estimates (red dots) as 
well as the bootstrapped incremental costs and effect pairs (blue dots). These scatter plots illustrate 
the uncertainty surrounding the estimates of expected costs and effects of RT+C compared to RT 
alone, for two scenarios and three time horizons.
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dIsCussIon
Cost-effectiveness results of both base case scenarios suggest that RT+C therapy provides 
good value for money when compared to RT. As cetuximab increases survival, the incre-
mental costs per QALY gained decrease along extended time horizons. Incremental costs per 
QALY are higher for scenario 2 than for scenario 1. The RW study shows that patients in the 
RT+C group had relatively poor prognostic characteristics; it is likely the ICERs of scenario 2 
better reflect cost-effectiveness of RT+C in daily practice than scenario 1.
Cost-effectiveness of RT+C has been previously reported.59-62 Using patient data from EMR 
62202-006 as a starting point for CE modelling, Brown et al. performed analyses for Belgium, 
France, Italy, Switzerland and England, with country-specific unit cost data.61 Based on clini-
cal expert opinion, medical resource use from the Bonner trial was translated to country-
specific estimates. Costs were determined from the applicable health system perspective or 
major national payer perspective. For patients alive at the end of the trial, costs and effects 
were extrapolated using parametric survival models. It was assumed some patients had 
been cured and would therefore never experience progression or death related to SCCHN.
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Cetuximab+RT, scenario 2, horizon = lifetime
Cetuximab+RT, scenario 1, horizon = 10 year
Cetuximab+RT, scenario 2, horizon = 10 year
Cetuximab+RT, scenario 1, horizon = 5 year
Cetuximab+RT, scenario 2, horizon = 5 year
Figure 3.4. Cost-effectiveness acceptability curves for RT+C (radiotherapy+cetuximab) versus RT alone, 
by scenario.
These acceptability curves show the probability that RT+C is cost-effective compared with RT alone, 
for a range of monetary values that a decision-maker might consider the maximum acceptable cost-
effectiveness ratio.
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With a lifetime horizon and 3.5% discounting of costs and effects, estimated ICERs ranged 
from €7,538 (Italy) to €10,836 (France) per QALY. In our scenario 1, which best resembles 
that scenario (lifetime horizon, discounting 4% for costs, 1.5% for effects), we calculated an 
ICER of €14,624 per QALY. The difference is explained by the different model assumptions61 
and the measurement of actual Dutch RW costs vs. costs based on trial data, clinical practice 
norms and expert opinion.
Limitations of our outcomes study were discussed elsewhere (chapter II) and include relying 
on retrospective chart review to obtain RW data. Information was collected in only two large 
academic hospitals. As head and neck cancer care in the Netherlands is highly centralised, 
treatment there is considered standard practice.13
Furthermore, the combined use of RW and trial data was required to obtain effect estimates, 
due to the lack of a suitable comparator group in daily practice (chapter II). Such a synthesis 
approach has been taken more often to inform cost-effectiveness modelling52,53, yet this 
does not solve the issues surrounding the paucity of data on RW effectiveness.
Selection and matching of patient samples for resource use estimates eliminated part of 
the significant differences in baseline characteristics between treatment groups in our 
outcomes study. However, selective allocation to treatment in daily practice limited our 
options for near-perfect matching. In RW, hypopharyngeal or oropharyngeal carcinomas 
are more often treated with RT+C, while laryngeal carcinomas are more often subject to 
RT treatment alone. Although laryngeal localisation of SCCHN is associated with improved 
clinical outcomes and prognosis, it is unlikely this resulted in a bias in resource use between 
groups beyond initial treatment. Next to treatment costs, costs relating to follow-up and 
progression were determined for the patient group as a whole.
Uncertainty around the outcome estimates, reflected in the cost-effectiveness planes was in 
part determined by the small patient sample size.
We chose a hospital perspective for cost estimates. While indirect costs within the health-
care system are evaluated in a univariate sensitivity analysis, non-medical costs were not 
assessed. For RW patients receiving RT+C included in our study, inclusion of productivity 
costs would most likely not alter the conclusions. The mean age of these patients is 65 years; 
few of these patients are expected to return to work.
Since current modelling is partly based on effect estimates obtained in a clinical trial, no 
conclusions can be drawn directly regarding the incremental effectiveness of cetuximab 
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in daily clinical practice. However, current results show RT+C is a potentially cost-effective 
treatment option for patients with LA SSCHN, for each of the scenarios. Presented data, in 
addition to data on appropriate use of the drug (chapter II), informs decisions on continued 
reimbursement of cetuximab for locally advanced SCC of the head and neck.63
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AbstrACt
For patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck 
(R/M SCCHN), chemotherapy can prolong life and alleviate symptoms. However, expected 
gains may be small, not necessarily outweighing considerable toxicity and high costs. Treat-
ment choice is to a large extent dependent on preferences of doctors and patients and data 
on these choices are scarce. The purpose of this study is to obtain real-world information on 
palliative systemic treatment and costs of R/M SCCHN in the Netherlands.
In six Dutch head and neck treatment centres, data were collected on patient and tumour 
characteristics, treatment patterns, disease progression, survival, adverse events, and re-
source use for R/M SCCHN, between 2006 and 2013.
Hundred and twenty-five (14%) out of 893 R/M SCCHN patients received palliative, non-
trial first-line systemic treatment, mainly platinum+5FU+cetuximab (32%), other platinum-
based combination therapy (13%), methotrexate monotherapy (27%) and capecitabine 
monotherapy (14%). Median progression-free survival and overall survival were 3.4 and 6.0 
months, respectively. Thirty-four (27%) patients experienced severe adverse events. Mean 
total hospital costs ranged from €10,075 (±€9,891) (methotrexate monotherapy) to €39,459 
(±€21,149) (platinum+5FU+cetuximab). Primary cost drivers were hospital stays and anti-
cancer drug treatments.
Major healthcare utilisation and costs are involved in systemically treating R/M SCCHN 
patients with a limited survival.
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IntroduCtIon
In the Netherlands, 2,970 new cases of head and neck cancer were diagnosed in 2011, ap-
proximately 1 per 6,000 inhabitants.7 In up to 90% of cases, this concerns squamous cell car-
cinoma (SCCHN).64 Approximately 17% of SCCHN patients develop local tumour recurrence, 
10% of patients develop regional tumour recurrence and 11% progress to distant metastatic 
disease.65 Distant metastases are present at initial diagnosis in 1.8% of patients.65 Median 
survival for patients with recurrent and/or metastatic SCCHN (R/M SCCHN) is 6–9 months.66
For some patients with locoregional tumour recurrence, surgery or radiotherapy may still 
cure the disease.67 For patients with non-curable locoregional tumour recurrence and 
patients with distant metastasis, palliation may be offered by surgery, radiotherapy, photo-
dynamic therapy (PDT), or systemic treatment.
Radiotherapy may be used for locoregional recurrent tumours for radiation naïve patients 
or when re-irradiation is possible, typically with curative intent. Radiotherapy is also the 
mainstay therapy to treat symptomatic bone metastases. Systemic treatment may be used 
for the palliative treatment of locoregional recurrent disease and/or distantly metastasised 
tumours. However, this treatment is only considered in case of good performance status 
and symptoms related to tumour growth. The primary aim of palliative chemotherapy is to 
alleviate symptoms.34-36
Active pharmaceutical agents registered for palliative treatment in R/M SCCHN include 
the platinum compounds (cisplatin and carboplatin), 5-fluorouracil (5FU), methotrexate, 
taxanes, bleomycin, and the monoclonal antibody cetuximab.37 They can be used as mono-
therapy or in various combination regimens. No new compounds have been identified in the 
past 5 years that demonstrate clinical benefit in late stage clinical trials.
Historically, the usual first-line treatment for incurable SCCHN has been combination chemo-
therapy with cisplatin and 5FU. For clinically fit patients (performance score 0–1), interna-
tional guidelines37,68 advise treatment with platinum+5FU+cetuximab. Cetuximab, an EGFR 
inhibitor added to platinum-5FU, increased overall survival (median 10.1 vs. 7.4 months) 
and progression-free survival (median 5.6 vs. 3.3 months) in a randomised controlled phase 
III trial.12 In November 2009, the scientific committee (CieBOM) of the Dutch Association for 
Medical Oncology (NVMO) considered addition of cetuximab to platinum-5FU to provide 
added therapeutic benefit for clinically fit patients with R/M SCCHN.69
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Treatment with single agents may be offered to patients who may not tolerate combination 
chemotherapy. For these patients, Dutch guidelines recommend methotrexate monother-
apy. Although response percentages with methotrexate are lower than with platinum-5FU, 
overall survival is similar.70
Due to possible side effects and limited clinical benefit of palliative systemic treatment in 
R/M SCCHN, treatment choice is, to a large extent dependent on individual preferences 
of doctors and their patients. In the Netherlands, a lack of data exists on daily practice 
treatment patterns, survival, adverse events and costs associated with management of R/M 
SCCHN. The aim of this study is to provide insight into these outcome measures.
Methods
data collection
More than 90% of SCCHN patients are treated in one of the head and neck treatment centre13, 
making head and neck cancer care a highly centralised field of medicine in the Netherlands. 
A retrospective, observational study was conducted in six of a total of eight Dutch head and 
neck treatment centres. Patients were identified from hospital and pharmacy databases.
Medical charts were reviewed for patients diagnosed with recurrent and/or metastatic (M+) 
squamous cell carcinoma of the head and neck (ICD-O C01–C14 and C30–C32) between 
January 1, 2006 and July 3, 2013. Recurrence was defined as occurring within 2 cm of the 
original tumour or lymph node site and within 5 years after primary treatment of the initial, 
usually locally advanced, tumour. Data on all local and systemic treatments were recorded 
on case report forms. For all study patients with at least one line of palliative, non-trial sys-
temic treatment, additional patient and tumour characteristics, treatment details, resource 
use and clinical outcomes were collected. Information on treatment history was collected 
as well, but not used for selection purposes. Patients who only received systemic treatment 
in a clinical trial (n=20), were excluded from this extensive data collection since we aimed to 
present real-world, daily practice treatment patterns and outcomes. For patients treated in 
trials, management and therefore resource use are usually guided by the trial protocol and, 
therefore, not representative of daily practice.
Comorbidity was determined from medical records, measured at baseline, using the up-
dated Charlson comorbidity index. This index is valid for head and neck cancer patients and 
predicts the 1-year in-hospital mortality based on comorbidity.71,72
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Clinical outcomes
Overall survival (OS) was defined as the duration between date of treatment start (for the 
first palliative, systemic, non-trial treatment) and date of death as registered in the hospital 
record. For none of the patients a cause of death other than head and neck cancer was 
registered. Progression-free survival (PFS) was defined as the time from treatment start to 
disease progression, defined as: (1) clinical or radiological progression of recurrent tumour 
and/or distant metastases; (2) start of new treatment (with the exception of treatment 
change due to toxicity); or (3) death, whichever occurred first. A second primary tumour 
was not classified as disease progression.
Adverse events (AEs) reported in the patient chart and graded by a physician were recorded 
using the Common Terminology Criteria for Adverse Events (case report form based on CTC 
version 4.03). Adverse events for which no grade was provided were recorded as severe 
adverse events if they resulted in hospital admission or dose reduction, postponement or 
change of treatment. No AE information was derived from laboratory values or administered 
treatments.
economic outcomes
Resource use included inpatient hospital days, daycare hospital admissions, outpatient 
visits, drug usage, radiotherapy, surgery and other invasive procedures, laboratory diagnos-
tics, imaging and pathology. Drug use other than anti-cancer drugs, including treatments 
for adverse events, was determined in a sub-selection of patients (n=49), for reasons of 
feasibility. Mean per patient treatment costs were calculated combining resource use and 
unit costs, derived from literature55,56 or official tariff lists. Treatment costs were calculated 
from start of the respective treatment onwards and include all subsequent resource use. 
Costs are reported from the head and neck cancer centre perspective, in Euros. Unit costs 
are from 2013 or were inflated to reflect the 2013 price level.
Analyses
Descriptive analyses were performed in IBM SPSS Statistics 21. The Kaplan Meier method 
was used for survival estimates.
results
treatment patterns
Eight hundred and ninety-three patients diagnosed with R/M SCCHN were identified (Fig-
ure 4.1), twenty of whom received systemic trial treatment only. If patients received trial 
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treatment at one point in time but non-trial systemic treatment at another point in time, 
these patients were included from start of the non-trial treatment onwards (costs for trial 
treatment are set to €0 from a hospital perspective). Two hundred and seventy-three pa-
tients received no antitumour treatment at all. Hundred and twenty-five patients received 
at least one line of palliative, non-trial systemic treatment and were included in the study. 
Of these 125 study patients, 7 patients had metastasised SCCHN at primary diagnosis and 
118 patients had R/M SCCHN after primary treatment. Ninety-three study patients received 
non-trial systemic treatment as first treatment after diagnosis of R/M SCCHN and 32 study 
patients as second, third or fourth treatment.
treatment characteristics
Multiple treatment modalities were administered (Figure 4.1). The most common first-line 
systemic treatment choices (Table 4.1) were platinum+5FU+cetuximab (n=40, 32%), other 
platinum-based combination therapies (n=16, 13%), methotrexate monotherapy (n=34, 27%) 
and capecitabine monotherapy (n=18, 14%). An example of an “other” first-line drug therapy 
was platinum monotherapy (n=9). Patients treated with first-line platinum-based combina-
tion therapy without cetuximab received platinum+fluorouracil (n=6), cisplatin+gemcitabine 
(n=4), platinum+capecitabine (n=2), and other platinum combination regimens (n=4).
No treatment
 273 (31%)
Surgery 372
 (42%)
Radiotherapy
105 (12%)
Chemotherapy 
119 (13%)
Other
24 (3%)
R/
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  S
CC
H
N
89
3 
(1
00
%
)
1st treatment modality 2nd treatment modality
No treatment 198 (22%)
Surgery 37 (4%)
Radiotherapy 100 (11%)
Chemotherapy 19 (2%)
Other 18 (2%)
No treatment 75 (8%)
Radiotherapy 10 (1%)
Chemotherapy 32 (4%)
Other 2 (0%)
No treatment 15 (2%)
Surgery 2 (0%)
Radiotherapy 1 (0%)
Chemotherapy 4 (0%)
Other 2 (0%)
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9
2
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11
No treatment 121 (14%)
Surgery 17 (2%)
Radiotherapy 19 (2%)
Chemotherapy 15 (2%)
Other 2 (0%)
No treatment 17  (2%)
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No treatment 26 (3%)
Surgery 2 (0%)
Radiotherapy 7 (1%)
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No treatment 5 (1%)
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Radiotherapy 2 (0%)
Chemotherapy 0 (0%)
Other 0 (0%)
Further treatments
No treatment 74  (8%)
Surgery 4 (0%)
Radiotherapy 15 (2%)
Chemotherapy 12 (1%)
Figure 4.1. Treatment patterns for R/M SCCHN patients. The numbers with the dotted lines represent 
eligible patients, therefore included in the study. For the sake of readability, treatments after the third 
line were not further specified.
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The percentage of patients treated with platinum+5FU+cetuximab has increased steeply 
since 2010 (data not presented), following a positive decision on reimbursement. In patients 
receiving platinum+5FU+cetuximab, 40 patients (32%) received this combination in first line, 
4 (10%) in second line, and 0 (0%) in subsequent treatment lines. Other platinum-based com-
bination therapies were administered to 16 patients (13%) as first-line therapy and to 1 (3%) 
in second line. This regimen was administered as subsequent treatment to 1 patient (14%).
In the second systemic treatment line, methotrexate monotherapy was the most frequently 
prescribed drug regimen.
Patient and tumour characteristics
Patient and tumour characteristics are depicted in Table 4.2. Seventy-four percent of pa-
tients were male and the median age was 60. Unfortunately, performance status was not 
routinely registered in all medical charts.
survival measures
Table 4.3 shows PFS and OS per treatment group, from treatment start onwards, without 
correction for baseline characteristics. Median PFS and OS for the cohort studied were 3.4 
and 6.0 months, respectively. Due to heterogeneity, possibilities for matching on baseline 
characteristics were limited and did not solve the issue of confounding by indication. There-
fore, survival estimates should be interpreted as descriptive of the respective treatment 
groups rather than measures of treatment effect. Wide, overlapping confidence intervals 
reflect non-significance of the survival differences, due to small size of the treatment groups.
Due to heterogeneity, possibilities for matching on baseline characteristics were limited and 
did not solve the issue of confounding by indication. Therefore, survival estimates should 
be interpreted as descriptive of the respective treatment groups rather than measures of 
treatment effect.
table 4.1: Drug treatment in daily practice
treatment First systemic 
treatment line
(n=125)
second systemic 
treatment line
(n=39)
Platinum + 5FU + cetuximab 40 (32%) 4 (10%)
Other platinum-based combination therapy 16 (13%) 1 (3%)
Methotrexate monotherapy 34 (27%) 15 (38%)
Capecitabine monotherapy 18 (14%) 7 (18%)
Other 17 (14%) 12 (31%)
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Adverse events
In the initial palliative treatment line, 34 patients (27%) experienced severe adverse events, 
defined as any adverse events with registered record of: CTC AE grade ≥3, treatment dose 
reduction(s), postponement or change of treatment, and/or hospital admission. Twenty-one 
hospital stays (4% of total hospital stays) resulted from AEs, for a total of 16 patients (13%). 
Median duration of these hospital stays was 8 days. Severe adverse events were observed 
more often in patients receiving combination therapy than methotrexate or capecitabine 
monotherapy (Table 4.4).
Costs
Table 4.5 presents mean costs per treatment group and cost category. Mean total costs 
per patient were €24,211 (±€22,432), ranging from €10,075 (±€9,891) (methotrexate 
monotherapy) to €39,459 (±€21,149) (platinum+5FU+cetuximab). Primary cost drivers are 
hospital stays and drug costs.
table 4.3: Overall survival and progression free survival per treatment group
First systemic treatment line overall survival
Median (95% CI)
Progression-free survival
Median (95% CI)
Platinum+5FU+cetuximab (n=40) 6.7 (4.4 – 8.9) 4.8 (3.2 – 6.4)
Other platinum-based combination therapy (n=16) 10.5 (5.8 – 15.1) 4.0 (3.5 – 4.4)
Methotrexate monotherapy (n=34) 4.8 (3.5 – 6.1) 3.1 (1.9 – 4.3)
Capecitabine monotherapy (n=18) 3.7 (1.4 – 5.9) 1.7 (1.5 – 1.9)
Other (n=17) 5.7 (1.2 – 10.3) 1.6 (0.3 – 2.9)
All (n=125) 6.0 (4.2 – 7.8) 3.4 (2.3 – 4.5)
Due to heterogeneity, possibilities for matching on baseline characteristics were limited and did not 
solve the issue of confounding by indication. Therefore, survival estimates should be interpreted as 
descriptive of the respective treatment groups rather than measures of treatment effect.
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table 4.4: Adverse events
First systemic 
treatment regimen
severe 
adverse 
events 
 
n (%)
reported severe adverse 
events
CTC AE grade ≥III, patient 
was hospitalized, and/or 
treatment was adapted for 
toxicity reasons
reported non-severe adverse 
events
CTC AE grade I and grade IIa
Cisplatinum +5FU + 
cetuximab (n=40)
19 (48%) Anorexia, cardiac toxicity, 
ear and labyrinth disorder, 
febrile neutropenia, hand-
foot syndrome, nausea, oral 
mucositis, thrombocytopenia, 
pneumonia, renal toxicity and 
skin and subcutaneous tissue 
disorders.
Acneiform rash, constipation, 
diarrhea, dehydration, dry 
skin, fatigue, erythema 
multiforme, hand-foot 
syndrome, hypokalemia, 
mucositis, nausea, other skin 
and subcutaneous tissue 
disorders, ototoxicity, pain, 
papulopustular rash, pruritus, 
renal disorders and vomiting.
Other platinum-
based combi-nation 
therapy
(n=16)
5 (31%) Diarrhea, febrile neutropenia, 
renal disorder and vomiting.
Anorexia, dysphagia, dry skin, 
fatigue, hand-foot syndrome, 
leukopenia, nausea, pneumonia 
and vomiting.
Methotrexate 
monotherapy (n=34)
5 (15%) Liver toxicity, malaise, 
neutropenia, and oral 
mucositis.
Dysphagia, pneumonia, pain 
and fatigue.
Capecitabine 
monotherapy (n=18)
0 (0%) NONE REPORTED NONE REPORTED
Other (n=17) 5 (29%) Renal disorders, cardiac 
disorder, fatigue and 
constipation.
Alopecia and nausea.
a Although these adverse events were only recorded if their severity had been assessed by a physician 
and reported in the patient file, we could not make a clear distinction between grade I and grade II 
adverse events due to non-specificity in reporting habits (reading, for example, “headache grade I/II” 
or “low-grade headache”).
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dIsCussIon
Relatively few (14%) patients in the Netherlands with R/M SCCHN received palliative 
systemic treatment. Patient and treatment heterogeneity as well as small sample size pre-
vented us from statistically comparing treatment costs and outcomes. The most frequently 
prescribed first-line drug regimen consists of cisplatin+5FU+cetuximab, followed by metho-
trexate monotherapy. In the second systemic treatment line, methotrexate monotherapy 
is the most frequently prescribed drug regimen. Treatment with single agents is associated 
with fewer adverse events than combination treatments. The choice of treatment is hospital 
dependent (stratified data not presented for confidentiality reasons).
A multi-country survey of 256 head and neck specialists in France, Germany, Italy and Spain 
showed that 72% of R/M SCCHN patients were treated with first-line combination therapy: 
65% of these patients were treated with cetuximab containing regimens and 35% with other 
platinum-based combination chemotherapy. Combination treatment with cetuximab is a 
common first-line choice in these countries (data published as abstract only).73 In the Neth-
erlands, head and neck cancer specialists seem to take a more conservative approach with 
respect to prescribing chemotherapy in general and platinum+5FU+cetuximab in particular 
(32% of all palliative, first-line, non-trial, systemic regimens). However, the difference could 
be explained by different study designs, recall bias and possibly a preselected patient popu-
lation of the head and neck specialists in the multi-country survey. It is likely that survey 
results provide less reliable information on treatment allocation than medical chart review 
for all diagnosed R/M SCCHN patients.
For the study population as a whole, median overall survival from diagnosis was 6.0 months. 
Patients treated with combination platinum regimens other than platinum+5FU+cetuximab 
live longer, possibly due to their lower age and a higher proportion of tumours that are 
relatively sensitive to treatment, such as nasopharyngeal carcinomas. Nasopharyngeal 
carcinomas are a distinct subgroup known to respond differently to treatment than SCCHN 
in other localisations. They constitute a relatively favourable prognostic group.74
Survival of 95% CIs of patients treated with platinum+5FU+cetuximab in Dutch daily practice 
(median OS 6.7 months, 95% CI 4.4–8.9, median PFS 4.8, 95% CI 3.2–6.4) overlap with those 
from the EXTREME trial12 (median OS 10.1 months, 95% CI 8.6–11.2, median PFS 5.6, 95% 
CI 5.0–6.0) and a retrospective, observational study from Portugal75 (median OS 11 months, 
95% CI 8.7–13.3, median PFS 8, 95% CI 6.1–9.9).
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The data presented are the only published evidence on the costs of systemically treated 
R/M SCCHN in the Netherlands. Hospital stays and chemotherapeutics are the main cost 
drivers. We report mean costs of management of systemically treated R/M SCCHN of € 
24,211. These costs are considerable, yet not as high as published end-of-life healthcare 
consumption for various cancers in a US study population (inpatient and outpatient costs 
$70,956, in 2009 USD).76 For the Netherlands, mean costs of late stage cancer management 
have not been explored in great detail.
Costs incurred for cancer care do not automatically result in better outcomes.77 Policy mak-
ers, oncologists and public media increasingly express the need to curtail the rise in costs 
of cancer care. Suggested changes include limiting the use of chemotherapy combination 
regimens for metastatic cancers and limiting chemotherapy on the basis of performance 
status.78 Even disregarding the costs, extensive use of chemotherapy at the end of life can 
be an important signal of poor quality care.79 Our study shows relatively few R/M SCCHN pa-
tients to receive systemic palliative treatment, which might reflect careful patient selection 
due to the small expected gains of such treatments, considerable toxicity and high costs.
Still the presented cost estimates raise the question about the value for money that is 
achieved. Very little is known about this for the R/M SCCHN patient population. There is 
relatively little high-quality research in these patients, possibly due to rarity of the disease in 
western countries, heterogeneity within the patient population (amongst others in tumour 
localisation), lack of new treatment compounds, and difficulties associated with quality of 
life measurements in end stage cancer patients. To our knowledge, no pharmacoeconomic 
studies have been published about systemic R/M SCCHN treatments except for cost-effec-
tiveness studies regarding platinum+5FU+cetuximab versus platinum+5FU.80,81
Analysis of the cost-effectiveness of systemic treatments in daily practice requires informa-
tion about (changes in) health-related quality of life and a large enough patient population 
to compare treatment strategies while correcting for confounding by indication. Preferably 
these data should be collected within a population-based patient registry, including all 
newly diagnosed patients with head and neck SCC in the Netherlands. Such a register has 
the potential to boost the quality of head and neck cancer research and has a reasonable 
feasibility in the Netherlands due to the centralised nature of head and neck cancer care. 
However, several challenges exist regarding patient identification as well as patient follow-
up in the terminal phase.
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limitations of the study
Squamous cell carcinoma of the head and neck patients form a relatively small and het-
erogeneous population. This limited possibilities to correct for confounding by indication. 
As a result the effect of treatment choice on outcomes could not be assessed and only 
descriptive results were presented.
Furthermore, the level of detail in medical records varied greatly. This prevented uniform 
capture of several variables, such as performance status and adverse events. For example, 
the lack of adverse events seen in patients receiving capecitabine monotherapy could be 
due to a less intensive follow-up since this treatment is self-administered at home. The lack 
of certain anticipated adverse events, such as hypomagnesaemia with the platinum-based 
treatments, results from the data managers recording AEs only when explicitly reported by 
clinicians, without, for example, consulting laboratory values themselves.
Notably, our research was conducted in patients identified through hospital records and 
focused on treatment in a specialised head and neck centre setting. Some 90% of SCCHN 
patients in the Netherlands visit these head and neck centres.13 However, patients who do 
not seek specialised medical care were not included in this study. Therefore, the proportion 
of patients not receiving systemic therapy is likely to be underestimated. Furthermore, two 
out of eight head and neck centres did not participate in the study and might have had 
different treatment patterns. Also, hospital and pharmacy databases can be incomplete, 
especially when patients had only few hospital contacts.
Resource consumption of interventions offered outside the study hospital, i.e. for patients 
referred to other (outpatient) clinics for drug administration, was not recorded. Therefore, 
presented cost estimates reflect the costs incurred within the head and neck treatment 
centres. Cost utility of treatments for R/M SCCHN could not be assessed due to a lack of 
comprehensive outcomes reporting, specifically on quality of life.
ConClusIon
For systemically treated patients with R/M SCCHN, healthcare utilisation and associated 
costs are considerable, while the survival is limited.
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treatment and survival of non-small cell lung cancer 
patients in the netherlands
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AbstrACt
objectives
The aims of this study are to provide insight in treatment patterns in the Netherlands and 
to analyse differences in survival between academic and non-academic hospitals. Current 
results will show the state of non-small cell lung cancer (NSCLC) care and survival in the 
Netherlands and will serve as foundation for future cost- and cost-effectiveness studies of 
treatment alternatives.
Material and Methods
Data on treatment patterns in Dutch hospitals was obtained from four, not randomly 
selected hospitals (two academic, two non-academic). A random sample of unselected 
patients diagnosed with NSCLC from 31 January 2009 until 31 January 2011 was identified 
through the four hospital databases. Data was obtained on patient characteristics, tumour 
characteristics, treatments and survival outcomes. Additionally, the Netherlands Cancer 
Registry provided data on survival for all Dutch hospitals. We compared overall survival for 
patients treated in different hospital types. We used Kaplan-Meier methods to estimate 
overall survival rates by hospital type and Cox proportional hazards models to estimate 
the relative risk of mortality (expressed as hazard ratios, HRs) and their 95% confidence 
intervals (95% CI) per hospital type, with all non-academic hospitals as the reference group. 
All statistical tests were two-sided and conducted at the 0.05 level of significance.
results
For non-metastasised disease, patients treated in academic hospitals had superior overall 
survival as compared to patients treated in non-academic hospitals. Median survival was 2.66 
years (95% CI 2.14-3.18) in academic versus 1.83 years (95% CI 1.73-1.93) in non-academic 
hospitals. For metastasised disease, median survival was 0.41 years (95% CI 0.35-0.48) in 
academic versus 0.39 years (95% CI 0.38-0.41) in non-academic hospitals.
Conclusion
Patients treated in academic hospitals have better median overall survival than patients 
treated in non-academic hospitals, mainly due to differences in overall survival for patients 
treated with radiotherapy, systemic treatment or combinations.
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IntroduCtIon
Incidence as well as mortality from lung cancer is relatively high in the Netherlands. In 2012, 
lung cancer incidence was 66.1 in males and 44.5 in females per 100.000 person years 
(European Standardised Rates). Lung cancer mortality was 59.6 males and 35.6 females per 
100.000 person years.82
More than 85% of lung cancers are from the non-small cell type.7 Patients in early stage 
of disease (stage I-II) that are eligible for surgery have a relatively good prognosis. Even 
so, the estimated 5-year survival for early stage patients is only between 45% and 50%. 
Unfortunately, only 20% of the patients is eligible for a tumour resection. For patients that 
are ineligible for resection, stereotactic radiotherapy is the best alternative for surgery, that 
is, if no locoregional metastases are present and if the tumour is located centrally.20
Alternatively, concurrent chemo-radiotherapy is the standard treatment option for inoper-
able non-metastatic patients. There is evidence from a meta-analysis that radiotherapy with 
concurrent chemotherapy reduces locally recurrent disease and mortality compared to 
sequential chemo-radiotherapy.84 In the absence of distant metastases these patients have 
a 5-year survival of 5–30%. Patients in advanced stage of disease (stage IV) are treated with 
combinations of chemotherapeutic agents or targeted therapy. The 5-year survival is 1%.85
Within the Netherlands, differences exist between hospitals with respect to treatment 
and survival of patients with NSCLC. For patients diagnosed with stage I and II NSCLC in 
2001-2006, the probability of tumour resection increased with the surgical experience (lung 
resection volume) of the hospital as well as the available expertise.86 Therefore, minimum 
surgical volumes and various other conditions have been agreed upon to concentrate lung 
resections in specialised centres.87
For stage III NSCLC, probability of receiving combination treatment in the Netherlands was 
highly dependent on hospital as well, but no correlation was demonstrated with defined 
structural hospital characteristics such as teaching status or the availability of radiotherapy 
facilities.86 The same was true for the probability of receiving chemotherapy for stage IV 
NSCLC.88 Unfortunately, it was not reported if and how treatment variability between hos-
pitals affected overall survival.
Apart from the minimum surgical volumes, also broader standards exist for Dutch hospitals 
treating patients with lung carcinoma. They include requirements regarding (multidisci-
plinary) staff composition and available facilities.14 Further, a Dutch evidence-based guide-
70 | Chapter V
line for the diagnosis and treatment of NSCLC exists and (modular) revisions are performed 
regularly to ensure actuality.20
Despite efforts to standardise NSCLC treatments across the Netherlands, differences may 
exist in diagnostic and treatment patterns between hospitals and may result in differences 
in survival. The aims of this study are to provide the reader with more information regard-
ing treatment patterns in the Netherlands and to analyse differences in survival between 
academic and non-academic hospitals. Current results will show the state of NSCLC care 
and survival in the Netherlands and will serve as foundation for future cost- and cost-
effectiveness studies of treatment alternatives.
MAterIAls And Methods
Patients and data
Detailed data on treatment patterns in Dutch hospitals was obtained from four, not randomly 
selected hospitals (two academic, two non-academic). A random sample of unselected pa-
tients diagnosed with NSCLC between 31 January 2009 and 31 January 2011 was identified 
through the four hospital databases. This sample included patients who were referred to 
one of the four selected hospitals from elsewhere without receiving any NSCLC treatment 
before their arrival in the selected hospital. The random selection was performed by listing 
all NSCLC patients in Microsoft Excel, shuffling their order and including them listwise. Clini-
cal data was manually abstracted from medical records and coded by trained data assistants, 
using a web-based case report form. Data was obtained on patient characteristics, tumour 
characteristics, treatments and survival outcomes.
Data from the Netherlands Cancer Registry (NCR) was used to validate tumour histology and 
disease stage collected from the hospital databases, and to update follow-up time. Patients 
who could not be matched reliably to NCR records were excluded from the survival analyses.
Population based NCR data was used to analyse survival differences between academic and 
non-academic hospitals. The NCR provided population based data on all patients diagnosed 
with NSCLC between January 2009 until January 2011, as identified through the automated 
pathological archive (PALGA) and The National Registry of Hospital Discharge Diagnoses. 
Clinical information was manually abstracted from medical records and coded by trained 
NCR data managers, using a national manual and case report form. Data was obtained on 
patient characteristics, tumour characteristics, primary treatment and overall survival.
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Hospital type (academic versus non-academic) represents the type of hospital at diagnosis 
as registered in the NCR. In the four selected hospitals, patients were included only if they 
received treatment and/or follow-up in the study hospital.
Selected tumour histologies included ICD-O (International Classification of Diseases for Oncol-
ogy) codes 8010 to 8035, 8046 to 8230, 8244 to 8246 and 8250 to 8576 (all NSCLC). Presence 
of distant metastasis was recorded following the NSCLC stage classification system in use at di-
agnosis of the tumour, being either the sixth (2009) or the seventh (2010, 2011) TNM edition. 
However, TNM stage can change during the diagnostic period, can differ between clinicians, 
and cannot always reliably be obtained from patient charts. This was a limitation of both the 
data we collected and the NCR data, which we used to validate our stage information. We 
therefore decided not to separate stages I-III, in order to minimise potential misclassification.
As our study design is not subject to the Medical Research Involving Human Subjects Act, 
the Medical Research Ethics Committee of VU University Medical Centre exempted the 
study from ethical appraisal. Informed consent was not required for chart review.
statistical analyses
All analyses were performed in IBM SPSS Statistics 21.
We used descriptive analyses to report treatment patterns. Treatments were allocated 
to the categories ‘aimed at non-metastasised disease’ or ‘aimed at metastasised disease’ 
dependent on disease stage (M0 or M+) at treatment start. For the survival curves, disease 
stage was determined at diagnosis.
Treatments were classified to be either surgery, radiotherapy, systemic treatment (including 
chemotherapy and targeted therapies) or combinations of the above. Chemo-radiation was 
defined as definitive radiotherapy combined with concurrent or sequential systemic treat-
ment.
We compared overall survival for patients in academic hospitals, non-academic hospitals and 
patients in the four selected hospitals, for the following groups: (1) patients with non-met-
astatic NSCLC, (2) patients with metastatic NSCLC, (3) patients treated with primary surgery 
for non-metastatic NSCLC, (4) patients treated with primary surgery for metastatic NSCLC, (5) 
patients treated with primary radiotherapy for non-metastatic NSCLC, (6) patients treated 
with primary radiotherapy for metastatic NSCLC, (7) patients treated with primary systemic 
treatment for non-metastatic NSCLC, (8) patients treated with primary systemic treatment 
for metastatic NSCLC, and (9) NSCLC patients who did not receive anti-tumour treatment.
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We used Kaplan-Meier methods to estimate overall survival rates by hospital type and Cox 
proportional hazards models to estimate the relative risk of mortality (expressed as hazard 
ratios, HRs) and their 95% confidence intervals (95% CI) per hospital type, with all non-
academic hospitals as the reference group, with and without adjustment for age, gender 
and tumour histology and stratifying for disease stage (M0 or M+). All statistical tests were 
two-sided and conducted at the 0.05 level of significance.
results
NCR included 13,992 patients fulfilling the selection criteria, 1,289 (9%) of whom were 
diagnosed in academic hospitals. In the four selected hospitals, data was collected on 
1,067 patients. 58 patients (5.4%) were excluded because they came for a second opinion 
only. Only limited information was available about these patients, since they were treated 
in other hospitals than the four study hospitals. Of the remainder (n=1,009), 170 patients 
(17%) could not be matched reliably to NCR records and were excluded from the survival 
analyses. The distribution of the 1,009 patients over the four study hospitals was 195 (St. 
Antonius Hospital) versus 239 (University Medical Centre Groningen) versus 258 (Medical 
Centre Alkmaar) versus 317 (VU University Medical Centre) patients.
Table 5.1 shows baseline characteristics of both study populations. Distributions of age, 
gender and tumour histology in the four selected hospitals are similar to these distributions 
in the total NSCLC population. The total NSCLC population also includes the patients from 
the four selected hospitals. In the four selected hospitals, a relatively high proportion of 
tumours was classified as clinical stage <IV (n=616, 61% versus 6,552, 47%), mainly due to 
referrals from other hospitals for specialised treatments. In addition to the 363 patients 
diagnosed with stage IV NSCLC at baseline in the four study hospitals, 113 patients initially 
had other stage disease that metastasised during our study period.
WHO performance status and forced expiratory volume in 1 second (FEV1) were often not 
reported in the medical charts (WHO performance status 80,8% and FEV1 76% not reported).
Within the total Dutch population, 9% of patients were diagnosed in academic hospitals as 
opposed to non-academic hospitals. In these academic hospitals, there were less elderly pa-
tients (over 75 years of age, n=239, 19% versus n=3,275, 26% in non-academic hospitals), less 
squamous cell carcinomas (n=327, 25% versus n=3,734, 29%) and less large cell carcinomas 
(n=125, 10% versus 1,757, 14%) as opposed to adenocarcinomas (n=649, 51% versus 5,572, 
44%). In the academic hospitals, relatively many patients (n=644, 50%) were diagnosed with 
stage <IV NSCLC, though not as many as in the four selected hospitals (n=616, 61%).
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total study population, survival
For non-metastasised disease, patients treated in academic hospitals had superior overall 
survival as compared to patients treated in non-academic hospitals (see Figure 5.1a). Median 
survival was 2.66 years (95% CI 2.14-3.18) in academic versus 1.83 years (95% CI 1.73-1.93) 
in non-academic hospitals for non-metastasised disease. For metastasised disease(see Fig-
ure 5.1b), median survival was 0.41 years (95% CI 0.35-0.48) in academic versus 0.39 years 
table 5.1 Baseline characteristics
Four selected 
hospitals (two 
academic, two 
non-academic)
2009-2011 
 
n (%)
total dutch 
population
2009-2011 
 
 
 
n (%)
dutch 
population, 
patients 
diagnosed 
in academic 
hospitals
2009-2011
n (%)
dutch 
population, 
patients 
diagnosed in 
non-academic 
hospitals
2009-2011
n (%)
total patients 1,009 (100) 13,992 (100)* 1,289 (100) 12,698 (100)
Age (years)
<60 272 (27) 3,566 (26) 391 (30) 3,175 (25)
60-74 501 (50) 6,910 (49) 659 (51) 6,248 (49)
≥75 236 (23) 3,516 (25) 239 (19) 3,275 (26)
Gender
Male 660 (65)** 8,841 (63) 780 (61) 8,059 (64)
histology
Adenocarcinoma 490 (49) 6,222 (45) 649 (51) 5,572 (44)
Squamous cell carcinoma 256 (25) 4,062 (29) 327 (25) 3,734 (29)
Large cell carcinoma 101 (10) 1,884 (14) 125 (10) 1,757 (14)
Other histology 33 (3) 407 (3) 48 (4) 358 (3)
Unknown 129 (13) 1,417 (10) 140 (11) 1,277 (10)
Clinical stage
Stage <IV 616 (61) 6,552 (47) 644 (50) 5,904 (47)
Stage =IV 363 (36) 6,887 (49) 588 (46) 6,298 (50)
Unknown 30 (3) 553 (4) 57 (4) 496 (4)
*For five patients, hospital type was not registered.
**For one patient, gender was not registered.
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(95% CI 0.38-0.41) in non-academic hospitals. Overall survival for metastasised disease in 
the selected hospitals was 0.59 years (95% CI 0.46-0.71).
Primary surgery patients, treatment characteristics and survival
Surgery for non-metastasised disease
Out of 616 patients with non-metastasised disease, 268 patients (43.5%) were operated in 
the study hospitals. Including reoperations, a total of 292 surgeries for non-metastasised 
disease were performed during the 2-year study period. Majority of surgeries were lobec-
tomies (66.1%, n=193), followed by wedge resections (10.3%, n=30) and pneumonectomies 
(7.2%, n=21). For 148 operated patients (55.2%), surgery was the only antitumour treatment 
received in the study hospital.
Adjuvant radiotherapy is common in case of R1 or R2 resections. In the study hospitals, 
7.5% of operated patients (n=20) received adjuvant radiotherapy within two months of at-
tempted surgery. Adjuvant systemic therapy is recommended for stage II-IIIA patients with 
a good performance score. Unfortunately it was not known for which proportion of patients 
adjuvant chemotherapy was indicated in the study hospitals, but it was prescribed within 
1a. Crude cumulative survival non-metastasized 
NSCLC
1b. Crude cumulative survival metastasized 
NSCLC
Follow-up duration in years Follow-up duration in years
Blue = four selected teaching hospitals
Green = all academic hospitals
Red = all non-academic hospitals
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Figure 5.1a. Crude cumulative survival non-me-
tastasized NSCLC. 
Blue = four selected teaching hospitals
Green = all academic hospitals
Red = all non-academic hospitals
Figure 5.1b. Crude cumulative survival metas-
tasized NSCLC.
Blue = four selected teaching hospitals
Green = all academic hospitals
Red = all non-academic hospitals
Follow-up duration in yearsFollow-up duration in years
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two months of the surgery to 48 patients (17.9%). Chemo-radiation preceded surgery in 
6.0% of cases (n=16).
Surgery for metastasised disease
Including patients who developed metastasis during the course of their disease (n=113), 41 
patients with metastasised disease were operated (8.6%), receiving a total of 45 operations. 
Most of these surgeries (n=24) were non loco-regional (53.3%), mostly targeting the brain 
(n=9). 46.7% of surgeries (n=21) were loco-regional, most often lobectomy (n=8) or wedge 
resection (n=7).
Survival for surgery patients
For non-metastasised as well as metastasised disease, no significant differences were found 
in overall survival of operated patients (see Figure 5.2). Mean overall survival for patients 
operated for non-metastasised disease, was 3.16 years (95% CI 3.02-3.30) for academic 
hospitals, 3.05 years (95% CI 3.00-3.10) for non-academic hospitals and 2.92 years (95% CI 
2.76-3.09) in the four selected hospitals (median survival unknown, >50% of patients still 
alive at end of follow-up). Median overall survival for patients operated for metastasised dis-
ease was 1.48 years (95% CI 0.12-2.85) for academic hospitals, 1.55 years (95% CI 0.92-2.18) 
for non-academic hospitals and 1.04 years (95% CI 0.48-1.60) in the four selected hospitals.
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Figure 5.2a. Crude cumulative survival non-
metastasized NSCLC, primary surgery patients.
Blue = four selected teaching hospitals
Green = all academic hospitals
Red = all non-academic hospitals
Figure 5.2b. Crude cumulative survival metasta-
sized NSCLC, primary surgery patients.
Blue = four selected teaching hospitals
Green = all academic hospitals
Red = all non-academic hospitals
Follow-up duration in years Follow-up duration in years
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Figure 5.3a. Crude cumulative survival non-
metastasized NSCLC, primary radiotherapy pa-
tients.
Blue = four selected teaching hospitals
Green = all academic hospitals
Red = all non-academic hospitals
Figure 5.3b. Crude cumulative survival metas-
tasized NSCLC, primary radiotherapy patients.
Blue = four selected teaching hospitals
Green = all academic hospitals
Red = all non-academic hospitals
Primary radiotherapy patients, treatment characteristics and survival
Radiotherapy for non-metastasised disease
In addition to the 268 patients operated for non-metastasised disease, 142 patients received 
stereotactic radiotherapy (SBRT). In total, 353 out of 616 patients with non-metastasised 
disease (57.3%) received any type of radiotherapy, including combined modality treat-
ments. Twenty-five patients received locoregional radiotherapy that was classified as being 
of palliative intent (n=25, 7.1%).
Radiotherapy for metastasised disease
Including patients who developed metastasis during the course of their disease (n=113), 
273 patients with metastasised disease were treated with (any) radiotherapy (57.4%, includ-
ing combined modality treatments), 198 of whom received at least one fraction on a distant 
metastasis (72.5%).
Survival for radiotherapy patients
Patients treated with radiotherapy for non-metastasised disease survived significantly 
longer when diagnosed in an academic hospital (median 2.11 years, 95% CI 1.72-2.50) or 
one of the fo r selected study ho pi ls (median 2.20 years, 95% CI 1.77-2.61) as opposed 
Follow-up duration in yearsFollow-up duration in ye rs
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to a non-academic hospital (median 1.64 years, 95% CI 1.55-1.72). For patients treated with 
palliative radiotherapy for metastasised disease, median survival was longest for patients 
from the four selected study hospitals (0.79 years, 95% CI 0.61-0.97) as opposed to patients 
diagnosed in academic (0.45 years, 0.36-0.54) or non-academic (0.13, 95% CI 0.40-0.46) 
hospitals (see Figure 5.3).
Primary systemic treatment patients, treatment characteristics and survival
Systemic treatment for non-metastasised diseases
Two hundred and forty-two patients with non-metastasised NSCLC (39.3%) received sys-
temic treatment in the study hospital (including combined modality treatments). The most 
commonly prescribed drug regimen for non-metastasised disease was gemcitabine plus cis-
platin (n=70, see Table 5.2). Hundred and thirty-seven patients were registered to received 
chemoradiation, defined as systemic treatment with concurrent or sequential definitive, 
loco-regional radiotherapy.
table 5.2 Frequency of prescription of systemic treatment regimens for non-metastasised disease 
(including combined modality treatments)
Treatment Number of patients receiving at  
least one administration of treatment (%)*
Gemcitabine / cisplatin 70 (28.9)
Pemetrexed / cisplatin 59 (24.4)
Vinorelbine / cisplatin 24 (9.9)
Etoposide / cisplatin 22 (9.1)
Gemcitabine / carboplatin 15 (6.2)
Gemcitabine 13 (5.4)
Pemetrexed / carboplatin 10 (4.1)
Docetaxel / carboplatin 7 (2.9)
Docetaxel 6 (2.5)
Vinorelbine / carboplatin 6 (2.5)
Other 14 (5.8)
Unknown 15 (6.2)
* Percentages do not add up to 100, since patients can receive multiple treatments.
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Systemic treatment for metastasised disease
Including patients who developed metastasis during the course of their disease (n=113), 234 
patients with metastasised NSCLC (49.2%) received systemic treatment in the study hospital 
(including combined modality treatments), see Table 5.3. For 50.8% of the patients with 
metastasised disease, no systemic treatment was prescribed in the study hospital. Most 
commonly prescribed drug regimen was pemetrexed with platinum (n=105). For patients 
who did not receive antitumour treatment, reasons are provided in paragraph 3.5.
table 5.3 Frequency of prescription of systemic treatment regimens for metastasised disease
Treatment Number of patients receiving  
at least one administration of treatment (%)*
Pemetrexed / cisplatin 57 (24.4)
Pemetrexed / carboplatin 48 (20.5)
Erlotinib 44 (18.8)
Gemcitabine / cisplatin 23 (9.8)
Docetaxel / carboplatin 22 (9.4)
Docetaxel 19 (8.1)
Gemcitabine / carboplatin 18 (7.7)
Pemetrexed 18 (7.7)
Paclitaxel / carboplatin 15 (6.4)
Sorafenib 10 (4.3)
Paclitaxel / carboplatin / bevacizumab 10 (4.3)
Gefitinib 7 (3.0)
Etoposide / cisplatin 6 (2.6)
Gemcitabine 5 (2.1)
GDC0941 (PI3K inhibitor, clinical trial) 5 (2.1)
Paclitaxel 5 (2.1)
Other 30 (12.8)
Unknown 11 (4.7)
* Percentages do not add up to 100, since patients can receive multiple treatments.
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Survival for systemically treated patients
For systemically treated patients with non-metastasised disease, patients from academic 
hospitals and the four selected hospitals had better survival than patients treated in non-
academic hospitals (see Figure 5.4). Median survival was 2.22 years (95% CI 1.95-2.49) in 
academic hospitals, 2.43 years (95% CI 1.97-2.88) in selected hospitals, and 1.66 years (95% 
CI 1.57-1.76) in non-academic hospitals. A similar pattern was seen for systemically treated 
patients with metastasised disease. Median survival was longer for patients from academic 
hospitals (0.81 years, 95% CI 0.74-0.89) or the four selected study hospitals (0.92 years, 95% 
CI 0.78-1.05) than for patients from non-academic hospitals (0.69 years, 95% CI 0.66-0.71).
Patients who did not receive primary antitumour treatment, characteristics and survival
In the selected study hospitals, 114 patients (11.3%) did not receive any antitumour treat-
ment. Fourteen out of 114 patients were registered to have received previous treatment in 
another hospital (n=5) or to be referred for treatment to another hospital during the study 
period (n=9). 56 (56.0%) of the remaining patients without antitumour treatment received 
supportive care only. An additional 18 patients did not receive antitumour treatment follow-
ing their own specific wishes (18.0%). Fifteen patients died before treatment was started 
(15.0%), 4 patients had limited/no treatment options due to comorbidities (4.0%), in 4 cases 
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Figure 5.4a. Crude cumulative survival non-me-
tastasized NSCLC, primary systemic treatment 
patients.
Blue = four selected teaching hospitals
Green = all academic hospitals
Red = all non-academic hospitals
Figure 5.4b. Crude cumulative survival metas-
tasized NSCLC, primary systemic treatment pa-
tients.
Blue = four selected teaching hospitals
Green = all academic hospitals
Red = all non-academic hospitals
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a wait and see policy was followed (4.0%) and for one patient, treatment for another type 
of cancer had priority over the symptom-free lung cancer (1.0%). For 2 patients, reason for 
not receiving antitumour treatment was not registered.
Patients from academic hospitals who did not receive antitumour treatment (median 
survival 0.10, 95% CI 0.07-0.14), did not perform better than patients from non-academic 
hospitals who did not receive antitumour treatment (median survival 0.15 years, 95% CI 
0.14-0.16), see Figure 5.5. Median survival of patients from the four selected hospitals was 
longest (0.25, 95% CI 0.15-0.35).
hospital type and mortality, adjusted for age, gender and tumour histology
Cox proportional hazard models show a significantly decreased hazard of mortality for 
patients from the four selected hospitals as well as for patients diagnosed in academic 
hospitals, as opposed to patients diagnosed in non-academic hospitals. This is specifically 
true for primary radiotherapy patients and patients who receive systemic treatment for 
non-metastasised NSCLC. For primary surgery patients and patients who receive systemic 
treatment for metastasised NSCLC, no significant differences in mortality existed between 
hospital types. For patients receiving radiotherapy for metastasised disease, the improved 
survival in academic hospitals was non-significant when corrected for age, gender and 
tumour histology (Table 5.4).
5. Crude cumulative survival NSCLC, patients who did not receive antitumor treatment
Follow-up duration in years
Blue = four selected teaching hospitals
Green = all academic hospitals
Red = all non-academic hospitals
 
Figure 5
Figure 5.5. Crude cumulative survival NSCLC, pa-
tients who did not receive antitumor treatment.
Blue = four selected teaching hospitals
Green = all academic hospitals
Red = all non-academic hospitals
Follow-up duration in years
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dIsCussIon
This article describes treatment patterns for patients treated and/or followed for NSCLC in 
four selected hospitals. Our study as well as other studies89 show a multitude of treatments 
to be prescribed to these patients. Choice of treatment is very much patient and tumour 
dependent. This heterogeneity poses a challenge for cost-effectiveness studies, amongst 
others in selecting appropriate comparator treatment groups.
Overall survival curves are presented for patients from the selected hospitals as well as 
the total of NSCLC patients diagnosed in academic versus non-academic hospitals in the 
Netherlands. We found that patients with non-metastasised NSCLC that are treated in aca-
demic hospitals have better median overall survival than patients treated in non-academic 
hospitals. For metastasised disease, overall survival was best for patients diagnosed in the 
four selected hospitals. These differences mainly reflect differences in overall survival for 
patients treated with radiotherapy, systemic treatment or combinations. No significant dif-
ferences in overall survival between hospital types were found for the subgroup of patients 
treated with surgery.
Patients who did not receive any antitumour treatment had significantly better survival in 
the four study hospitals compared to the total of non-academic hospitals in the Netherlands. 
The difference reduces when correcting for age, gender and tumour histology, but remains 
present. This can either result from better supportive care in the study hospitals, or from 
remaining confounding. We could not correct for all relevant prognostic factors since they 
were not registered systematically in the patient charts. For instance, WHO performance 
status was only registered in 19% of the cases (at baseline).
The generally improved survival of patients from academic hospitals might be explained 
by the higher level of experience available in (generally large) academic centres as well as 
their pioneer role in adopting innovations. New or improved treatment regimens are usu-
ally not uniformly implemented in all hospitals from the start. This can be a matter of (un)
awareness or (lack of) available information on the new treatment and outcomes, and on 
current practice and outcomes. Data collection, sharing, self-reflection and communication 
between doctors are crucial feedback and improvement tools.90
Also, further centralisation of NSCLC treatments may improve treatment outcomes and 
reduce variability between hospitals. While literature about differences in treatments and/
or survival between hospital types is mostly about surgery, recent innovation in cancer care 
has been mainly about combining treatment modalities.88 Therefore, patients may benefit 
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from critical assessments of the minimum skills and experience in hospitals prescribing and 
applying these treatments for NSCLC.14
Obviously, “treatment in an academic hospital” does not automatically mean good quality 
of care, or the other way around. Academic or non-academic hospital type is probably not 
the main predictor of treatment or survival differences. Other important factors might be 
hospital- and treatment volume, infrastructure, dedication of multidisciplinary teams and 
adoption of innovative treatments.88 These factors might also explain the relatively good 
survival of patients from the four selected study hospitals, which are relatively active in 
teaching and training, scientific studies, benchmarking activities and guideline development.
Selection bias may have occurred since patients referred to the study hospitals from other 
hospitals were included as long as they did not receive treatment before their arrival in the 
study hospital. Although we corrected for age, gender and tumour histology and stratified by 
disease stage (M0 or M+) in the Cox proportional hazard analysis, the referred patients may 
have better (unmeasured) prognostic characteristics. Treatment patterns were presented as 
such, so they include patients who were referred for specialised treatment. This reduces the 
generalisability of treatment patterns to other, non-specialised hospitals.
Patients who could not be matched reliably to NCR records were excluded from the survival 
analyses, which may bias the results in unknown direction. A reason for having no match in 
NCR records is the lack of NSCLC pathology or hospital admission.
The follow-up time of this study was relatively short. Since patients were included in the 
study as they were diagnosed within a two-year time frame, we collected relatively more 
data on the early phases of disease. Patients with a relatively good prognosis become cen-
sored cases as they survive end of the study follow-up. While survival was updated using 
NCR data, information about later treatment lines for these patients was lacking.
Since the data was collected retrospectively and was subtracted from medical charts, the 
resulting data was dependent on the patient information obtained by the hospital and on 
the registration in medical charts. Furthermore, some patients were treated in multiple 
hospitals. Permission to collect and use patient chart data could only be obtained for the 
four study hospitals. Therefore, patients were ‘lost’ and considered ‘censored’ from the mo-
ment they were referred to a different hospital than the study hospitals. It would be more 
insightful to follow patients during their entire disease course, even when multiple hospitals 
are visited for diagnosis and treatment.
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Another challenge was the registration of disease stages. The TNM staging system has 
changed to the 7th edition halfway the study period, so for each patient we used the TNM 
edition in use at the time the clinician recorded the disease stage in the patient chart. How-
ever, TNM stage can change during the diagnostic period, can differ between clinicians, and 
cannot always reliably be obtained from patient charts. This was a limitation of both the 
data we collected and the NCR data, which we used to validate our stage information. We 
therefore decided not to separate stages I-III, in order to minimise potential misclassifica-
tion.
The demand for real world evidence (RWE) has increased recently, as policy makers recog-
nise its value in providing information on treatment effectiveness and cost-effectiveness. 
Resource use data obtained from clinical trials partly reflects resource use resulting from 
the trial protocols and therefore, does not reflect the resource use of clinical daily practice. 
With this study, we provided real world data on resource use, which can be used directly in 
future model-based cost-effectiveness studies.
Future outcomes research should focus on utilities as well, as this was not included in this 
study. However, reliable utility estimates for treatment alternatives, as well as various 
other aspects of real-world NSCLC management, would best be studied within a prospec-
tive population-based patient registry, including all NSCLC patients. This type of data is 
extremely important to evaluate the large number of new, mainly targeted, therapies that 
are expected to be launched in the coming years, improving not only survival but quality of 
life as well.
ConClusIons
Differences in survival between hospital types suggest possibilities for improvement in 
NSCLC care in the Netherlands. However, due to limitations of the data from the current 
study, confirmation by other studies is advised.
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letter to the edItor
Cancer patients undergo a wide range of laboratory procedures, from simple blood tests 
to complex molecular diagnostics. These laboratory procedures involve various categories, 
such as clinical chemistry, pathology, microbiology, serology, hematology and pharmacol-
ogy. Recent developments, amongst others in genetic biomarker testing, add complexity 
and costs to the range of laboratory procedures. Several new techniques reduce costs per 
test, but also new tests are added to an already large volume of laboratory procedures in 
the management of cancer in general, and non-small cell lung cancer (NSCLC) in particular.
For oncologists, policy makers, and health economists, it is difficult to determine the mag-
nitude of the cost burden of laboratory testing. We could find no publications presenting 
real-world cost data for laboratory testing in NSCLC. It is reasonably easy to collect resource 
use and cost data for one specific test. However, in economic decision making, one would 
want to take all costs associated with all laboratory testing into account if these contribute 
significantly to the total cost burden. Especially for tests related to treatment choice, labora-
tory costs might impact cost-effectiveness estimates of treatment alternatives since they 
essentially increase the cost of the treatment. The same is true for life extending treatments 
when additional testing is performed during life time gained.
Recently published cost-effectiveness studies in NSCLC did not take laboratory costs into 
account or did not report them.91,92 In other studies, estimates of total cost of laboratory 
testing was based on guidelines93, the Summary of Product Characteristics of the drugs un-
der evaluation94, or expert opinion. Furthermore, several studies estimate total laboratory 
costs from a clinical trial database.95 Laboratory costs within the clinical trial setting might 
differ significantly from real-world costs since ordering of diagnostic testing in trials is mainly 
guided by trial protocol and is usually limited to the duration of the trial. In studies that did 
take real-world laboratory costs into account, size of these costs was not reported separately 
from other cost categories96, or methods of determining these costs were unclear.97
Here, we present recent real-world costs of laboratory procedures for NSCLC patients 
(inpatient as well as outpatient). We calculated these costs with the aim to inform health-
economic studies and models to evaluate the cost-effectiveness of diagnostic or treatment 
alternatives in NSCLC. Laboratory tests were categorised in order to identify tests with the 
largest impact on costs associated with NSCLC.
Data was collected in an academic medical centre in the Netherlands. All hospital laboratory 
tests performed for stage I to IV NSCLC patients between 2009 and 2011 were recorded. 
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Dates and types of the tests were registered, further clinical information (e.g., disease stage, 
treatment sequence, inpatient/outpatient setting and death date) could not be collected. 
All laboratory procedures were included, irrespective of the reason to order the test or 
department of the clinician who ordered it. The study was exempt from ethical review by 
the Medical Ethical Committee of VU University Medical Centre.
Costs per laboratory test were obtained from The Dutch Healthcare Authority (Nederlandse 
Zorgautoriteit) in Euros (2012). Costs were determined for the total follow-up period as well 
as per day. Costs per day were calculated in two ways, to serve different objectives. First, 
total costs per patient were divided by the number of days with at least one laboratory 
procedure. The outcome can be used to estimate total laboratory costs for a patient in case 
the number of days with laboratory testing is known. Second, total costs per patient were 
divided by the number of days between the first and the last laboratory test for this patient 
during the follow-up period. This outcome can be used when the number of actual days with 
laboratory testing is unknown.
Categorisation of laboratory procedures was performed by the corresponding author and 
critically reviewed by Prof.dr. Smit. Following classes of laboratory tests were distinguished: 
1) clinical chemistry; 2) pathology (including genetic biomarkers); 3) microbiology; 4) serol-
ogy, hematology, transfusion; 5) pharmacology; 6) other or unknown category (including 
order processing fees). Analyses were performed in IBM SPSS Statistics 22.
A total of 1015 patients were included, accounting for a total of 171,632 laboratory proce-
dures, with a mean of 169 laboratory procedures per patient during a mean follow-up of 6.5 
months. Table 6.1 shows the number of patients, number of tests and laboratory costs per 
category. In total, 392 different types of tests were performed. Cost of laboratory testing per 
patient is mean €96 (95% confidence interval (CI) 91–101) and median €51 per day with at 
least one laboratory procedure. Cost of laboratory testing per patient is mean €49 (95% CI 
34–65) and median €10 per day between the first and last laboratory test (Table 6.1).
Costs are driven by categories pathology (26%), other (25%, mainly order processing fees) 
and clinical chemistry (24%, due to high test volumes). Distribution of laboratory costs was 
skewed to the right (see Figure 6.1).
The previous most recent real-world cost estimate for laboratory testing in lung cancer was 
published by Kutikova et al. (2005).98 Databases of claims data for the years 1998–2000 
were used in order to estimate the economic burden of lung cancer, including the costs of 
outpatient laboratory testing. The average number of laboratory procedures per patient 
per month was 2.0 (SD 3.6), resulting in an average cost of €98 (SD €207) per patient per 
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month (using an United States dollars to euros exchange rate of 0.809). When compared to 
the costs of laboratory procedures for patients without lungcancer, the incremental costs 
attributed to lung cancer were €89 per month. Most of these costs were made in the initial 
treatment phase, as opposed to later in the course of the disease. Cost estimates in our 
study are higher, possibly due to an increase of these costs in the last decade as well as the 
inclusion of inpatient costs in our study.
An important limitation of this study is the use of unit costs based on tariffs instead of 
microcosting studies. Due to the large number of different tests (392), microcosting per test 
type was not feasible. It is unknown to what extent current tariffs reflect accurate estimates 
of the actual costs. National tariffs for molecular testing, such as the tariff for epidermal 
growth factor receptor (EGFR) mutation analysis (€912), might be higher than actual costs 
spend on performing these tests. In comparison, other studies estimate costs of EGFR test-
ing to be €23699 and €197.100
As a result of the substantial cost impact of complex molecular tests, reliable estimates are 
important and should be used in cost-effectiveness analyses. Such cost estimates should 
also take into account any efficiency gains that are reached by performing multiple tests on 
the same sample, as is increasingly the case in molecular testing.
Costs per patient per day
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Figure 6.1. Distribution of laboratory costs was skewed to the right.
Eight patients made costs of more than €2,000 per day, since they were followed only one day, with 
several expensive pathology procedures.
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Furthermore, note that this study was performed in an academic hospital. Due to research 
activities in the academic setting, test order behavior in this setting might be different from 
off protocol clinical care.
This study provides oncologists, policy makers, and health economists with an initial esti-
mate of the costs of laboratory testing in NSCLC. In economic evaluations, laboratory costs 
might significantly impact the results when testing practices or survival gain differs between 
treatment alternatives. Especially when evaluating targeted therapies, costs of associated 
biomarker tests should be taken into account. However, relatively simple blood tests, such 
as renal and liver function tests, should not be easily ignored, as they can significantly impact 
cost estimates due to high test volumes.
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AbstrACt
objectives
Real-world resource use and cost data on non-small cell lung cancer (NSCLC) are scarce. This 
data is needed to inform health-economic modelling to assess the impact of new diagnostic 
and/or treatment technologies. This study provides detailed insight into real-world medical 
resource use and costs of stage I-IV NSCLC in the Netherlands.
Materials and methods
A random sample of patients newly diagnosed with NSCLC (2009-2011) was selected from 
four Dutch hospitals. Data was retrospectively collected from patient charts. This data 
included patient characteristics, tumour characteristics, treatment details, adverse events, 
survival and resource use. Resource use was multiplied by Dutch unit costs expressed in EUR 
2012. Total mean costs were corrected for censoring using the Bang and Tsiatis weighted 
complete-case estimator. Furthermore, costs of adverse events, costs per phase of NSCLC 
management and costs of second opinions are presented.
results
Data was collected on 1,067 patients. Total mean costs for NSCLC diagnosis, treatment and 
follow-up are €28,468 during the study period and €33,143 when corrected for censoring. 
Adverse events were recorded in the patient charts for 369 patients (41%) and 82 patients 
(9%) experienced an adverse event of grade III or higher. For these patients, adverse event-
related hospital admissions cost on average €2,091. Mean total costs are €1,725 for the 
diagnostic period, €17,296 for first treatment line, and €13,236 for each later treatment 
line. Costs of providing a second opinion are €2,580 per patient.
Conclusions
Total mean hospital costs per NSCLC patient are €33,143 for the total duration of the dis-
ease. Ignoring censoring in our data underestimates these costs by 14%. Main limitations of 
the study relate to the short follow-up time, staging difficulties and missing data. Its main 
strength is that it provides highly detailed, real-world data on the costs of NSCLC.
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IntroduCtIon
Of new cancer cases, lung cancer has the second highest incidence. Although incidence 
and mortality have been reduced101,102, due to a reduction in smoking and recent develop-
ments in diagnosis and treatment, the health burden remains considerable. In addition, the 
economic burden of lung cancer care on society is high; in the Netherlands, costs of lung 
cancer were estimated to be over 400 million euro in the year 2011. The majority of these 
costs involve hospital care (82%).103
Healthcare spending for NSCLC has increased due to the growing number of new, expensive 
treatments.104 Because of the economic burden of lung cancer, it is critical to estimate the 
cost-effectiveness of new developments in diagnosis and treatment. Mathematical models 
that estimate cost-effectiveness of new strategies using available data are commonly used 
to support decision making.105 Such models synthesise evidence on health effects and 
costs from many different sources, including data from clinical trials, claims databases, 
registry data and public health statistics. To inform such health-economic models with data, 
it is important that the best available evidence is used, and preferably data that reflects 
clinical practice.106 Resulting cost-effectiveness estimates can inform hospital, industry and 
governmental policy makers on costs of NSCLC and impact of new diagnostic or treatment 
technologies.
The health effects of new interventions can generally be obtained from trial data or litera-
ture. Data from pooled clinical trials is considered the best available evidence for estimating 
clinical treatment efficacy of new interventions. However, health-economic trial data reflects 
the resource use and costs of the trial protocol and not the resource use and costs in “the 
real world”.107 The real-world resource use and cost data that is needed for health-economic 
modelling of non-small cell lung cancer (NSCLC) is scarce. In general, cost estimates in the 
literature are not complete enough for modelling purposes. Often, costs are not separated 
by phase in the treatment pathway, or different types of costs are merged into one cost.108
At present, two Dutch studies present NSCLC costs that can be used for health-economic 
modelling. One study from 2009 focused on late-stage disease109, while the other study 
included a detailed analysis of the costs of radiotherapy in 2010.110 Both studies have been 
used in health-economic modelling.111,112
The objective of this study is to provide insight into real-world medical resource use and 
costs of NSCLC in the Netherlands. We aimed to estimate costs for all cost items of hospital-
based lung cancer care. These cost items include the full diagnostic work-up, cancer treat-
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ments, concomitant medication, hospital visits, and adverse events for all phases of lung 
cancer care. The results can be used in a decision model of lung cancer.
MAterIAls And Methods
study design
A retrospective outcomes study was conducted to capture medical resource use and costs in 
the management of all stages of NSCLC in the Netherlands. Patients newly diagnosed with 
stage I-IV NSCLC between January 31, 2009 and January 31, 2011 in participating hospitals 
(VU University Medical Centre, Amsterdam; University Medical Centre Groningen; Medical 
Centre Alkmaar; St. Antonius Hospital, Nieuwegein) were eligible. Eligible patients were 
identified through hospital databases and were followed until study end, transfer to another 
hospital, or death. Last month of data collection was July 2012.
Data was collected on 1,067 randomly selected patients and abstracted from patient charts 
by trained data assistants, using a web-based case report form (CRF). The CRF captured in-
formation about patient characteristics, tumour characteristics, treatment details, adverse 
events (AEs), survival and resource use. Adverse events were obtained from the patient 
charts, which noted the grade of the event according to the common terminology criteria 
for adverse events (CTC AE) version 4.03. In case grade was not registered by the clinician, it 
was derived by the data manager if the patient chart contained the necessary information. 
If the necessary information was not registered, the grade was considered missing.
Data from the Netherlands Cancer Registry (NCR) was used to validate tumour histology 
and disease stage collected from the patient charts. The NCR also provided population-
based data on patient and tumour characteristics of all patients diagnosed with NSCLC in the 
Netherlands between January 2009 until January 2011, as identified through the automated 
pathological archive (PALGA) and the National Registry of Hospital Discharge Diagnoses. This 
information was used to assess the representativeness of the study sample.
This study was performed from a hospital perspective. Direct medical costs outside the 
hospital (such as care by a general practitioner) and indirect medical and non-medical costs 
were outside the scope of the study. Oral oncolytics and other specialist drugs were consid-
ered hospital care and included in the cost.
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resource use
Information was collected on all relevant resources consumed within the hospital setting, 
including surgeries, radiotherapy, anticancer drug therapy, laboratory tests (including 
pathology, microbiology, hematology, chemistry, immunology), medical imaging services, 
other medical diagnostics and procedures, outpatient visits, telephone consultations, day-
care visits, hospitalisations and intensive care stay.
Per patient, the number and types of resources used were counted. In the case of hospital 
admissions, it was specified whether admissions were needed for treatment of disease, for 
treatment of adverse events or other reasons.
Costs
Costs were estimated by linking resource use to Dutch unit costs, based on the Dutch costing 
manual57 and NZa (Dutch Healthcare Authority) tariffs.113 All costs were based on EUR 2012 
unit cost data or were adjusted to 2012 prices using the general price index as published 
by Statistics Netherlands. Mean costs for drug use other than anti-cancer drugs, including 
treatments for adverse events, were determined for a subsample of VU University Medical 
Centre patients (n=107), for feasibility reasons. Mean costs for laboratory tests were ob-
tained from a separate database, containing information on all laboratory tests performed 
for NSCLC patients in the VU University Medical Centre (chapter VI).
Analyses
For all analyses, costs were estimated for the two subgroups stage I-III and stage IV patients 
separately, as determined at diagnosis.
First, mean costs were estimated separately for relevant cost items of NSCLC, such as 
chemotherapy, consultations and hospitalisations. Total mean costs per patient were cal-
culated, from the patient’s first NSCLC-related hospital visit until the patient’s death. Mean 
follow-up times are presented. Since 51% of patients were still alive at the end of the study, 
these patients could not be followed until the event of interest. This means that they were 
censored; complete follow-up information on these patients was not available for the full 
duration of interest. Ignoring censoring will lead to an underestimation of the total mean 
costs. Therefore, we corrected these costs for censoring, using the Bang and Tsiatis weighted 
complete-case estimator.114 The mean total costs were estimated by:
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that is, censoring is treated as the event. The basic idea of the BT estimator is that the costs 
of patients who die within the time frame of the study (complete cases) are weighted by 
the inverse of the probability of not being censored before the time of death. Thus, costs of 
censored patients are represented by patients with complete data.
Second, costs of adverse events (grade ≥3) were analysed. Third, mean costs per phase of 
NSCLC management were analysed by splitting the relevant cost items into the following 
phases: diagnosis, initial treatment, and second and later treatments. The diagnostic period 
runs from baseline (first NSCLC-related hospital visit) until the start of the first treatment/
censoring/death. Treatment periods run from start of the treatment until the start of the 
next treatment/censoring/death (including follow-up).
Finally, we separately analysed the resource use and costs of patients in the study who 
came for a second opinion. Although these patients did not receive treatment in the study 
hospital and were referred back to their original hospital after the second opinion, they 
incur costs for, amongst others, diagnostic testing and hospital visits.
All analyses were performed in IBM SPSS Statistics 21 and Microsoft Excel 2010.
results
Data was collected on 1067 patients, 102 (9.6%) of whom received previous treatment in 
another hospital and 58 (5.4%) of whom came for a second opinion only. The remainder of 
the patients (n=907) is included in Table 7.1. Table 7.1 shows baseline characteristics of the 
study population compared to the Dutch NSCLC population as a whole. Distributions of age, 
gender and tumour histology are similar, while tumours with stage <IV are overrepresented 
in the study population.
Eighty-six patients (9.5%) were treated within a clinical trial.
Table 7.2 shows unit costs and their sources, per item of resource use.
Total crude mean costs for NSCLC diagnosis, treatment and follow-up, as measured dur-
ing the study period, are €28,468 (see Table 7.3). Total, corrected mean costs for NSCLC 
diagnosis, treatment and follow-up are €33,143. Although costs per time unit are highest 
for patients with metastasised NSCLC, total costs are higher for non-metastasised disease 
due to the longer diagnosis, treatment and follow-up duration (mean 29.9 versus 12.6 
months). Main cost drivers are hospital admissions, medical imaging and procedures and 
radiotherapy.
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table 7.1: Baseline characteristics
study sample, 2009-
2011
n (%)
dutch population, 
2001-2006
n (%)
total patients 907 (100)* 13,992 (100)
Age (years)
<60
60-74
≥75
235 (26)
450 (50)
222 (25)
3,566 (26)
6,910 (49)
3,516 (25)
Gender
Male 601 (66)* 8,841 (63)
smoking status
Non-smoker
Smoker
Former smoker (quit >1 month ago)
Not reported
60 (7)
295 (33)
296 (33)
256 (28)
NA
Charlson comorbidity score
0
1
2
≥3
383 (42)
269 (30)
145 (16)
110 (12)
NA
histology
Adenocarcinoma
Squamous cell carcinoma
Large cell carcinoma
Other histology
Unknown
442 (49)
237 (26)
90 (10)
29 (3)
107 (12)
6,222 (45)
4,062 (29)
1,884 (14)
407 (3)
1,417 (10)
Clinical stage
Stage <IV
Stage =IV
Unknown
561 (62)
321 (35)
25 (3)
6,552 (47)
6,887 (49)
553 (4)
*Initially, data was collected on 1067 patients. 1067 minus 102 (previous treatment in another hospi-
tal) minus 58 (second opinion only) = 907 patients.
**For one patient, gender was not registered.
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table 7.2: Unit costs
unit costs source
Concomitant 
medication, stage I
€644.95 These are the mean concomitant medication costs per NSCLC 
patient per treatment line, as determined in a side study 
(n=107) in VU University Medical Centre. Detailed information 
on drug use was collected from the medical charts of a 
randomly selected subsample of 107 patients and multiplied by 
Dutch unit costs from www.medicijnkosten.nl. Main cost drivers 
were aprepitant, ondansetron and erytromycine.
Concomitant 
medication, stage II
€319.15
Concomitant 
medication, stage III
€630.27
Concomitant 
medication, stage IV
€254.90
Concomitant 
medication, stage 
unknown
€528.96
Consultations by 
telephone
€14.51 Dutch costing manual 2010. Inflated from €14 using Statistics 
Netherlands general inflation rates.
Day with laboratory 
testing
€71.37 Excluding pathology and genetic biomarker tests (see chapter 
VI).
Day care €260.11 Dutch costing manual 2010. Inflated from €251 using Statistics 
Netherlands general inflation rates.
Definitive 
radiotherapy
€8,839.75 NZa tariff, “T4 Intensive radiotherapy excluding expensive 
imaging”.
Drug therapies Various Z-index price via www.medicijnkosten.nl.
Genetic biomarker 
tests
€912.30 NZA tariff, “Complex molecular diagnostics – tests on isolated 
DNA, RNA or protein other than frequently requested tests on 
micro-organisms”, including specialist fee.
In-patient hospital 
day, academic 
hospital
€595.87 Dutch costing manual 2010. Inflated from €575 using Statistics 
Netherlands general inflation rates.
In-patient hospital 
day, general hospital
€450.79 Dutch costing manual 2010. Inflated from €435 using Statistics 
Netherlands general inflation rates.
Intensive care unit 
day
€2262.20 €1788.61 additional to weighted average hospital day costs.
Mediastinoscopy, 
thoracotomy
€4,852.99 NZa tariff, “11 SURGICAL LUNG 103, declaration code 140533”
Medical imaging 
services & other 
procedures
Various NZa tariff, 129 different types of procedures, ranging from 
simple pulmonary function tests to neurosurgery.
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Of all patients, 41% had adverse events and 9% had adverse events of grade III or higher (see 
Table 7.4). Grade ≥III adverse event-related hospital admissions cost on average €2,081 for 
stage I-III and €2,105 for stage IV NSCLC patients.
Costs for concomitant medication were not significantly associated with incidence and costs 
of AEs, possibly due to the preventive use of concomitant medication. For example, the pre-
ventive use of concomitant anti-emetics with chemotherapy reduces nausea and therefore 
decreases incidence of this adverse event.
Table 7.5 shows NSCLC costs and number of patient months per diagnostic or treatment 
period. Mean total costs are €1,725 for the diagnosis period, €17,296 for the first treatment 
line (and follow-up), and €13,236 for later treatment lines (and follow-up). Average duration 
of these periods is 2.4, 9.4 and 6.0 months respectively. The shorter duration of second and 
later treatment lines explains the lower costs compared to the first treatment line.
Note that a proportion of the patients did not receive treatment at all, or received more 
than two treatment lines. Therefore, mean total cost per patient (see totals in Table 7.3) is 
not equal to the sum of the mean costs per period.
Part of the patients (n=58) did not receive treatment in the study hospital, but came for a 
second opinion. Costs of providing a second opinion, per patient, including all diagnostics 
and hospital contacts for second opinion patients, are €2,580 (SD €4,907).
table 7.2: Unit costs (continued)
unit costs source
Outpatient visit, 
academic hospital
€133.68 Dutch costing manual 2010. Inflated from €129 using Statistics 
Netherlands general inflation rates.
Outpatient visit, 
general hospital
€66.32 Dutch costing manual 2010. Inflated from €64 using Statistics 
Netherlands general inflation rates.
Palliative 
radiotherapy
€1,872.64 NZa tariff, “T1 Standard radiotherapy”
Pathology (cytology, 
histology)
€62.78 NZA tariff, “Anatomic pathology (histology) testing and other 
cytodiagnostic tests”, including specialist fee.
Wedge resection, 
lobectomy, 
segmentectomy, 
pneumectomy, other 
large lung surgery
€5,956.64 NZa tariff, “11 SURGICAL LUNG 104, declaration code 140534”
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table 7.4: Costs for adverse event-related outpatient visits and hospital admissions, ignoring censoring
stage 
I-III 
nsClC
stage IV 
nsClC
total (incl. 
stage = 
unk)
Patients with registered adverse events, N (%) 233 (42) 129 (40) 369 (41)
Costs for adverse event-related hospital admissions per patient 
with any adverse event, Mean € (SD)
1,133
(2,865)
1,180
(2,804)
1,133
(2,816)
Patients with registered grade ≥III adverse events, N (%) 49 (9) 33 (10) 82 (9)
Costs for adverse event-related hospital admissions per patient 
with grade ≥III adverse events, Mean € (SD)
2,081
(3,976)
2,105
(4,275)
2,091
(4,073)
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table 7.5: Costs per phase of NSCLC management, ignoring censoring
stage I-III nsClC
Mean € (sd) 
[number of 
periods]
stage IV nsClC
Mean € (sd) 
[number of 
periods]
total (incl. stage 
= unk)
Mean € (sd) 
[number of 
periods]
Chemotherapy*
Diagnosis - - -
1st treatment 1,104 (2,740) [523] 3,500 (7,551) [259] 1,860 (4,969) [798]
2nd and later treatments 1,706 (3,277) [278] 2,623 (4,749) [286] 2,142 (4,091) [572]
Concomitant medication**
Diagnosis - - -
1st treatment 575 (123) [523] 289 (104) [259] 481 (177) [798]
2nd and later treatments 544 (144) [278] 273 (79) [286] 409 (175) [572]
Consultations by telephone
Diagnosis 6 (15) [561] 7 (13) [321] 6 (14) [907]
1st treatment 15 (29) [523] 16 (28) [259] 16 (29) [798]
2nd and later treatments 18 (28) [278] 17 (27) [286] 18 (28) [572]
day-care
Diagnosis 137 (218) [561] 155 (229) [321] 142 (221) [907]
1st treatment 187 (468) [523] 240 (569) [259] 201 (499) [798]
2nd and later treatments 265 (523) [278] 285 (744) [286] 274 (640) [572]
day with laboratory testing 
(excluding pathology and genetic 
biomarker tests)
Diagnosis 248 (353) [561] 280 (339) [321] 263 (352) [907]
1st treatment 819 (1,034) [523] 576 (744) [259] 740 (963) [798]
2nd and later treatments 652 (798) [278] 454 (538) [286] 552 (683) [572]
Genetic biomarker tests***
Diagnosis 81 (271) [561] 207 (416) [321] 128 (339) [907]
1st treatment - - -
2nd and later treatments - - -
In-patient hospital days
Diagnosis 1,808 (18,840) 
[561]
1,706 (3,167) [321] 1,778 (14,948) 
[907]
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table 7.5: Costs per phase of NSCLC management, ignoring censoring (continued)
stage I-III nsClC
Mean € (sd) 
[number of 
periods]
stage IV nsClC
Mean € (sd) 
[number of 
periods]
total (incl. stage 
= unk)
Mean € (sd) 
[number of 
periods]
1st treatment 5,564 (10,489) 
[523]
3,419 (5,335) [259] 4,872 (9,152) [798]
2nd and later treatments 4,631 (12,322) 
[278]
2,330 (4,071) [286] 3,467 (9,145) [572]
Intensive care unit days****
Diagnosis 41 (644) [561] 33 (446) [321] 37 (572) [907]
1st treatment 917 (3,894) [523] 159 (1,215) [259] 657 (3,249) [798]
2nd and later treatments 360 (2,052) [278] 94 (1,017) [286] 228 (1,612) [572]
lung surgery
Diagnosis - - -
1st treatment 2,688 (2,939) [523] 359 (1,406) [259] 1,928 (2,765) [798]
2nd and later treatments 909 (2,133) [278] 288 (1,272) [286] 607 (1,793) [572]
Medical imaging services & 
procedures
Diagnosis 1,680 (1,314) [561] 1,821 (1,221) [321] 1,725 (1,280) [907]
1st treatment 1,523 (1,640) [523] 902 (1,116) [259] 1,316 (1,508) [798]
2nd and later treatments 1,292 (1,487) [278] 967 (1,276) [286] 1,140 (1,396) [572]
out-patient visits
Diagnosis 723 (781) [561] 713 (615) [321] 719 (723) [907]
1st treatment 1,631 (2,395) [523] 1,169 (1,502) [259] 1,471 (2,140) [798]
2nd and later treatments 1,392 (1,775) [278] 1,230 (1,603) [286] 1,306 (1,683) [572]
Pathology (cytology, histology)
Diagnosis 96 (92) [561] 122 (94) [321] 105 (94) [907]
1st treatment 73 (83) [523] 29 (63) [259] 58 (80) [798]
2nd and later treatments 47 (84) [278] 22 (52) [286] 34 (70) [572]
radiotherapy
Diagnosis - - -
1st treatment 3,914 (4,263) [523] 1,555 (2,245) [259] 3,141 (3,884) [798]
2nd and later treatments 2,737 (3,592) [278] 1,253 (1,849) [286] 1,969 (2,928) [572]
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table 7.5: Costs per phase of NSCLC management, ignoring censoring (continued)
stage I-III nsClC
Mean € (sd) 
[number of 
periods]
stage IV nsClC
Mean € (sd) 
[number of 
periods]
total (incl. stage 
= unk)
Mean € (sd) 
[number of 
periods]
targeted therapy*
Diagnosis - - -
1st treatment 156 (1,974) [523] 1,230 (8,030) [259] 554 (5,068) [798]
2nd and later treatments 551 (2,374) [278] 1,630 (6,847) [286] 1,090 (5,141) [572]
total
Diagnosis 4,819 (19,215) 
[561]
5,045 (4,159) [321] 1,725 (1,280) [907]
1st treatment 19,166 (16,319) 
[523]
13,445 (16,757) 
[259]
17,296 (16,665) 
[798]
2nd and later treatments 15,104 (15,905) 
[278]
11,466 (11,886) 
[286]
13,236 (13,940) 
[572]
duration in months
Diagnosis: median, mean (SD) 1.4, 2.4 (3.9) 1.2, 2.3 (4.0) 1.4, 2.4 (4.0)
1st treatment: median, mean (SD) 11.0, 11.9 (9.7) 2.4, 4.6 (5.1) 5.9, 9.4 (9.1)
2nd and later treatments: median, 
mean (SD)
5.0, 7.9 (8.2) 3.1, 4.2 (3.4) 3.9, 6.0 (6.9)
*Including drug spillage.
**As determined in a side study among a random sample of 107 patients from VU University Medical 
Centre.
***For genetic biomarker tests, data was not registered so all were allocated to the diagnosis period.
****Costs additional to the costs of a “regular” in-patient hospital day.
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dIsCussIon
Crude mean hospital costs per NSCLC patient in the Netherlands were €28,468 during our 
study period and €33,143 for the total disease duration, corrected for censoring. The largest 
component of these costs (29%) is costs for inpatient hospital days. The Dutch National In-
stitute of Public Health and the Environment (RIVM) reported the total costs for lung cancer 
in the Netherlands to be 401 million euro in 2011. With an estimated prevalence of 20,500 
patients in that same year, costs of lung cancer are expected to be less than €20,000 per 
patient per year; 82% (±€16,000 per patient per year) is spent on hospital care.103 Given the 
mean duration (23.6 months) and mean hospital costs (€28,468) in the present study, costs 
amount to €14,475 per patient per year. In the present study, costs were calculated bottom-
up; resource use per patient was multiplied by prices and summed over all patients. The 
RIVM calculated costs top-down: total national healthcare expenditures were divided over 
the diseases. Both outcomes are fairly similar, especially given the uncertainties associated 
with costing studies. The difference of ±€1,500 might be due to patients generating costs at 
hospitals other than those in the study.
Table 7.6 shows a summary of lung cancer costs reported in other studies published from 
2003 onwards. These studies were obtained from a non-systematic review of the literature, 
selecting cost studies with any estimate of the general (not specific for one therapy) costs 
of lung cancer from a hospital or oncology practice perspective. Reported costs range from 
€10,578 to €69,562 per NSCLC patient, compared to €33,143 per patient (corrected for 
censoring) in our study. Variations are partly due to differences in healthcare systems, unit 
costs and research methodology.
The smallest cost estimate is from an Australian study by Kang et al. This study was car-
ried out for 210 NSCLC and small-cell lung cancer (SCLC) patients.115 By subtracting data 
retrospectively from clinical records, they calculated mean costs of €10,578 (A$ 13,659) 
per NSCLC patient. Patient inclusion criteria were not reported, except that patients with 
recurrent disease were excluded from the analyses. There was a larger proportion of stage 
IV patients than in the present study (51% versus 35%), relatively more patients with large 
cell carcinoma (37% versus 10%) and fewer patients with adeno (36% versus 49%) and 
squamous cell carcinoma (21% versus 26%). The inclusion of cost components was similar to 
the current study, except that the Australian cost study did not include routine blood tests. 
However, it is not likely that these differences in patient case mix and cost components 
explain the lower mean costs in their study. One possible explanation may be that several 
unit costs in Australia are significantly lower than they are in the Netherlands, for example 
for hospitalisation (approximately €202 compared to €451 per hospital admission day in the 
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Netherlands57). Furthermore, the median follow-up time was 16.6 months for both NSCLC 
and SCLC patients, which is lower than in the present study (20.2 months).
The largest cost estimate is from an American study by Lang et al.116 All patients included 
in this study were aged 65 years or older, had stage IIIB or stage IV NSCLC and were treated 
with two-drug chemotherapy. Since two-drug chemotherapy is a relatively expensive treat-
ment and our study included patients irrespective of treatment (including patients receiving 
supportive care only), this selection criterion may be the most important reason for the 
large cost difference. Furthermore, the study by Lang et al. also included home healthcare, 
hospice and physician service costs, while these were excluded from our study.
Only one other NSCLC cost study was performed in the Netherlands. Dutch data from 2005109 
showed annual costs of hospital treatment of patients with unresectable advanced NSCLC 
to be on average €32,840 (group A: first-line chemotherapy, second-“line” best supportive 
care) and €31,187 (group B: first and second-line chemotherapy). In our study, yearly costs 
for stage IV NSCLC were mean €24,866 (€26,109/12.6*12) (2012 prices). As Pompen et al. 
followed patients for almost four years after diagnosis, relatively more complete informa-
tion was available (18 out of 102 patients were still alive at the end of follow-up). Mean 
follow-up time was similar to our study (12.2 and 14.4 months in the two study groups). 
Their sample size was very small (n=106) compared to our sample size (n=907 total, n=321 
stage IV). Patient selection was more restricted than in our study, as they selected patients 
who received first-line chemotherapy followed by either best supportive care or second-line 
chemotherapy. This selection based on treatment may explain the higher costs in the study 
by Pompen et al. Both in our study and in the study of Pompen et al., hospital admissions 
were the major cost driver.
limitations of this study
Hospital care and (the fees of) medical specialists account for 82% (330 million euro) of 
lung cancer costs. By taking a hospital perspective, we limited our analyses to hospital care 
and medical specialists, thereby excluding the other 18% of medical costs incurred by lung 
cancer patients.103 These costs arise from, amongst others, visits to the general practitioner, 
other healthcare providers (such as a physiotherapist), other institutions (such as a hospice), 
and extramural drugs not prescribed by a clinician from the hospital. Moreover, non-medical 
and indirect costs for lung cancer patients, which can be considerable, were excluded from 
our study.
Furthermore, this study did not assess the cost-effectiveness of NSCLC management or the 
cost-effectiveness of alternative treatment choices. Unfortunately, increased spending on 
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cancer care does not necessarily result in better outcomes77. Since this study did not evalu-
ate diagnostic or treatment (cost-)effectiveness, it does not provide information on how to 
decrease NSCLC spending or improve cost-effective allocation of resources.
Additionally, this study included only four out of eighty-four Dutch hospitals. Although 
the results represent real-world costs, these costs are not necessarily representative for 
other hospitals in the Netherlands and elsewhere. In order to promote generalisability, two 
academic as well as two non-academic hospitals were included. However, all participating 
hospitals are teaching hospitals, are relatively large, and they employ some of the key opin-
ion leaders in the Dutch field of lung oncology. Innovative practices may therefore be more 
common in our study sample than elsewhere in the Netherlands.
limitations of the data
We aimed to present the costs of the complete disease course of NSCLC patients. However, 
the follow-up time of this study was relatively short. Furthermore, since patients were 
included in the study as they were diagnosed within a two-year time frame, we collected 
relatively more data on the early phases of disease. By using the Bang and Tsiatis estimator 
we corrected for the fact that cost data was censored.
When censoring was ignored, total mean costs were underestimated by 14%. For surgery 
the Bang and Tsiatis correction resulted in lower cost estimates than the original estimates. 
This is due to the fact that a surgery is usually the first treatment choice, and costs are 
therefore high at the beginning of the disease course. These patients have a relatively good 
prognosis and become censored cases as they survive past the end of the study follow-up. 
The B&T estimator only includes costs of complete cases, that is, patients who have died 
within the study follow-up. In the case of surgery, these are patients who have died during 
or shortly after surgery. As they have died shortly after the start of follow-up, the Kaplan 
Meier estimator weights these costs less than it weights other cost items, where the death 
is more equally distributed over the follow-up time.
Next, selection bias may have occurred, as we had information on the full course of disease 
only for those patients who were diagnosed and who had died within these two years. 
These patients may be more expensive patients, requiring more intensive treatment than 
patients who died after the two-year follow-up period.
Furthermore, some patients were treated in multiple hospitals. Permission to collect and use 
patient chart data could only be obtained for the four study hospitals. Therefore, patients 
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were “lost” and considered “censored” from the moment they were referred to a hospital 
that was not one of the study hospitals.
Another challenge was the registration of disease stages. The TNM staging system changed 
to the 7th edition halfway through the study period, so for each patient we used the TNM 
edition that was in use at the time the clinician recorded the disease stage in the patient 
chart. However, TNM stage can change during the diagnostic period, can differ between 
clinicians, and cannot always reliably be obtained from patient charts. This was a limita-
tion of both the data we collected and the NCR data, which we used to validate our stage 
information. We therefore decided not to separate stages I-III, in order to minimise potential 
misclassification.
Finally, we found that many relevant prognostic factors were not registered systematically. 
For instance, WHO performance status was only registered in 19% of the cases (at baseline). 
The same was true for important disease-related events over time, such as a local or locore-
gional recurrence and a metastasis. However, we were able to register if patients moved to 
metastatic disease within the follow-up time of the study.
Future perspective
The demand for real-world evidence (RWE) has increased recently, as policy makers recog-
nise its value in providing information on treatment effectiveness and cost-effectiveness.126 
Such RWE cannot be obtained from clinical trials, since the resource use in clinical trials 
does not reflect the resource use in daily practice. In clinical trials, resource use is partly 
determined by the trial protocol. In the current study, we provided actual real-world data 
on resource use and costs. The results can be used in future model-based cost-effectiveness 
studies.
Future outcomes research should focus on utilities as well, as this was not included in this 
study. However, reliable utility estimates for treatment alternatives, as well as various 
other aspects of real-world NSCLC management, would best be studied within a prospective 
population-based patient registry that included all newly diagnosed NSCLC patients. This 
type of data is extremely important for evaluating the large number of new, mainly targeted, 
therapies that are expected to be launched in the coming years, which aim to improve not 
only survival but quality of life as well.127
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ConClusIons
The current study provides real-world data on the costs of NSCLC, per cost category, from a 
hospital perspective. This data can be used to inform health-economic models and decision 
making by hospital, industry and governmental stakeholders. Total mean hospital costs per 
NSCLC patient are €33,366 for the total duration of the disease.
Chapter VIII
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A practical guide for setting up patient registries for the 
collection of real-world data for healthcare decision making
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AbstrACt
objective
The aim of this paper is to provide practical guidance in setting up patient registries to 
facilitate real-world data collection for healthcare decision making.
Methods
This guidance was based on our experiences and involvement in setting up patient registries 
in The Netherlands. All aspects were structured according to i) “the Why” (mission and 
goals), ii) “the Who” (stakeholders and funding), iii) “the What” (type and content), and 
iv) “the How” (identification and recruitment of patients, data handling and pharmacovigi-
lance).
results
The mission of most patient registries is improving patient health by improving patient care; 
monitoring patient care is often the primary goal (“the Why”). It is important to align the 
objectives of the registry and agree on a clear and functional governance structure with 
all stakeholders (“the Who”). Expertise is essential on both clinical and real-world data to 
select appropriate data elements. There is often a trade-off between reliability, validity and 
specificity of data elements and feasibility of data collection (“the What”). Patient privacy 
should be carefully protected including training in Good Clinical Practice and addressing 
(inter-)national and local regulations. Patient registries can reveal unique safety information 
but it can be challenging to comply with pharmacovigilance regulations (“the How”).
Conclusion
It is crucial to set up an efficient patient registry that serves its aims by collecting the right 
data of the right real-world patient in the right way. It can be expected that patient registries 
become the new standard alongside RCTs considering their unique value.
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IntroduCtIon
Globally, there is an increasing trend to use real-world data to inform decision making in 
health care. Real-world data is often collected using a patient registry. A patient registry 
can be defined as “an organised system that uses observational study methods to collect 
uniform data (clinical and other) to evaluate specified outcomes for a population defined 
by a particular disease, condition, or exposure, and that serves one or more predetermined 
scientific, clinical, or policy purposes”.128
The United States Food and Drug Administration (FDA) can require a Risk Evaluation and 
Mitigation Strategy (REMS) from manufacturers to ensure that the benefits of a drug or 
biological product outweigh its risks. A REMS could involve a registry. Similarly, a registry 
could be part of a risk management plan which can be required by the European Medicines 
Agency (EMA).129 Besides regulatory authorities, local reimbursement agencies can use 
real-world data in reimbursement decisions. Furthermore, countries as Denmark, Finland, 
Iceland, Norway and Sweden have extensive experience with patient registries. These 
countries implemented national databases to track prescription drugs in ambulatory care130 
that are linked to other data sources (e.g., cancer registries and health surveys). With these 
databases drug use can be studied, just as beneficial or adverse outcomes of drug use in 
real-world clinical practice.130
As consequence of a coverage with evidence development policy implemented in 2006, the 
number of patient registries is rapidly increasing in The Netherlands. This policy guarantees 
early access to expensive drugs, but requires in return the collection of additional data 
regarding appropriate drug use, effectiveness and cost-effectiveness in real-world clinical 
practice. These data are used to evaluate a drug’s real-world value after four years of initial 
reimbursement.
In this paper, we provide practical guidance in setting up patient registries for the collection 
of real-world data on behalf of health care decision making. This paper is based on our 
experiences and involvement in setting up patient registries in The Netherlands for various 
types of cancer such as melanoma (e.g., DMTR), lung (e.g., POSEIDON), prostate (CAPRI and 
PRO-CAPRI), renal cell (PERCEPTION), haematological (PHAROS 1)131,132, colorectal and head 
and neck cancer (chapter I-III). This paper first discusses the mission and goals (“the Why”) 
of patient registries and highlights issues related to the involvement of diverse stakeholders 
and the funding of registries (“the Who”). After that, challenges and solutions will be dis-
cussed regarding the type and content of a patient registry and data collection (“the What”) 
and the identification and recruitment of patients, data handling, and pharmacovigilance 
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(“the How”). Lastly, we discuss the main challenges in balancing the optimal and the feasible 
in setting up patient registries.
MIssIon And GoAls (“the WhY”)
Why use a patient registry, and how to guarantee valorisation of outcomes to real-world 
clinical practice?
The mission of most registries is improving patient health by improving patient care. There-
fore, monitoring patient care is often the primary goal of a registry. But patient registries 
can serve many additional goals. For example, patient registries are one of EMA’s tools to 
gain more insight into known and potential risks of a certain product in real-world clinical 
practice.129 In addition, patient registries can provide information on appropriate drug use 
(which indicates whether a drug is used in the right way in the right patients), effectiveness 
(as opposed to efficacy in a clinical trial), costs, and cost-effectiveness in real-world clinical 
practice.133,134 Besides effectiveness in terms of progression-free survival, overall survival or 
response rates, registries can provide essential information on patient reported outcomes 
in case data is prospectively collected (Table 8.1). This gives important insight into patient’s 
experiences and health-related quality of life, and enables the estimation of quality adjusted 
life years for economic evaluations. These outcomes are important in reimbursement deci-
sion making. Furthermore, data from patient registries can inform public health planning, 
for example by detecting common causes of a disease illustrating the need for a prevention 
program.135
It should be noted that gathering all these data will not immediately improve patient health. 
It is essential to frequently discuss the findings with clinicians and ensure a quality-of-care 
feedback loop. In this way clinicians are able to improve their patient care. Furthermore, 
outcomes can be used in the development of clinical guidelines to improve the (efficiency 
of) delivery of care. Although all registries in which we are involved ensure transparency 
to the public through presentations and publications, the DMTR is the only registry that 
uses clinical auditing and fortnightly provides clinicians with online feedback regarding a 
predefined set of quality indicators developed by the professional organisation (see Table 
8.1). This benchmarking facilitates insights in clinician and hospital performance. Creating 
a feedback loop (with or without a benchmark) will not immediately improve patient care 
or impact the health of current patients, but could improve the health of future patients.
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stAkeholders And FundInG (“the Who”)
Who are involved in the registry?
Broad support for the registry and its goals is needed to maximise the benefits. Stakeholders 
can include clinicians, researchers, patients, governmental parties, healthcare insurers and 
manufacturers. Involvement from clinical experts (including key opinion leaders) improves 
the valorisation of the research results. Involvement of patient representatives secures 
patient participation and may help to ensure that the aims of the registry are pursued with 
minimal burden to patients. Participation of manufacturers may financially support the 
registry. Note that the term “manufacturers” is used in this article to refer to all companies 
involved in manufacturing, marketing or selling pharmaceuticals or medical devices.
Stakeholder can, however, have conflicting interests, for example with respect to aims, 
(level of) data access and data ownership (including publishing rights). Table 8.2 shows the 
different involvement of stakeholders in the registries we are familiar with. An essential 
and possibly time-consuming step in setting up a registry, is to align the main aim(s) of the 
registry. It is important to discuss primary and secondary objectives with key stakeholders at 
an early stage of drafting the plans for a new registry. It is also important to establish a clear 
and functional governance structure with all stakeholders, to define tasks and responsibili-
ties and agree on the decision-making processes.
Furthermore, data sharing might be an issue. For example when multiple manufacturers 
fund the registry, they may not be willing to share access to product-specific data with their 
competitors. In this case, detailed product-specific data can be shared with the manufacturer 
of the respective product, while sharing only aggregated data on products owned by other 
companies. By allowing variation in the level of data sharing136, even competing parties can 
participate and may benefit from collaboration within the same registry.
Technical solutions are available to many practical challenges, but agreeing on the objec-
tives and governance structure is crucial before moving on to technical matters. Identifying 
and engaging relevant stakeholders is, therefore, key to the success of a patient registry.
Who funds the registry?
It is crucial to secure sufficient funding for designing and running a registry to ensure viability 
and sustainability. Funding can be a challenge, especially when a large amount of money is 
needed, for example, due to extensive data collection or long-term follow-up. Funding must 
be sufficient to secure commitment from competent staff and experts. Long-term funding 
arrangements (e.g., four years or longer) are essential for the sustainability of a registry.
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Registries can be funded from one or more sources including public and private sources (see 
Table 8.2). Potential funding sources are manufacturers, healthcare insurers, governmental 
organisations, patient organisations, professional societies, private foundations and advo-
cacy groups. Dependent on the healthcare system, a more structural way to fund disease 
registries could be the inclusion of registry’s expenses in the cost of treating the disease 
(e.g., by increasing the price of a Diagnosis Treatment Combination or Diagnosis Related 
Group).
We are involved in various registries that have been funded by multiple manufacturers. 
These registries were largely motivated by the need to collect real-world data on the perfor-
mance of drugs for the Dutch reimbursement authority. Multi-sponsor registries have the 
advantage of decreasing the financial burden for each party and securing wider support for 
the registry. On the other hand, however, funders may have competing interests and ideas 
about the planning and design of the registry. In cases where multiple parties are involved, 
reaching consensus can be difficult and may require a long time. For example, multiple 
manufacturers were involved in PHAROS-1 and had products for various haematological 
indications in various treatment lines. Since the optimal approach for data collection differs 
per treatment (e.g., dependent on treatment line), priorities need to be set and need to be 
acceptable for all parties involved.
Another example is the POSEIDON lung cancer registry. The set-up of this registry started 
three years ago, but we still do not know whether or not data collection will actually com-
mence. During the design of this registry, more and more stakeholders became involved 
and objectives became broader. While this increases the potential benefits of the registry, it 
also complicates decision making. Time-consuming processes include agreeing on the study 
protocol, governance structure and funding. It is important not only to secure funding for 
the design and running of the registry, but also for all other activities needed prior to the 
start of data collection (e.g., stakeholder meetings, writing/revising the study protocol, ethi-
cal approval, defining data sets).
tYPe, Content, And dAtA ColleCtIon (“the WhAt”)
What is a suitable type and content of the registry?
A patient registry can either be disease-based or intervention-based.128 An intervention-
based registry can answer questions regarding appropriate use, effectiveness, cost-effec-
tiveness and safety. Disease-based registries provide additional information; for example, 
the number of untreated patients and whether these patients would have been eligible 
Balancing the optimal and the feasible | 127
VIII
ta
bl
e 
8.
3:
 T
yp
e 
an
d 
co
nt
en
t 
of
 t
he
 r
eg
is
tr
y 
(“
th
e 
W
ha
t”
)
n
am
e 
of
 r
eg
is
tr
y
th
e 
W
ha
t
PH
A
RO
S 
1
CA
PR
I 
an
d 
PR
O
-
CA
PR
I
D
M
TR
M
el
a-
no
m
a
M
et
a-
st
ati
c 
co
lo
re
ct
al
 
ca
rc
in
om
a
PE
RC
EP
-
TI
O
N
N
on
-s
m
al
l 
ce
ll 
lu
ng
 
ca
rc
in
om
a
PO
SE
I-
D
O
N
Lo
ca
lly
 
ad
va
nc
ed
 
H
ea
d 
&
 
N
ec
k
Re
cu
rr
en
t 
an
d/
or
 
m
et
as
ta
t-
ic
 H
ea
d 
&
 
N
ec
k
ty
pe
:
D
is
ea
se
-b
as
ed
x
x
x
x
x
x
x
In
te
rv
en
ti
on
-
ba
se
d
x
x
x
sc
op
e:
Po
pu
la
ti
on
-b
as
ed
x
Sa
m
pl
e-
ba
se
d
x
x
x
x
x
x
x
x
x
Co
n-
te
nt
:
Cl
in
ic
al
 o
ut
co
m
es
x
x
x
x
x
x
x
x
x
x
Ec
on
om
ic
 o
ut
-
co
m
es
x
x
x
x
x
x
x
x
x
x
Pa
ti
en
t 
re
po
rt
ed
 
ou
tc
om
es
x
x
x
x
x
Q
ua
lit
y 
of
 c
ar
e 
in
di
ca
to
rs
*
x
Pa
ti
en
t 
m
at
er
ia
l
To
 b
e 
de
ci
de
d
x
To
 b
e 
de
ci
de
d
*Q
ua
lit
y 
of
 c
ar
e 
in
di
ca
to
rs
 c
an
 b
e 
de
ri
ve
d 
fr
om
 a
ll 
re
gi
st
ri
es
 (
e.
g.
, l
en
gt
h 
of
 a
 s
ta
y 
in
 a
 h
os
pi
ta
l).
 H
ow
ev
er
, t
he
 D
M
TR
 is
 t
he
 o
nl
y 
re
gi
st
ry
 p
ro
vi
di
ng
 
on
lin
e 
be
nc
hm
ar
ke
d 
fe
ed
ba
ck
 t
o 
cl
in
ic
ia
ns
, h
os
pi
ta
ls
 a
nd
 m
an
uf
ac
tu
re
rs
.
128 | Chapter VIII
for treatment (appropriate use). Moreover, it is possible to study the full disease course. 
In contrast to intervention-based registries, disease-based registries can provide complete 
information on (sequential) treatment pathways (Table 8.3). However, it should be noted 
that this adds to complexity, time and costs of a registry.
Both disease-based and intervention-based registries can include all patients that meet the 
inclusion criteria of the registry or can only include a sample of the population of interest 
(Table 8.3). Including all patients adds to time and costs, whereas selecting a sample could 
be more efficient but can have pitfalls as well. In particular, the representativeness of the 
total patient population (external validity) may be hampered. A random sample or a cluster 
sample can be taken to prevent selection bias. In a cluster sample, some or all patients in a 
certain cluster, for example a region or a hospital are included, assuming that this cluster is 
comparable to the clusters not included in the registry.
To increase efficiency, it may be an option to use multiple-phase sampling. For example, 
in a two-phase design, limited data is first collected in a large sample, then a subsample 
is selected consisting of patients fulfilling a certain defined set of criteria. In this manner, 
minimal data can be collected on all patients and more comprehensive data can be collected 
from a smaller sample. The DMTR uses such an approach. Minimal data is collected on 
patients who are not treated in a melanoma centre (due to a worse prognosis), whereas full 
data (clinical, economic, PROMs) are collected for all patients who were treated in one of 
the fourteen Dutch melanoma centres (Table 8.3). Furthermore, detailed data (additional 
health care resource use, productivity losses and informal care) are only collected in a selec-
tion of four of the fourteen melanoma centres.
What data elements should be included?
After determining the type and content, the actual data elements for the registry need to 
be carefully selected. Preferably, this selection is based on clinical data standards (e.g., from 
the Clinical Data Interchange Standards Consortium, CDISC), current data sets (e.g., national 
disease registry), and/or on standard terminology (e.g., Systematised Nomenclature of 
Medicine, SNOMED). This facilitates comparison of registry data to other studies and cre-
ates the possibility to link different data sets using the same data definitions.
An expert advisory board can be consulted to ensure the selection of appropriate data 
elements.137 It is important to involve clinical experts as well as experts in real-world data 
handling. Clinical experts who are not experienced with outcomes research may advise on 
the inclusion of data elements that are difficult to collect in a real-world setting. It is advis-
able to always test the availability of data elements, for example in a pilot study. If there 
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is a lack of reliable data about certain variables (e.g., progression-free survival) it may be 
possible to substitute them with other variables (e.g., time to next treatment as a proxy for 
progression-free survival).
Using real-world data implies that there is always a trade-off between reliability, valid-
ity and specificity of data elements on the one hand, and the feasibility of data collection 
(affordability and completeness) on the other hand. The available data sources will set 
boundaries to what can be collected and will influence the way of data collection.
For example, in clinical trials data on adverse event is commonly reported by using the Com-
mon Terminology Criteria for Adverse Events (CTC AE) and the grade of the adverse event 
is scored by the clinician. This is, however, often not feasible in a registry, unless the CTC AE 
are consistently used and concisely reported in patients’ medical charts in clinical practice. 
In our lung cancer study, data were retrospectively collected from medical charts. Only 81 
out of 956 adverse events (8.5%) were graded by a clinician using a standardised grading 
system and subsequently reported in the medical chart. Only 491 adverse events (51.4%) 
were reported with sufficient information to retrospectively derive a grade, as judged by 
data managers. Therefore, a tension may exist between optimising reliability (only register 
an adverse event grade if recorded by the treating clinician) and optimising other properties 
of the registry such as data completeness.
To improve data quality, clinicians can be requested to register or verify registry data. How-
ever, this is often not feasible, especially when clinicians lack time to do so. Furthermore, 
in cases where registry data is used for the evaluation of the quality of care, using external 
data managers may increase objectivity and may enable the collection of data in multiple 
hospitals in a uniform way.
In the DMTR, all data that is recorded by data managers needs to be validated by the treat-
ing clinician. However, the validation process lags behind; clinicians clearly indicated that 
the validation process was too time consuming. Another way of improving the quality of 
the DMTR data was that 10% of all patients have been recorded by two data managers (one 
external) and all of these records were compared in order to increase uniformity of data 
recording.
To conclude, it is crucial to be aware of the quality and efficiency trade-offs, involve experts, 
extensively test the data elements, and perform preliminary analyses as early as possible.
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IdentIFICAtIon And reCruItMent oF PAtIents, dAtA hAndlInG, 
And PhArMACoVIGIlAnCe (“the hoW”)
how to identify patients?
Any type of registry may bring practical hurdles in identifying patients. In population-based 
patient registries, it is essential to identify all patients with the diagnosis of interest or 
treated with the intervention of interest. When selecting a sample of the target population, 
it is crucial to ensure the sample’s representativeness.
In the retrospective part of PERCEPTION, patients were identified through the Netherlands 
Cancer Registry, which includes basic information on 95% of all cancer patients (see Table 
8.4). A cluster sample, i.e. all patients with metastatic renal cell carcinoma within 42 from 51 
hospitals in four regions, was selected from this registry. A practical hurdle may arise in case 
there is no sufficient information available on the target population. For the prospective part 
of PERCEPTION, the Netherlands Cancer Registry did not fulfil the prerequisite of containing 
a timely and complete list of eligible patients given the mission and goals of PERCEPTION. 
Therefore, lists of patients with metastatic renal cell carcinoma were fortnightly derived 
from hospitals’ financing systems. As such, we ensured a complete overview of all patients 
eligible for PERCEPTION.
Alternative ways for patient identification can be the involvement of treating clinicians 
and patient associations.
how to recruit patients?
The next step is recruiting patients for participation in the registry. This can be a serious chal-
lenge. Participation in a patient registry by patients and clinicians can be voluntary or com-
pulsory. To increase participation, it could be made compulsory for patients to gain access 
to a health care product, for example an expensive drug or it could be made compulsory for 
a provider in order to be eligible for payment of this health care service. This was the case 
in the DMTR, the Dutch minister made the financing of a melanoma drug conditional on 
the set-up of a population-based registry and centralisation of melanoma care in fourteen 
specialist centres.
However, participation in most registries is voluntary. Patients can have multiple incentives 
for participating in a registry. Because a registry most likely does not change a patient’s 
current treatment, improving future patients’ health may be the most important incentive. 
Clinicians or hospitals may be incentivised by a particular research interest or the ability to 
achieve other goals through the registry (e.g., transparency, reimbursement and improve-
ment of quality of care).128 Furthermore, a (financial) compensation for time invested by 
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either clinicians or patients, may help to increase participation, but may induce selection 
bias.
how to handle the data?
Paper or electronic case report forms (CRFs) can be used to record patient and treatment 
information. Electronic CRFs offer the advantage of automatic validation checks and do not 
require transferring data from paper to an electronic database. The database needs to be 
suitable for the specific registry, including the level of detail that is collected with the CRF. 
The process of data collection, data management and data analysis should be organised in 
such a way that it protects patient privacy and maximises data quality.
It is crucial to ensure patients’ privacy in a registry, in particularly for patient identifiers. 
Training in Good Clinical Practice (GCP) and awareness of local rules and regulations will 
help designing the registry in such a way that patient privacy will be fully protected. This 
includes anonymisation or pseudonymisation of the data to ensure that information cannot 
be traced back to the patient. Anonymisation may not be an option when patient identifiers 
are needed for specific registry functionalities (e.g., to combine data from different sources). 
Pseudonymisation is a procedure by which identifying fields in a dataset are replaced by 
artificial identifiers, or pseudonyms. Pseudonymisation can be performed using a Trusted 
Third Party (TTP), guarding the encryption to the procedure while enabling re-identification 
when necessary. However, even in cases where a TTP is used, the inclusion of identifiable 
information in the CRF should be carefully scrutinised and only allowed in cases where this 
is absolutely necessary. Approval by a medical-ethical authority is required.
Furthermore, it is essential to ensure adequate and ongoing training for data managers 
including a detailed and up-to-date manual. This also includes guidance on when to record 
a value as missing, unknown, or as negative. For example, there is a difference between 
a patient who had no test for locating metastases and a patient who had a test but no 
metastases were found. Inconsistencies in data recording hamper a valid interpretation of 
the results.
Training of data managers and preliminary analyses allow identifying and sharing informa-
tion on common mistakes in order to continuously improve the quality of data in the registry.
how should pharmacovigilance be incorporated in the registry?
In most patient registries, information is collected on safety outcomes. This is, for example, 
important to attribute resource use to an adverse event in order to facilitate economic evalu-
ations. However, such information is often not sufficient for pharmacovigilance. European 
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and national legislation and sponsor policies increasingly require that pharmacovigilance is 
a formal part of a patient registry and requirements on pharmacovigilance increase as well. 
Patient registries have the potential to reveal unique pharmacovigilance information since 
the follow up allows for the identification of long term toxicity, and real world toxicity may 
differ from toxicity profiles in clinical trials because of differential populations, treatment 
patterns, adverse event handling and clinician experience.138 However, it can be a difficult 
challenge to comprehensively collect safety data within a registry, especially in case data 
is collected retrospectively. While adverse events may have occurred weeks, months or 
even years prior to the data collection, pharmacovigilance regulations may require serious 
adverse events reporting within 24 hours of recording them in the registry database. Such 
a timeframe allows manufacturers and authorities to take immediate action when needed 
to prevent that these serious adverse events occur in other patients. However, this requires 
a clear workflow and infrastructure. Another challenge is preventing double registration of 
adverse events in case the event has been reported at time of occurrence (e.g., to a national 
Pharmacovigilance Centre), which should usually be the case with serious adverse events.
Furthermore, dependent on the data sources of the registry, it may be difficult to com-
prehensively collect safety information. It may, for example, not be possible to determine 
causality. Another complicating factor is that safety reporting requires medical expertise of 
the study team and short communication lines with the treating clinicians. Furthermore, 
safety reporting can be extremely time consuming for clinicians and data managers.
Interim analyses in CAPRI revealed that 50% of patients had a recorded hospitalisation or 
death during treatment with chemotherapy. Although this percentage includes both related 
and unrelated adverse events, all needed to be reported. This illustrates that SAEs are 
common and may significantly add to data management time and thus costs of running a 
registry. However, it also emphasises that pharmacovigilance may be an important aspect in 
improving patient health.
Therefore, a plan for pharmacovigilance can be part of setting up a patient registry. This 
needs to be consistent with national and international guidelines, and agreed upon by all 
involved stakeholders. Ideally, however, all safety information should already be registered 
and reported by the clinician at the moment of occurrence of the adverse event.
lessons leArned
Patient registries provide valuable information on real-world patients, real-world practice, 
real-world costs, real-world effects, and real-world cost-effectiveness. If designed and 
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executed properly, registries can support decision-making at different levels. Regulatory 
authorities and local reimbursement agencies can use real-world data in market access and 
reimbursement decisions. Furthermore, sharing real-world outcomes can improve decision 
making at the individual patient level, and, ultimately, improve patient health.
Since patient registries can serve multiple goals and inform decision making at different 
levels, practical guidance in setting up a registry is important to ensure a proper design and 
execution. This paper provides a practical guidance on the Why, Who, What and How in 
setting up a patient registry, which is based on experiences from multiple registries in The 
Netherlands. It is essential to cooperate with all relevant stakeholders and collect the right 
data from the right patients in the right way. The “right” is not always the most extensive 
approach. It is crucial that the registry is designed in such a way that it serves its aims and 
it as efficient as possible. In registries, it is, therefore, particularly important to balance the 
optimal and the feasible in order to maximise the gains within the constraints of the avail-
able resources.
Although our experiences in setting up patient registries are based on registries in cancer, 
we believe that our recommendations are applicable to patient registries in all other disease 
areas. We also believe that our experiences in The Netherlands will benefit researchers in 
other countries.
Future prospects of registries
The number of patient registries will continue to rise in the near future.139 Their importance 
was shown in many areas including general practice140, neurology141,142, orthopedics143,144, 
and oncology.145,146
Various initiatives exist to facilitate designing high quality registries, such as the High-Value 
Health Care Project147 and the PARENT project (cross-border PAtient REgistries iNiTiative) 
for European member states (2012-2015). The PARENT project recommended tools for 
implementation of interoperable and cross-border patient registries. They also created a 
registry of registries which is online available.148
Several trends may influence the design of patient registries in the near future. First of all, 
there will be a further evolution of data standards and an improvement of interoperability of 
registries with electronic health records.149 Moreover, there is an increasing trend in setting 
up multi-institution and multi-country registries.150 Especially in rare diseases, multi-country 
registries are needed to include a sufficient number of comparable patients. Finally, the 
content of registries will reflect important clinical developments (e.g., biobanking).151
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Considering the unique value of and increasing demand for real-world evidence, we expect 
that patient registries will become the new standard alongside RCTs.

Chapter IX
General discussion
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Clinical studies, including randomised controlled clinical trials (RCTs), provide indispensable 
evidence about the efficacy and safety of new oncology drugs. This evidence is needed for 
a drug to be approved for marketing. However, after marketing approval, important ques-
tions still remain to be answered. These questions concern the real-world (RW) efficacy and 
safety of the drug as well as additional information on (appropriate) use, patient-reported 
outcomes, costs, budget impact and/or cost-effectiveness.
WhAt Are the dIFFerenCes betWeen rW eVIdenCe And eVIdenCe 
obtAIned In rCts?
In modern medicine, high-quality RCTs are considered the golden standard for judging 
treatment efficacy. Due to the randomisation procedure, observed differences in clinical 
outcomes between treatment groups in RCTs are likely caused by the treatment alone, 
rather than other differences between the treatment groups. However, this is not the case 
in observational studies. Differences between treatment groups in observational studies 
can either be caused by pre-existing differences between the treatment groups or by the 
treatment itself.
Pre-existing differences between treatment groups are common. Clinicians usually have 
a reason to prescribe treatment one to person A and treatment two to person B. If this 
reason/indication (e.g.: age) is also related to a patients’ prognosis, differences between 
groups A and B can be due to the treatment as well as the treatment indication. This is 
called “confounding by indication”. Various techniques exist to handle this problem, such 
as propensity score matching.152 However, unobserved differences cannot be matched or 
corrected for and may therefore continue to confound the results of observational studies. 
RCTs prevent this problem through randomisation and – all other things being equal – are 
therefore better able to attribute effects to treatments than non-randomised studies. How-
ever, this does not mean that randomised studies are always best suited to answer the type 
of research question(s) at hand.153
RCTs may suffer from other sources of bias154 as well as significant generalisability issues. 
“Randomly subjecting a person to a milieu of hidden exposures and then spotlighting him 
or her with relentless observation does not nurture normalcy”.154 The generalisability of 
RCT results to the real world can be limited due to differences in patient characteristics, 
clinicians, procedures and any other factors influencing treatment results.
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Considering the differences in patients, Stuart et al. stated that “participants in […] trials are 
rarely representative of the target population of interest and effects often vary for different 
types of people and in different contexts.”155 This is called “heterogeneity of treatment ef-
fect”. If the treatment effect was homogeneous, it would be applicable to everyone with an 
indication for treatment. However, often we expect a treatment’s effect to differ depending 
on the patient, provider or situation.156 In these cases, trial evidence is not necessarily ap-
plicable to the real world when RW patients differ from trial patients.
In this thesis, differences between RW and trial patients were demonstrated for patients 
with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN). Chapter II 
shows RW patients treated with radiotherapy plus cetuximab (RT+C) for LA SCCHN to have 
unfavourable baseline characteristics compared to the pivotal trial patients. Median age of 
the RW patients was higher and RW tumour characteristics at baseline were also indicative 
of poor prognosis compared to trial patients. This was reflected in survival outcomes since, 
beyond one year after treatment start, the patients treated with RT+C in daily practice died 
earlier than patients treated with RT+C in the trial.
Unfortunately, such a difference between the RW and RCT outcomes is not exceptional. In 
2011, Al-Refaie et al. published a study which identified predictors of enrolment in cancer 
trials by using RW data from the California Cancer Registry. They found, amongst others, that 
older patients (>65 years) and early stage cancer patients were less likely to be enrolled in 
cancer trials.157 RCTs commonly have an extensive list of eligibility criteria, selecting patients 
on, for example, age, comorbidities and performance status. However, outcomes in these 
patients may differ from outcomes in the general population. For example, in laryngeal 
cancer it was shown that elderly patients do not demonstrate similar treatment outcomes 
to those reported in clinical trials.158 This decreases the generalisability of trials to the real 
world. As a solution, the authors appeal to physicians, payers, the National Cancer Institute 
and other stakeholders to develop broader cancer trials.157
A relatively “broad” type of cancer trial would be a practical clinical trial, also called prag-
matic clinical trial. While “regular” (“explanatory”) clinical trials evaluate if a treatment 
works under ideal conditions, the aim of a practical clinical trial is to study risks and benefits 
of a treatment under clinical conditions. Therefore, in a practical clinical trial, the study 
setting(s) as well as study population and outcomes are chosen to be representative of the 
real world.159,160 Since pragmatic trials are designed to study RW practice and therefore 
represent less-perfect experiments than “regular”/explanatory/efficacy trials, they sacrifice 
some internal validity to achieve more generalisability.161
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Practical clinical trials provide a valuable addition to explanatory trials, since they can evalu-
ate treatment effect under clinical conditions. Furthermore, their randomised setting allows 
for direct comparison between treatment groups. However, they often require relatively 
large sample sizes and, while having higher external validity, can have lower internal validity 
than explanatory trials.162 Therefore, explanatory trials remain the most efficient way to 
demonstrate treatment efficacy, especially initially, when rapid market access is pursued.
Furthermore, although practical clinical trials approximate the real world as closely as 
possible in the trial setting, they are still protocol-guided and therefore unable to answer re-
search questions about the actual real world. In order to study RW treatment patterns, RW 
clinical outcomes and RW costs, observational outcome studies are needed. These studies 
solely observe what happens in daily practice, without prescribing diagnostic or treatment 
protocols.
RCTs and observational outcome studies have complementary roles. Both can answer a dif-
ferent type of important questions. The choice of study should match the questions at hand. 
In general, RCTs are best suited to further scientific knowledge, while outcome studies are 
best suited to study the translation of this knowledge to clinical practice. Both study designs 
can be relevant for treatment decisions and can be combined in decision-analytic modelling.
hoW CAn the AddItIon oF rW eVIdenCe to rCt eVIdenCe 
suPPort deCIsIon MAkInG?
In decision-analytical modelling, costs and consequences of treatment alternatives can 
be compared by synthesising information from multiple sources, including RCTs as well as 
observational studies.163 The aim is to provide the best available evidence to reach a deci-
sion, for example on whether or not to approve a drug for reimbursement. Many different 
types of modelling approaches exist to answer various types of questions. In chapter III of 
this thesis we used a Markov model to evaluate the cost-effectiveness of cetuximab in LA 
SCCHN, to inform a decision on drug reimbursement.
Since the aim was to estimate Dutch, RW cost-effectiveness of RT+C, RW information was 
used as much as possible to inform the model. However, effectiveness information was 
not available from the real world due to limited possibilities to correct for confounding by 
indication. Therefore, the relative effect of the treatments was taken from the pivotal trial 
(efficacy).11 The prognoses of patients in both treatment groups were adjusted downwards 
in one of the two model scenarios, to match RW survival estimates without altering the 
relative treatment effect. Thereby information from the trial and the outcome study were 
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combined to approach the question at hand (chapter III). Unfortunately, the actual RW cost-
effectiveness could not be calculated, since we had to rely on trial efficacy outcomes instead 
of RW effectiveness evidence. However, RW cost data were used, since resource use could 
be collected in RW clinical practice.
It is not exceptional that valid effectiveness outcomes cannot be obtained from observational 
data, for example due to limited possibilities to correct for confounding by indication.53,164 
Van Gils et al. also experienced this problem in their study on the RW cost-effectiveness of 
oxaliplatin. Similarly, they decided to inform their decision-analytic model with trial evidence 
in addition to RW data. Based on the trial selection criteria, they were able to determine 
which part of the RW patients would have been eligible for the RCT. They therefore included 
four scenarios in their modelling: (1) cost-effectiveness analyses based on trial patients 
only; (2) cost-effectiveness analyses using trial patients and trial-eligible RW patients; (3) 
cost-effectiveness analyses using trial patients and both trial-eligible and trial-ineligible RW 
patients, assuming oxaliplatin had an equal effect in ineligible and eligible patients; and (4) 
cost-effectiveness analyses using trial patients and both trial-eligible and trial-ineligible RW 
patients, assuming oxaliplatin had no effect amongst ineligibles.52 This approach provided 
the decision maker with a good idea about the range of probable values given various alter-
native assumptions on Dutch, RW treatment effectiveness. Costs were based on actual RW 
resource use as obtained in the observational study.
In the Netherlands, RW evidence is required within the context of conditional drug reim-
bursement. At the time the studies in this thesis were performed, hospitals could receive 
additional reimbursement for expensive drugs, given that an initial (T=0) value dossier 
showed that the drug would cost Dutch hospitals more than 2.5 million euro per year. Fur-
thermore, pharmacotherapeutic evidence, pharmacoeconomic evidence and a study plan 
for outcomes research had to be submitted. After four years (T=4), approved drugs were re-
evaluated and cost-effectiveness had to be substantiated with RW data.30,165 Chapter III and 
IV of this thesis were based on studies performed within the context of such re-evaluations.
For both indications, LA SCCHN and recurrent/metastatic squamous cell carcinoma of the 
head and neck (RM SCCHN), cetuximab was approved for continuation of reimbursement. 
Cost-effectiveness of treatment with cetuximab was reasonable for patients with LA SCCHN 
and was not evaluated for patients with RM SCCHN, due to limitations of the data. However, 
the budget impact of the drug was small for both indications and therefore the financial risk 
and opportunity costs involved with a positive reimbursement decision were small as well.
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Recently Cerri et al. published a study about multivariate analyses to evaluate which vari-
ables were determining CVZ reimbursement decisions (in 2004-2009). One of the outcomes 
was that budget impact estimates had a significant influence on these decisions. As opposed 
to budget impact, cost-effectiveness estimates did not seem to impact reimbursement 
decisions.166 With respect to the practical use of RW cost-effectiveness estimates and other 
health-economic evidence, much work still remains to be done in the Netherlands and else-
where. One important issue is the apparent failure of evidence from economic evaluations 
to influence governmental decision making as much as expected.167
In the United Kingdom, cost-effectiveness requirements are applied more strictly. From a 
British health perspective, cetuximab was not recommended for patients with RM SCCHN. 
It was concluded that patients “were not shown to receive a significant survival benefit 
from cetuximab plus [chemotherapy] compared with [chemotherapy] alone and that even 
setting a lower price for cetuximab would not strengthen the manufacturer’s case for cost-
effectiveness”.80 Meanwhile, “it is the preferred regimen in commonly used guidelines in 
the US, where economic evaluations are not incorporated in the drug approval process.”40
A negative decision regarding reimbursement has commonly caused criticism by patients 
and clinicians. Patients may worry that they are being denied a potentially effective treat-
ment and clinicians may share this worry and feel their professional freedom is being 
restricted for the sake of money. However, since the volume as well as the prices of new 
drugs keep rising28, choices need to be made. Since 2011, expenditure on expensive drugs 
in the Netherlands increased with 80% to €675 million per year, paid from hospital budgets. 
For 2016 an extra increase of €300 million is foreseen, €75 million of which will be spend on 
immunotherapy for non-small cell lung cancer (NSCLC).168
When reimbursement of non-cost-effective drugs is denied, this allows the available 
resources to be spent in a more cost-effective way, on care that provides more value to 
the patients in need. Another option is not to deny reimbursement of these drugs, but to 
negotiate a more favourable price. Moreover, various countries have experimented with the 
use of risk-sharing agreements between healthcare payers and product manufacturers, for 
example by relating the price of a product to its actual RW performance in clinical practice.169
In clinical practice, RW evidence is considered by clinicians, including oncologists. Narayanan 
(2013) performed a multi-country survey to assess the perception of oncologists about their 
country-specific healthcare reforms and the consideration of RW evidence when prescrib-
ing medications. The study was performed in five European countries (United Kingdom, 
Germany, Spain, France and Italy), the United States, Brazil and China. Twenty-three percent 
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of the oncologists indicated that healthcare reforms in their country did not have enough 
focus on the need for RW evidence and evidence on cost-effectiveness of medications. Be-
tween one-third and half of the oncologists reported considering RW data while prescribing 
medicines. RW evidence on patient quality of life was used more often than RW evidence on 
product effectiveness, safety or costs.170 Unfortunately, for many clinical decisions, impact 
on patient quality of life is unknown.
hoW CAn rW Cost dAtA IMProVe lunG And heAd And neCk 
CAnCer CAre?
Clearly, medical spending on cancer care can improve patient quality of life and survival.77,171 
However, this relation is not linear at all77. In this thesis, chapters III, IV, VI and VII present 
RW cost estimates of cancer diagnostics and treatments. Of these four chapters, chapter III 
is the only one addressing the cost-effectiveness of treatments. Since the other chapters in 
this thesis do not provide information about value for money, they do not inform decisions 
on cost reductions. They do, however, provide insight into the most important cost drivers 
and the financial burden associated with these aspects of cancer care.
It is important for clinicians to be aware of these costs in order to curtail the current escala-
tion of healthcare spending.172 In 2009, Howard Brody (MD, PhD) called upon the medical 
community to identify, per specialty, “five diagnostic tests or treatments that are very com-
monly ordered by members of that specialty, that are among the most expensive services 
provided, and that have been shown by the currently available evidence not to provide 
any meaningful benefit to at least some major categories of patients for whom they are 
commonly ordered.173 In oncology, many responded to his call.
In response to Brody’s call, Smith and Hillner78 created a list of five suggested changes in 
oncologists’ behaviour and five suggested changes in oncologists’ attitudes and practices. 
Their suggestions include adaptations of various diagnostic as well as treatment practices, 
including a more sparing use of chemotherapy. For example, they suggest clinicians “limit 
second-line and third-line treatment for metastatic cancer to sequential monotherapies 
for most solid tumours”, “limit chemotherapy to patients with good performance status, 
with an exception for highly responsive disease” and “for patients who are not responding 
to three consecutive regimens, limit further chemotherapy to clinical trials”. Furthermore, 
they stress the need for cost-effectiveness analyses.78 Stemming from within the profes-
sional society, these suggestions are very helpful in order to find possibilities to reduce costs 
while causing the least harm to patients.
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The American Society of Clinical Oncology (ASCO) also responded to Brody’s call with a top 
five list of diagnostic, surveillance and therapeutic interventions that may better be dis-
continued. Among them is the advice not to “use cancer-directed therapy for solid tumour 
patients with the following characteristics: low performance status (3 or 4), no benefit from 
prior evidence-based interventions, not eligible for a clinical trial, and no strong evidence 
supporting the clinical value of further anti-cancer treatment.”174 Given the results pre-
sented in chapter IV and VII of this thesis, these suggestions may be useful to decrease 
medical spending in RM SCCHN and NSCLC. However, a lack of evidence on the clinical value 
of treatments for certain patient groups, does not automatically mean these treatments 
should be discontinued. It emphasises the importance of RW evidence, especially about 
those patient groups excluded from clinical trials.
In the study presented in chapter IV, the study population consisted of patients with a poor 
prognosis. Kelly and Smith175 identify end-of-life care as one of three areas in which total 
cancer care costs could be reduced while causing the least harm. Since care at the end 
of life is expensive and sometimes ineffective, Kelly and Smith suggest that changes could 
actually improve quality and reduce costs. Possible approaches to achieve this, in general, 
are to provide clinicians with feedback on their centre’s use of end-of-life chemotherapy 
and discuss palliative care and dying with patients at a relatively early stage.175 Much may 
be gained with open communication between clinicians and patients on the expected costs 
and gains of treatments, on an individual as well as on a national basis. Shared decision 
making between patients and clinicians may favour less extensive hospital treatment and 
therefore lower costs.77,176
However, treatments that are initially considered to be end-of-life treatments may prove to 
have additional benefits. New drugs starting out as end-of-life treatments can move to other 
treatment lines over time. While their cost-effectiveness may be limited in the palliative 
phase, the indication of new treatments may expand over time, when more RCT results 
become available regarding their safety and efficacy in earlier treatment lines. Strictly deny-
ing access to drugs that initially seem non-cost-effective may deny clinicians the opportunity 
to gain experience with the drug and find out its optimal, possibly cost-effective, use and 
indication.
Chapter VI of this thesis presented the costs of laboratory testing for NSCLC patients. It 
shows that the costs associated with biomarker tests are substantial. However, results of 
such tests also have the potential to reduce costs in the longer run and improve clinical 
outcomes. When cancer biomarkers provide information about disease progression or 
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treatment response, they can be used to guide treatment and confer both clinical and 
economic benefits.172
In economic evaluations costs of both the targeted therapies and their companion diag-
nostics (such as biomarker tests) should be taken into account. Note that the number of 
patients receiving the test (and therefore inducing costs) may be considerably higher than 
the number of patients who will benefit from the targeted treatment; this ratio depends on 
the prevalence of the target that is tested for.177 However, in the future, “Next Generation 
Sequencing” (NGS) techniques may allow for simultaneous testing of multiple targets at 
once, and subsequently prescribing the optimal targeted therapy.
Cancer drugs are not the only treatments impacting costs and health outcomes in oncology. 
While other treatments and interventions may impact clinical and economic outcomes at 
least as much, in the Netherlands their cost-effectiveness does not need to be shown in 
order to obtain reimbursement. As was shown in chapter III, IV and VII, radiotherapy also 
has an important share of the costs of cancer management. Furthermore, radiotherapy is an 
innovative field of medicine as well, and “obtaining reliable and extensive local assessments 
on budget impact and costs of radiotherapy will be highly relevant for policy and planning 
in many world regions.”178 Recent technical advances in radiotherapy for NSCLC include the 
more widespread use of stereotactic body radiation for stage I NSCLC, concurrent chemora-
diation for stage III NSCLC, the implementation of 4-dimensional computed tomography and 
positron emission tomography and adaptive radiation therapy strategies.179
Advances in treatments may also reduce the costs of adverse events, such as surgical com-
plications. Research has shown that improvements in treatment-related patient safety are 
highly likely to reduce costs.180 However, while it is usually the costs of treatments in general 
and drugs specifically that get the most attention, other areas may be just as important for 
controlling cancer costs.
One of these other areas is prevention. The relatively high costs of cancer care underline the 
value of investing in effective cancer prevention. One effective type of cancer prevention is 
the prevention of smoking.181,182 In an article about lung cancer costs in Northern Ireland, 
Fleming et al. showed annual lung cancer related hospital costs to be 13 times as high as the 
estimated enforcement cost of the smoke-free legislation in Northern Ireland.121
Another area to consider is diagnostics. In the recent past, the adoption of the PET (positron 
emission tomography) and PET-CT (positron emission tomography-computed tomography) 
scan significantly reduced inpatient costs by reducing the number of patients undergoing 
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surgery or radiation therapy. Unfortunately however, this did not result in cost reductions: 
“[…] during the same period, the use of chemotherapy and non-inpatient expenditures 
increased rapidly, more than offsetting potential savings in inpatient expenditures.”119
hoW CAn rW dAtA on treAtMent PAtterns IMProVe lunG And 
heAd And neCk CAnCer CAre?
Previous chapters discuss treatment patterns (chapters IV and V) as well as differences 
in overall survival between academic and non-academic hospitals (chapter V). Apparent 
differences between hospital types can be caused by various factors, including clinician 
expertise, differences in case mix that could not be corrected for, or even differences in 
documentation.185 If differences are caused by differences in clinician experience or exper-
tise – indicating that clinicians in some hospitals treat their patients better than clinicians in 
other hospitals – this is reason for action.
One of the most efficient ways to allow hospitals to find opportunities for improving their 
practice is benchmarking. Comparing practices and outcomes between hospitals also al-
lows them to monitor progress after corrective action is taken.186 Real-world data is needed 
to inform this process. For example, some important variables from patient registries can 
be fed back to participating hospitals in a way that shows them how they are performing 
compared to other treatment centres (see chapter VIII).
Another important factor in reducing treatment heterogeneity between hospitals is the 
use of clear, evidence-based guidelines. Uptake of clinical guidelines can be hampered by 
concerns about evidence quality, medical culture, delay in process, and evolving treatment 
options not addressed in the guideline.187 This last concern may be especially relevant for 
chapter IV, since head and neck cancer guidelines were relatively old and did not include 
all available evidence regarding new treatment options. However, new guidelines will be 
published shortly.
Hall et al. advise frequently monitoring adherence to guidelines, especially when the guide-
line is controversial. Furthermore, a more fluid guideline format may be needed when the 
evidence is evolving rapidly.187 For the Dutch NSCLC guideline this is realised by undertaking 
modular revisions in addition to complete revisions.
Reames et al. evaluated US oncology guidelines and concluded they are not as “trust-
worthy” and complete as they should be.188 To our knowledge, such an evaluation of Dutch 
oncology guidelines has not been performed.
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As was discussed in chapter V, treatment volumes per hospital may also have an effect on 
the quality of care and on survival outcomes. Potential reasons for this in the case of surgery 
include patient selection, preoperative evaluation and preparation, surgical judgment, skill, 
and postoperative care, which require a multidisciplinary team approach in the periopera-
tive period and beyond.158 Studies on the influence of treatment volume on non-surgical 
treatments in oncology are scarce.
Centralisation of treatment within a limited number of hospitals, such as the head and neck 
cancer centres, may improve quality of care since it increases the number of patients per 
centre and therefore the treatment volumes. Furthermore, it may speed up the uptake of 
innovations, especially since these treatment centres are also heavily involved in clinical 
trials:
“It is well known that doctors who have participated in clinical trials are more eager to 
adopt an innovation than colleagues who did not. The “trial” doctors and “trial” centres 
already have experience with the innovation, thus when there is a proven clinical benefit 
they are inclined to administer the innovation to their patients.”77
However, rapid uptake of innovations is not necessarily a gain. Key opinion leaders can be 
too enthusiastic about an innovation, for example focusing on a gain in progression-free sur-
vival, rather than in overall survival, side effects or cost. However, in the case of cetuximab 
for the treatment of head and neck cancer, we did not find any indication of overtreatment. 
In fact, chapter IV shows that the prescription of cetuximab to R/M SCCHN patients in the 
Netherlands is highly selective. It would be interesting to compare the Dutch treatment 
decisions and outcomes for R/M SCCHN to the treatment decisions and outcomes in other 
countries as well as the clinical guidelines. Possibly more patients may benefit from treat-
ment with cetuximab than currently receive this drug.
hoW CAn PAtIent reGIstrIes be used to ColleCt hIGh-quAlItY 
rW dAtA?
Chapter VIII discusses patient registries as one of the possible sources of real-world data. 
Proper design and monitoring of patient registries can minimise some of the limitations 
commonly associated with real-world data.53,189 Furthermore, registries can be used for 
“studying heterogeneity of diseases, examining treatment patterns, measuring patient-
reported outcomes, examining economic outcomes, and performing comparative effec-
tiveness research”.190 Herewith, they can expand on clinical trial evidence and bring the 
real-world foundation needed to inform the daily practice of clinical cancer management.
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In order to impact the daily practice of cancer management, clinicians should be closely 
involved with the registry. An effective feedback loop should be created, informing the 
profession about its performance and about important study findings relevant to clinical 
practice. Furthermore, the profession should be open to feedback and willing to implement 
changes in their practice in order to improve results. This requires an open and self-critical 
culture as well as profound trust in the quality and relevance of the registry data.
Supportive IT infrastructure can improve the quality of RW data by facilitating the collec-
tion, storage, integration, analysis, and archiving of information. Continued improvement of 
clinical data standards as well as communication between and integration of medical infor-
mation systems increases the potential for automation of RW data collection for research 
purposes. However, many hurdles are still to be overcome, such as the use of different 
types of hospital information systems in different hospitals and the large amount of clinical 
information registered in non-standardised ways.
lIMItAtIons
The limitations of the studies in this thesis have been presented per study, in chapters II-
VIII. Most limitations were related to the use of real-world data that was retrospectively 
collected. Although real-world data has important advantages compared to clinical trial 
evidence – alleviating generalisability issues – it has important drawbacks as well. These 
drawbacks were discussed in the respective chapters and some will be repeated here.
First of all, availability of good-quality data was often a problem. Since we were depen-
dent on the completeness and level of detail available in patient charts, important data on 
some prognostic factors and treatment outcomes could not be collected reliably. The most 
troublesome in this respect were missing data on disease stage, WHO performance status 
and locoregional recurrences.
Furthermore, the data did often not cover the complete disease courses of HN SCCHN and 
NSCLC patients. For example, when patients were referred to other hospitals not participat-
ing in our studies, they were considered lost to follow-up. Our conclusions were therefore 
limited to the timeframe we were able to observe and we had to use statistical techniques 
(such as Kaplan Meier survival curves and the Bang and Tsiatis estimator for costs) to correct 
for censoring.
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Data availability also limited our information on resource use and costs. In all studies pre-
sented in this thesis, costs were calculated from a hospital perspective. This excludes impor-
tant cost categories, such as the costs of visits to the general practitioner, other healthcare 
providers and institutions (such as a hospice), and extramural drugs not prescribed by a 
clinician from the hospital. Additionally, non-medical and indirect costs can be considerable 
and were excluded from our studies, for feasibility reasons. Furthermore, some resource 
use had to be valued using tariffs instead of costs obtained from detailed costing studies. 
Although these tariffs were the best approximation we could find, they do not necessarily 
represent the actual cost prices and can be either higher or lower. However, for the most 
important items of resource use (cost drivers), reliable cost prices and/or reference prices 
were available and used.
An important area of concern in observational studies is the internal validity of the data 
and therefore the need to correct for confounding by indication when groups are being 
compared. Since the nature of our data did not allow for sufficient correction, some of our 
questions (regarding RW treatment effectiveness) could not be answered. All researchers 
working with RW data should be aware of the limitations of this type of data and refrain 
from analyses and conclusions they cannot substantiate with reliable and valid observa-
tional evidence.
ConCludInG reMArks
The development of large, high-quality, disease-wide patient registries, may be the answer to 
RW data needs in Dutch outcomes research and cost-effectiveness analysis. These registries 
should not only include clinical variables and quality of care indicators, but also information 
on resource use and quality of life. This information in crucial in order to evaluate the costs 
and benefits associated with new diagnostic and treatment interventions.
The collection of detailed information on resource use may be time-consuming. It is there-
fore advisable to collect only the most important items of resource use (such as hospital 
admissions) for all patients, and to collect less important items (such as the use of over-the-
counter medication) only for a subset of patients. Based on patient, tumour or treatment 
characteristics, the costs for less important items of resource use can than be extrapolated 
to the rest of the population. However, the need for such extrapolations may reduce over 
time. Interconnectivity of IT systems, such as hospital information systems and registry 
databases, may bring important advances in the efficiency of data collection.
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The comprehensive collection of quality of life data may be more challenging. Especially in 
the case of end-of-life care it may be burdensome for patients to complete quality of life 
questionnaires. However, improving quality of life is often an important treatment objective. 
Help of healthcare professionals (e.g. nurses) or family members as well as improvement of 
the instruments (questionaires) and tools (e.g. apps) to measure quality of life may relief 
some of the burden and increase response, in order for researchers to assess the value of 
new interventions.
However, importantly, the patient should always remain in the centre of all data collection 
efforts. IT advances may allow future patients to have more insight in and influence on 
the data collected about them. For example, advanced electronic medical files may allow 
patients to view their medical information online, give or deny permission for the use of 
certain data elements by researchers and provide and share additional information (e.g. on 
quality of life).
In the near future, advances in medical data collection will shape clinical as well as health 
economic research. If carefully designed, carefully analysed and carefully used to improve 
the quality and cost-effectiveness of diagnosis and treatment strategies, registries will prove 
invaluable to Dutch healthcare as a whole and oncology in particular.
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GenerAl IntroduCtIon
New oncology drugs have been studied extensively before they enter the market. In clinical 
trials, their safety and efficacy is evaluated. However, after they enter the market, important 
questions still remain to be answered. These include questions about real-world effective-
ness and safety, but also questions about appropriate use, patient-reported outcomes, 
budget impact and/or cost-effectiveness.
Information about real-world effectiveness and safety of new drugs is needed to evaluate 
if the harms and benefits of drugs in daily practice are acceptable and similar to what was 
expected based on clinical trial results. Data on treatment patterns can be used to evaluate 
how a certain drug is being prescribed and, for example, if this is according to guidelines. 
The budget impact of a new drug informs the payer about the extent to which it will take 
up available resources. Moreover, the value for money of a drug is represented by its cost-
effectiveness. Given the limited national healthcare budgets, information about budget 
impact and cost-effectiveness is increasingly important to ensure rational allocation of 
scarce resources.
This thesis discusses real-world evidence obtained from observational outcome studies in 
two clinical areas: head and neck cancer and lung cancer. It shows the use of real-world data 
in addition to clinical trial evidence. Furthermore, it discusses the design of patient registries 
to collect real-world data.
heAd And neCk CAnCer
Chapter II and chapter III discuss the use and cost-effectiveness of cetuximab for patients 
with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN). In a 
randomised controlled trial in patients with LA SCCHN, treatment with radiotherapy plus 
cetuximab (RT+C) resulted in prolonged median locoregional control (24.4 vs. 14.9 months), 
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progression-free survival (17.1 vs. 12.4 months) and overall survival (49.0 vs. 29.3 months) 
compared to treatment with RT alone. However, uncertainty existed about the generalis-
ability of these trial results for the Dutch healthcare setting and the value for money of 
cetuximab in daily practice. A retrospective study was designed to provide this information.
In this study 141 patients were included, diagnosed between 2007 and 2010 in two head 
and neck treatment centres. Patients were treated with first-line RT+C or RT alone. Patient 
characteristics, treatment characteristics and treatment outcomes were compared between 
trial patients and patients from daily practice. The resulting information was used in chapter 
II and III.
Chapter II shows that, in line with Dutch guidelines, RT+C was prescribed in patients who 
were unfit to receive traditional platinum-based chemotherapeutics. These patients had 
unfavourable baseline characteristics, due to selection on—amongst others—high age of 
the patients. Patients treated with RT+C in daily practice died earlier than patients treated 
with RT+C in the trial. It seems like selective treatment allocation in daily practice limits 
generalisability of the trial results. Evidence is needed about the effectiveness of RT+C for 
patients with unfavourable clinical baseline characteristics, in addition to the evidence 
obtained in the pivotal clinical trial.
Chapter III of this thesis was based on the same study. We estimated the real-world 
incremental cost per quality-adjusted life year gained for RT+C over RT alone in first-line 
treatment of LA SCCHN. A Markov model was constructed with health states “alive without 
progression”, “alive following progression” and “death”. Transition probabilities per month 
were estimated from clinical trial data and the real-world data discussed in chapter II. Five-
year, ten-year and lifetime horizons were used, without and with discounting (4% costs, 
1.5% effects) to calculate incremental cost-effectiveness ratios.
Two scenarios explored different assumptions on the prognosis of real-world versus trial 
patients. In scenario 1, transition probabilities were fully based on efficacy results from the 
clinical trial. In scenario 2, RW patients were assumed to have a less favourable prognosis 
than patients in the clinical trial, consistent with the results described in chapter II. Adding 
cetuximab to radiotherapy resulted in increased costs and health gains in both scenarios 
and across each of the time horizons.
Incremental costs per QALY gained ranged between €14,624 and €38,543 in the base-case. 
For a willingness to pay of €80,000 per QALY, the acceptability curves for the different sce-
narios showed probabilities between 76% and 87% of RT+C being cost-effective compared 
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to RT alone. In conclusion, current results show the combined treatment of RT+C to be 
a cost-effective treatment option for patients with LA SCCHN, when adopting clinical trial 
efficacy estimates.
Chapter IV, also about head and neck cancer, discusses real-world information on palliative 
systemic treatment and costs of recurrent and/or metastatic squamous cell carcinoma of 
the head and neck (R/M SCCHN) in the Netherlands. For patients with R/M SCCHN, chemo-
therapy can prolong life and alleviate symptoms. However, expected gains may be small, 
not necessarily outweighing considerable toxicity and high costs. Treatment choice is to a 
large extent dependent on preferences of doctors and patients and data on these choices is 
scarce. In this study, data were collected on patient and tumour characteristics, treatment 
patterns, disease progression, survival, adverse events, and resource use for R/M SCCHN.
The study was conducted in six Dutch head and neck treatment centres, for patients diagnosed 
between 2006 and 2013. Hundred and twenty-five (14%) out of 893 R/M SCCHN patients 
received palliative, non-trial first-line systemic treatment, mainly platinum+5FU+cetuximab 
(32%), other platinum-based combination therapy (13%), methotrexate monotherapy (27%) 
and capecitabine monotherapy (14%). Median progression-free survival and overall survival 
were 3.4 and 6.0 months, respectively. 34 (27%) patients experienced severe adverse events. 
Mean total hospital costs ranged from €10,075 (±€9,891) (methotrexate monotherapy) to 
€39,459 (±€21,149) (platinum+5FU+cetuximab). Primary cost drivers were hospital stays 
and anticancer drug treatments.
non-sMAll Cell lunG CAnCer
Chapter V-VII discuss survival, treatment patterns and costs of non-small cell lung cancer 
(NSCLC).
The aim of chapter V was to analyse differences in NSCLC survival between academic and 
non-academic hospitals and to provide insight in NSCLC treatment patterns. Population-
based information about NSCLC patients was obtained from the Netherlands Comprehen-
sive Cancer Organisation. Overall survival for patients in academic hospitals and patients 
in non-academic hospitals were compared. We used Kaplan Meier methods to estimate 
overall survival rates by hospital type and Cox proportional hazards models to estimate 
the relative risk of mortality (expressed as hazard ratios, adjusted for case mix) and their 
95% confidence intervals (95% CI) per hospital type, with all non-academic hospitals as the 
reference group. Data on treatment patterns in Dutch hospitals was obtained from four, 
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not randomly selected hospitals (two academic, two non-academic). A random sample of 
unselected patients newly diagnosed with NSCLC from 31 January 2009 until 31 January 
2011 was identified through the four hospital databases.
In NSCLC, choice of treatment is very much patient and tumour dependent. For non-
metastasised disease, patients treated in academic hospitals had superior overall survival 
as compared to patients treated in non-academic hospitals, even when adjusting for case 
mix. Median survival was 2.66 years (95% CI 2.14-3.18) in academic versus 1.83 years (95% 
CI 1.73-1.93) in non-academic hospitals. For metastasised disease, median survival was 0.41 
years (95% CI 0.35-0.48) in academic versus 0.39 years (95% CI 0.38-0.41) in non-academic 
hospitals.
Chapter VI reports the costs of laboratory tests for NSCLC management. Cancer patients un-
dergo a wide range of laboratory procedures, from simple blood tests to complex molecular 
diagnostics. In cost-effectiveness analyses, costs of laboratory testing are often ignored or 
estimated inappropriately. We present real-world costs of laboratory procedures for NSCLC 
patients, per category of laboratory testing. In a Dutch academic hospital, all laboratory 
tests performed for NSCLC patients between 2009 and 2011 were recorded and categorised 
in clinical chemistry; pathology; microbiology; serology, hematology, transfusion; pharma-
cology; and other or unknown. Number of tests per type were multiplied with unit costs per 
test obtained from The Dutch Healthcare Authority.
A total of 1,015 patients was included, with 171,632 laboratory procedures. The number of 
different types of tests was 392. Mean cost of laboratory testing per patient was €96 (95%CI 
91-101) per day with at least one laboratory procedure. This price can be used to value 
laboratory testing when the number of days with laboratory testing is known. A price of €49 
per day between the first and the last laboratory test can be used when the number of days 
with laboratory testing is unknown, but the number of days between the first and the last 
laboratory test is known.
Relatively simple blood tests contributed significantly to the laboratory costs due to high 
test volumes. Main cost driver however was molecular testing by the pathologist, for the 
use of targeted therapies. In pharmacoeconomic evaluations, taking laboratory costs into 
account significantly impacts results, especially when testing practices differ between treat-
ment alternatives.
Chapter VII uses data from the studies presented in chapter V and VI to present resource use 
and cost data on all aspects of hospital care for NSCLC patients. Data was retrospectively col-
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lected from patient charts and included detailed information on resource use. Resource use 
was multiplied by Dutch unit costs expressed in EUR 2012. Total mean costs were corrected 
for censoring using the Bang and Tsiatis weighted complete-case estimator.
Total mean costs for NSCLC diagnosis, treatment and follow-up were €28,468 during the 
study period and €33,143 when corrected for censoring. Adverse events were recorded in 
the patient charts for 369 patients (41%) and 82 patients (9%) experienced an adverse event 
of grade III or higher. For these patients, adverse event-related hospital admissions costed 
on average €2,091. Mean total costs were €1,725 for the diagnostic period, €17,296 for the 
first treatment line, and €13,236 for each later treatment line. Costs of providing a second 
opinion were €2,580 per patient. Although the study had important limitations related to 
the short follow-up time, staging difficulties and missing data, it provided highly detailed, 
real-world information on the costs of NSCLC.
PAtIent reGIstrIes
In chapter VIII we focused on the collection of real-world data instead of actual real-world 
outcomes. With this chapter we aimed to provide guidance in setting up patient registries 
for the collection of real-world data for healthcare decision making. We discuss the mission 
and goals of patient registries, stakeholders and funding, type of registry, content, data col-
lection, identification and recruitment of patients, data handling and pharmacovigilance.
The mission of most registries is improving patient health by improving patient care. 
Therefore, monitoring patient care is often the primary goal of registries. In order to reach 
this goal, registry objectives need to be aligned and stakeholders need to agree on a clear 
and functional governance structure. For the selection of data elements, help from clinical 
experts as well as experts in outcomes research can be valuable. In data collection there is a 
trade-off between reliability, validity and specificity of data elements on the one hand, and 
feasibility on the other hand. In order to design the registry in a way that protects patient 
privacy, training in Good Clinical Practice and awareness of local regulations is important. 
Moreover, since patient registries have the potential to provide unique safety information, 
a solid pharmacovigilance plan is needed.
Considering the unique value of real-world evidence, we expect patient registries to 
become the new standard in medical data collection, alongside RCTs. RCTs and observa-
tional outcome studies have complementary roles and the choice of study should match the 
questions at hand. In decision-analytical modelling, expected costs and consequences of 
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treatment alternatives can be compared by synthesising information from multiple sources, 
including RCTs as well as observational studies. Decision-analytic models can be used to 
calculate the cost-effectiveness of treatment alternatives in order to promote the rational 
use of healthcare resources.
Real-world data can also be used for other purposes, including benchmarking and compari-
son with guidelines in order to inform quality improvement processes. In the Netherlands, 
various initiatives now exist to collect real-world evidence within disease registries on a 
national level. If carefully designed, carefully analysed and carefully used to improve the 
quality and cost-effectiveness of diagnosis and treatment strategies, these registries will 
prove invaluable to Dutch healthcare.
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AlGeMene IntroduCtIe
Voordat nieuwe oncologische medicijnen op de markt komen, zijn zij al uitgebreid onder-
zocht. In klinische trials is hun veiligheid en doeltreffendheid bepaald. Hierna blijven er 
echter nog belangrijke vragen onbeantwoord. Dit zijn vragen over de effectiviteit en veilig-
heid in de dagelijkse praktijk, maar ook vragen over gepast gebruik, patiënt-gerapporteerde 
uitkomsten, budget impact en kosteneffectiviteit.
Informatie over de effectiviteit en veiligheid van nieuwe medicijnen in de dagelijkse praktijk 
is nodig om te evalueren of de kosten en baten van medicijnen acceptabel zijn en vergelijk-
baar met de verwachtingen op basis van klinische trial(s). Gegevens over behandelpatronen 
kunnen gebruikt worden om te evalueren hoe een medicijn wordt voorgeschreven en 
bijvoorbeeld of dit volgens de richtlijnen is. De budget impact van een nieuw medicijn infor-
meert de betalende partij over de mate waarin het medicijn beslag legt op de beschikbare 
middelen. De mate waarin een medicijn waar voor zijn geld oplevert, wordt de kostenef-
fectiviteit genoemd. Gegeven dat de nationale budgetten voor gezondheidszorg beperkt 
zijn, is informatie over budget impact en kosteneffectiviteit steeds belangrijker om rationele 
keuzes te maken over de inzet van schaarse middelen.
Dit proefschrift presenteert de resultaten van observationele uitkomstenstudies in de 
dagelijkse behandelpraktijk van twee ziektebeelden: hoofd-halskanker en longkanker. Het 
toont de toegevoegde waarde van data uit de dagelijkse praktijk in aanvulling op klinische 
trials. Bovendien wordt in dit proefschrift het opzetten van patiëntregisters besproken, ter 
verzameling van data uit de dagelijkse praktijk.
hooFd-hAlskAnker
Hoofdstuk II en hoofdstuk III tonen het gebruik en de kosteneffectiviteit van cetuximab 
voor patiënten met lokaal gevorderd plaveiselcelcarcinoom van het hoofd-hals gebied (LG 
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HHPCC). Uit een gerandomiseerde, gecontroleerde trial onder patiënten met LG HHPCC 
bleek dat behandeling met radiotherapie plus cetuximab (RT+C) leidt tot langere mediane 
locoregionale controle (24,4 vs. 14,9 maanden), progressievrije overleving (17,1 vs. 12,4 
months) en totale overleving (49,0 vs. 29,3 maanden) vergeleken met behandeling met 
alleen RT. Het was echter niet duidelijk in hoeverre deze studieresultaten generaliseerbaar 
waren naar de Nederlandse situatie en wat de kosteneffectiviteit van cetuximab was in de 
dagelijkse praktijk. Er is een retrospectieve uitkomstenstudie opgezet om in deze informatie 
te voorzien.
In deze studie werden 141 patiënten geïncludeerd, gediagnosticeerd tussen 2007 en 2010 in 
twee gespecialiseerde hoofd-hals centra. Patiënten werden behandeld met ofwel eerstelijns 
RT+C ofwel alleen RT. Patiëntkarakteristieken, behandelkarakteristieken en behandeluit-
komsten werden vergeleken tussen de trial en de uitkomstenstudie.
Hoofdstuk II laat zien dat, in overeenstemming met de Nederlandse richtlijnen, RT+C wordt 
voorgeschreven aan patiënten die combinatietherapie nodig hebben maar platinumhou-
dende chemotherapie niet kunnen verdragen. Deze patiënten hebben ongunstige baseline 
karakteristieken door selectie op onder andere hoge leeftijd. Vanaf een jaar na start van de 
behandeling stierven patiënten behandeld met RT+C in de dagelijkse praktijk sneller dan 
patiënten behandeld met RT+C in de trial. Het lijkt erop dat selectieve behandelkeuzes in de 
dagelijkse praktijk de generaliseerbaarheid van de trial verminderen. Er is meer informatie 
nodig over de effectiviteit van RT+C voor patiënten met ongunstige klinische baseline karak-
teristieken, in aanvulling op de resultaten van de klinische trial.
Hoofdstuk III van dit proefschrift is gebaseerd op dezelfde studie als hoofdstuk II. Met 
behulp van een Markov model hebben we de incrementele kosten per gewonnen QALY 
geschat voor RT+C ten opzichte van alleen RT als eerstelijns behandeling van LG HHPCC. 
Het Markov model bestond uit drie gezondheidstoestanden: “levend zonder progressie”, 
“levend na progressie” en “overleden”. Overgangskansen per maand werden geschat vanuit 
de klinische trial data en de uitkomstendata besproken in hoofdstuk II. De tijdshorizonnen 
waren 5 jaar, 10 jaar en levenslang en de incrementele kosteneffectiviteit is bepaald met en 
zonder discounting (4% voor kosten, 1,5% voor effecten).
Met behulp van twee scenario-analyses hebben we verschillende aannames getest wat 
betreft de prognose van patiënten uit de dagelijkse praktijk ten opzichte van patiënten 
uit de klinische trial. Het toevoegen van cetuximab aan RT resulteerde in hogere kosten 
en gezondheidswinsten in beide scenarios en voor alle tijdshorizonnen. De incrementele 
kosten per gewonnen QALY liggen tussen de €14.624 en €38.543 in de base case. Hiermee 
Samenvatting | 161
A
lag, bij een willingness to pay van €80.000 per QALY, de kans dat RT+C kosteneffectief is ten 
opzichte van alleen radiotherapie tussen de 76% en 87%. De resultaten van hoofdstuk III 
laten zien dat RT+C een kosteneffectieve behandeloptie is voor patiënten met LG HHPCC als 
we uitgaan van de resultaten uit de klinische trial.
Hoofdstuk IV, ook over hoofd-halskanker, bespreekt dagelijkse praktijk data over palliatieve, 
systemische behandeling en kosten voor teruggekeerd/gemetastaseerd plaveiselcelcarci-
noom van het hoofd-hals gebied (T/G HHPCC) in Nederland. Voor patiënten met T/G HHPCC 
kan chemotherapie het leven verlengen en symptomen verlichten. De verwachte baten zijn 
echter beperkt en wegen niet altijd op tegen de toxiciteit en hoge kosten. Hierdoor is de 
behandelkeuze sterk afhankelijk van de voorkeur van artsen en patiënten. Data over de be-
handelkeuzes die gemaakt worden, is beperkt. In deze studie werden gegevens verzameld 
over patiënt- en tumorkarakteristieken, behandelpatronen, ziekteprogressie, overleving, 
bijwerkingen en zorggebruik voor T/G HHPCC.
De studie is uitgevoerd in zes Nederlandse hoofd-hals centra, bij patiënten die gediagnos-
ticeerd zijn tussen 2006 en 2013. 125 (14%) van de 893 T/G HHPCC patiënten ontvingen 
palliatieve, eerstelijns systemische therapie buiten studieverband. De meest voorgeschre-
ven behandelingen waren: platinum+5FU+cetuximab (32%), andere platinumhoudende 
combinatietherapie (13%), methotrexaat monotherapie (27%) en capecitabine monothe-
rapie (14%). De mediane progressievrije- en totale overleving waren respectievelijk 3,4 
en 6,0 maanden. 34 (27%) patiënten hadden ernstige bijwerkingen. De gemiddelde totale 
ziekenhuiskosten liepen van €10.075 (±€9.891) (methotrexaat monotherapie) tot €39.459 
(±€21.149) (platinum+5FU+cetuximab). De grootste kostenposten waren ziekenhuisopna-
mes en medicatie tegen kanker.
nIet-kleInCellIG lonGkAnker
Hoofdstuk V-VII bespreken overleving, behandelpaden en kosten van niet-kleincellig long-
kanker (NKLK). Het doel van hoofdstuk V is om verschillen in overleving tussen academische 
en perifere ziekenhuizen in Nederland te analyseren en om inzicht te geven in NKLK behan-
delpatronen. Landelijke informatie over de overleving van NKLK patiënten werd verkregen 
via Integraal Kankercentrum Nederland. Data over behandelpaden is verkregen in vier, niet-
random geselecteerde ziekenhuizen (twee academisch, twee perifeer). Een random sample 
van patiënten, gediagnosticeerd met NKLK tussen 31 januari 2009 en 31 januari 2011, werd 
geïdentificeerd via vier ziekenhuisdatabases.
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De overleving van NKLK patiënten werd vergeleken tussen academische en de perifere 
ziekenhuizen. Met behulp van Kaplan Meier methoden werd de totale overleving geplot per 
ziekenhuistype en met behulp van een Cox proportional hazards analyse werd het relatieve 
risico op mortaliteit geschat (uitgedrukt in hazard ratios, gecorrigeerd voor case mix), met 
alle perifere ziekenhuizen als referentiecategorie.
Deze studie laat zien hoe NKLK patiënten behandeld worden. Behandelkeuze verschilt sterk 
tussen patiënten en type tumoren. Patiënten met niet-gemetastaseerde ziekte die behan-
deld werden in academische ziekenhuizen hadden een betere overleving dan patiënten met 
niet-gemetastaseerde ziekte in perifere ziekenhuizen, zelfs wanneer gecorrigeerd werd voor 
case mix. De mediane overleving was 2,66 jaar (95% BI 2,14-3,18) in academische versus 
1,83 jaar (95% BI 1,73-1,93) in perifere ziekenhuizen. Bij gemetastaseerde ziekte was de 
mediane overleving 0,41 jaar (95% BI 0,35-0,48) in academische versus 0,39 jaar (95% BI 
0,38-0,41) in perifere ziekenhuizen.
Hoofdstuk VI rapporteert de kosten van laboratoriumonderzoeken voor NKLK. Kankerpatiën-
ten ondergaan een breed spectrum aan laboratoriumonderzoeken, van simpele bloedtesten 
tot complexe moleculaire diagnostiek. In kosteneffectiviteitsanalyses worden de kosten van 
laboratoriumtesten vaak achterwege gelaten of op een verkeerde manier geschat. Wij pre-
senteren de daadwerkelijke kosten van laboratoriumonderzoek voor NKLK patiënten in de 
dagelijkse praktijk, per categorie testen. In een Nederlands, academisch ziekenhuis werden 
alle laboratoriumonderzoeken die uitgevoerd waren tussen 2009 en 2011 geregistreerd en 
gecategoriseerd in klinische chemie; pathologie; microbiologie; serologie, hematologie en 
transfusie; farmacologie; en overig of onbekend. Het aantal testen per type werd vermenig-
vuldigd met de eenheidskosten per test zoals verkregen van de Nederlandse Zorgautoriteit.
Een totaal van 1.015 patiënten werd geïncludeerd, met 171.632 laboratoriumonderzoeken. 
Het aantal verschillende soorten testen was 392. De gemiddelde kosten van laboratoriumon-
derzoeken per patiënt was €96 (95%BI 91-101) per dag met minimaal één laboratoriumon-
derzoek en €49 per dag tussen de eerste en de laatste laboratoriumtest. Een groot deel van 
de kosten kwam ten goede aan relatief simpele bloedtesten, omdat deze veel werden uitge-
voerd. De voornaamste kostenpost was echter moleculair onderzoek door de patholoog, ten 
behoeve van het gebruik van doelgerichte therapieën. In farmaco-economische evaluaties 
kunnen de kosten van laboratoriumonderzoek de resultaten significant beinvloeden, met 
name wanneer het laboratoriumonderzoek verschilt tussen de behandelalternatieven.
Hoofdstuk VII gebruikt data uit de studies uit hoofdstuk V en VI om een schatting te geven 
van het totale zorggebruik en kosten van alle onderdelen van ziekenhuiszorg voor NKLK 
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patiënten. Data werd retrospectief verzameld uit patientenstatussen en bestond onder 
andere uit gedetailleerde informatie over zorggebruik. Zorggebruik werd vermenigvuldigd 
met Nederlandse eenheidskosten in euro’s uit 2012. De totale gemiddelde kosten werden 
gecorrigeerd voor censoring met behulp van de “Bang and Tsiatis weighted complete-case 
estimator”.
De totale gemiddelde kosten voor NKLK diagnose, behandeling en follow-up waren €28.468 
gedurende de studieperiode en €33.143 gecorrigeerd voor censoring. Bijwerkingen werden 
geregistreerd voor 369 patiënten (41%) en 82 patiënten (9%) hadden een bijwerking van 
graad III of hoger. Voor deze patiënten kostten bijwerking-gerelateerde ziekenhuisopnamen 
gemiddeld €2.091. De gemiddelde kosten van NKLK waren €1.725 voor de diagnostische 
periode, €17.296 voor de eerste behandellijn, en €13.236 voor iedere latere behandellijn. 
De kosten voor het uitvoeren van een second opinion waren €2.580 per patiënt. Hoewel de 
studie belangrijke beperkingen heeft met betrekking tot de korte follow-up duur, stadiëring 
en ontbrekende gegevens, levert deze zeer gedetailleerde data over de kosten van NKLK in 
de dagelijkse praktijk.
PAtIëntenreGIsters
In hoofdstuk VIII hebben we ons gericht op de dataverzameling van dagelijkse praktijkgege-
vens in plaats van het daadwerkelijke gebruik van deze gegevens. Met dit hoofdstuk hebben 
we geprobeerd om onze ervaringen te delen wat betreft het opzetten van patiëntenregisters 
voor de verzameling van dagelijkse praktijk gegevens ten behoeve van besluitvorming. We 
bespreken de missie en doelen van patiëntenregisters, stakeholders en financiering, type 
register, inhoud, dataverzameling, identificatie en rekrutering van patiënten, manier van 
omgaan met de data en geneesmiddelenbewaking.
De missie die met de meeste patiëntenregisters wordt nagestreefd is het verbeteren van de 
gezondheid van patiënten door het verbeteren van de zorg. Het voornaamste doel is hier-
mee om de zorg van patiënten te monitoren. Om dit doel te bereiken moeten de belangen 
van stakeholders in lijn met elkaar zijn en moet men het eens zijn over de manier waarop 
het register bestuurd wordt. Voor de selectie van data elementen is het waardevol om de 
hulp in te schakelen van zowel klinische experts als experts in het doen van uitkomstenon-
derzoek. Bij dataverzameling moeten er altijd afwegingen worden gemaakt tussen enerzijds 
het maximaliseren van betrouwbaarheid, validiteit en specificiteit van data elementen en 
anderzijds de haalbaarheid. Om het register dusdanig op te zetten dat de privacy van patiën-
ten gewaarborgd blijft, dienen de onderzoekers bekend te zijn met Good Clinical Practice en 
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zich bewust te zijn van lokale regelgeving. Bovendien kunnen registers een goede bron zijn 
van informatie over de veiligheid van geneesmiddelen en mag een plan voor de geneesmid-
delbewaking niet ontbreken.
Gegeven de unieke waarde van uitkomsten uit de dagelijkse praktijk, verwachten we dat 
patiëntenregisters de nieuwe standaard zullen worden in medische dataverzameling, naast 
gerandomiseerde klinische studies. Gerandomiseerde studies en observationele studies zijn 
complementair en de keuze voor het type studie moet afhankelijk zijn van het type vraag. 
Met behulp van beslismodellen kunnen de verwachte kosten en effecten van behandelalter-
natieven worden vergeleken door het combineren van informatie uit verschillende bronnen 
waaronder zowel gerandomiseerde studies als observationele studies. Deze modellen kun-
nen gebruikt worden voor het berekenen van de kosteneffectiviteit van behandelalternatie-
ven ter bevordering van de rationele inzet van schaarse middelen.
Gegevens uit de dagelijkse praktijk kunnen gebruikt worden voor meerdere doelen, inclusief 
benchmarking en vergelijking met de richtlijnen ten behoeve van kwaliteitsverbetering. In 
Nederland bestaan er momenteel verschillende initiatieven om belangrijke dagelijkse prak-
tijk uitkomsten te verzamelen op nationaal niveau. Wanneer dit gebeurt op een zorgvuldige 
manier, met het doel om de kwaliteit en kosteneffectiviteit van zorg te verbeteren, zullen 
deze registers ontzettend waardevol worden voor de Nederlandse gezondheidszorg.
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Eind 2010 belde mijn promotor Carin mij met de vraag wat ik van promoveren zou vinden. 
Een paar maanden later lag mijn kersverse bureau vol met case report forms, hoofdhals-
kanker trials en aantekeningen voor wat mijn eerste studierapport zou worden. Carin, 
ontzettend bedankt voor het vertrouwen dat je me altijd hebt gegeven, jouw passie voor 
onze onderzoeken en jouw vakkundige begeleiding. Ik heb ongelofelijk veel van je geleerd 
en een heerlijke tijd gehad bij het iMTA.
Die heerlijke tijd heeft mede vorm gekregen door een geweldige groep collega’s. In het 
bijzonder door mijn kamergenootjes Parida en Remziye en na de verhuizing Maartje en 
Ellen. Bedankt voor de gezelligheid, de discussies, de thee, en al die successen en frustraties 
die we gedeeld hebben.
Chantal, ook jij was heel even mijn kamergenootje, in mijn tijd als student-assistent. Be-
dankt voor jouw enthousiaste begeleiding tijdens het eerste jaar van mijn promotie en jouw 
hulp bij het modelleren. Het heeft mijn onderzoek een vliegende start gegeven.
Ook na die vliegende start heb ik een hoop hulp van collega’s gekregen. Gezien er meerdere 
collega’s aan de slag waren met ziekteregisters, kwamen we regelmatig samen om ervarin-
gen en ideeën uit te wisselen (bedankt Hans!). Binnen deze groep hebben we onder andere 
gewerkt aan een workshop en een artikel over het opzetten van ziekteregisters (hoofdstuk 
VIII van mijn proefschrift). Saskia, Margreet, Hans, Hedwig, Brenda en Ellen, ik heb ervan 
genoten om met jullie te brainstormen, te presenteren, te schrijven en te reflecteren op 
onze onderzoeken.
Ook wil ik graag de collega’s bedanken met wie ik heb mogen samenwerken op projecten 
die niet in mijn proefschrift zitten. Clazien, Leona, Margreet, Matthijs, Nasuh en Tim, jullie 
energie is aanstekelijk en ik hoop dat onze wegen elkaar vaker zullen kruizen. Datzelfde geldt 
voor mijn collega’s uit andere ziekenhuizen en universiteiten. In het bijzonder wil ik graag 
Marlies en Veerle uit het VUMC bedanken voor onze samenwerking in de longkankerstudies, 
vanaf het hele begin tot (hopelijk binnenkort) de laatste publicatie!
Minder op de voorgrond maar niet minder belangrijk waren de student-assistenten, ver-
pleegkundigen, onderzoeksmedewerkers, administratiemedewerkers, artsen en natuurlijk 
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patiënten. Bedankt voor al jullie inzet en bijdragen die dit proefschrift mogelijk hebben 
gemaakt. Belangrijke bijdragen zijn ook geleverd door de Nederlandse Kankerregistratie, 
ZonMW, Merck (mede in de persoon van Chris Pescott) en GSK (mede in de persoon van 
Hans Tamminga). Bedankt voor jullie betrokkenheid, financiering en het beschikbaar stel-
len van de nodige data. Verder zijn de illustraties in dit proefschrift te danken aan Akha 
Hulzebos (omslag en boekenlegger) en Terese Winslow (anatomische illustraties): wat een 
mooi eindresultaat!
Heel graag bedank ik bij deze ook de promotiecommissie voor het lezen en beoordelen van 
mijn proefschrift en het opponeren bij de verdediging.
Tot slot, het dichtst bij huis, Alex en mijn familie: mijn geweldige oma’s, ouders, zusje en 
nichtje. Ik had dit proefschrift nooit kunnen schrijven zonder jullie.
Alex, vooral de laatste paar maanden waren nogal hectisch. Binnen drie maanden trouwen, 
promoveren en emigreren! Ik kan me niemand anders voorstellen met wie dat mogelijk (en 
zo ontzettend leuk!) zou zijn. Bedankt voor je onvoorwaardelijke steun bij- en interesse in 
alles wat ik doe. Ik kan niet wachten om met jou op avontuur te gaan.
Mam, bedankt voor alle suggesties, inspiratie en correcties de afgelopen jaren. In het 
dankwoord van jouw eigen proefschrift schreef je destijds dat ik beweerd heb dat jouw 
motivatie groter is dan je verstand. Nu was dat misschien waar in de context van natuurlijk 
logaritmen, verder is het natuurlijk onzin. Maar jouw onstuitbare motivatie heeft mij wel 
altijd geïnspireerd om overal vol voor te gaan. Ik hoop dat we samen nog veel onderzoek 
gaan doen, nu allebei gepromoveerd! Je bent mijn voorbeeld en mijn thuis.
Papa, jouw kritische blik op de medische wereld en evidence based medicine hebben mij 
een betere onderzoeker gemaakt. Je bent mijn geweten en mijn maatje. Bedankt dat je me 
altijd helpt herinneren dat schrijven geen haast heeft als de zon buiten schijnt.
Shanna, jij bent mijn wederhelft. We leven ons leven nu in tegengestelde volgorde: jij het 
gezin, ik de baan. Laten we samen twee oude vrouwtjes met lachrimpeltjes worden, op een 
bankje in een park.
Isa, mijn hart breekt als ik eraan denk dat ik je de komende jaren alleen tijdens vakanties ga 
zien. Je gaat misschien al naar school als ik terugkom. Het gaat tijd zijn die ik nooit meer in 
kan halen… je verandert elke week al zo veel. Ik beloof je dat ik terugkom en zoveel meer 
voor je zal zijn dan een-tante-in-Australië. Je bent het geweldigste meisje op aarde.
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PhD period: 2011-2015
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Master Clinical Epidemiology, Netherlands Institute for Health Sciences, Rotterdam, 
2012–2014.
Academic writing in English for PhD students, Erasmus University Rotterdam, Language and 
Training Centre, Rotterdam, 2013.
Propensity Scores and Observational Studies of Treatment Effect, International Society for 
Pharmacoeconomics and Outcomes Research, Berlin, 2012.
Elements of Pharmaceutical/Biotech Pricing, International Society for Pharmacoeconomics 
and Outcomes Research, Berlin, 2012.
Discrete Event Simulation for Economic Analyses – Concepts, International Society for Phar-
macoeconomics and Outcomes Research, Berlin, 2012.
Discrete Event Simulation for Economic Analyses – Applications, International Society for 
Pharmacoeconomics and Outcomes Research, Berlin, 2012.
Didactics (group dynamics, feedback, examination), Erasmus University Rotterdam, Risbo 
Research-Training-Consultancy, Rotterdam, 2012.
European Head and Neck course, Amsterdam, 2011.
Advanced Modeling Methods for Economic Evaluation, University of Glasgow, Centre for 
Health Economics, Glasgow, 2011.
Ready in four years, Hertz training for scientists, Rotterdam, 2011.
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(Inter)nAtIonAl ConFerenCes And MeetInGs
Podium presentations
“Treatments and costs for recurrent and/or metastatic squamous cell carcinoma of the head 
and neck (R/M SCCHN) in the Netherlands”, 5th International Federation of Head and Neck 
Oncologic Societies World Congress, July 2014, New York.
“Economic evaluation of SNB, USgFNAC and/or END to evaluate the clinically N0 neck”, 
5th International symposium on sentinel node biopsy in head and neck cancer, May 2012, 
Amsterdam.
“Technology as creator of proximity”, Symposium “The strength of professionalism”, Hoge-
school Rotterdam, Institute for Healthcare, 2009, Rotterdam.
Workshop
“As real as it gets: challenges in setting up patient registries for the collection of real-world 
data on behalf of policymaking”, International Society for Pharmacoeconomics and Out-
comes Research 16th Annual European Congress, November 2014, Amsterdam.
Poster presentations
“Real-world Costs of Laboratory Tests for Non-Small Cell Lung Cancer”, International Society 
for Pharmacoeconomics and Outcomes Research 16th Annual European Congress, Novem-
ber 2014, Amsterdam.
“Real-world data to calculate cost-effectiveness of monoclonal antibodies: problems and 
solutions”, International Society for Pharmacoeconomics and Outcomes Research 15th An-
nual European Congress, November 2012, Berlin.
“Return Visits to the Emergency Department: Avoidable?” (presented by co-author), Emer-
gency Nurses Association Annual Conference, September 2012, San Diego.
“Walk-out Patients in the Emergency Department” (presented by co-author), Emergency 
Nurses Association Annual Conference, September 2011, Tampa.
“A Virtual Acute Admission Unit: Nurses’ Perceived Effects” (presented by co-author), Emer-
gency Nurses Association Annual Conference, 2010, San Antonio.
Visits
International Society for Pharmacoeconomics and Outcomes Research 14th Annual Euro-
pean Congress, November 2011, Madrid.
Low Lands Health Economists’ Study Group, May 2011, Soesterberg.
Nederlandse Vereniging voor Technology Assessment in de Gezondheidszorg Lustrum Sym-
posium “Back to the Future”, April 2011, Rotterdam.
Lustrum symposium Nederlandse Kankerregistratie, March 2011, Utrecht.
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Fourth International Erasmus Master Class on Anaesthesia and Perioperative Care, focus-
sing on the Obese Patient, March 2010, Rotterdam.
teAChInG ACtIVItIes
Distribution problems, February-March 2013, 2014 and 2015, bachelor Healthcare Policy 
and Management, year 2, Erasmus University Rotterdam.
Supervision and coevaluation of bachelor and master thesis students, 2011-2015, institute 
for Healthcare Policy and Management, Erasmus University Rotterdam.
Writing and research skills, 2013-2014, premaster Healthcare Policy and Management, 
Erasmus University Rotterdam.
Introduction in Healthcare, September-November 2011 and 2013, bachelor Healthcare 
Policy and Management, year 1, Erasmus University Rotterdam.
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